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ABSTRACT 
PRP8 protein is a component of the nuclear pre-mRNA splicing machinery. 
The PRP8 gene had previously been cloned from yeast and antibodies raised against 
the protein. Using these it had been shown that PRP8 protein is a component of the 
U5 snRNP, U4/U6.U5 tri-snRNPs and of the spliceosome, in which it contacts the 
substrate RNA. In this thesis I present further work on the characterisation of the 
roles of the PRP8 protein in splicing complex assembly and splicing using these 
antibodies and two other approaches: genetic depletion of the protein in vivo and heat-
inactivation of temperature-sensitive forms of the protein. The in vivo depletion of an 
intrinsic snRNP protein has not previously been reported and this approach allowed 
a more definitive investigation of the function of PRP8 protein. 
Antibodies which recognise the native PRP8 protein inhibited splicing in vitro 
and this was shown to be due to a block in spliceosome assembly. A pre-spliceosome 
complex containing the U! and U2 snRNPs accumulated in splicing reactions 
inhibited by these antibodies. Anti-PRP8 antibodies also detected a change in the 
interactions of PRP8 protein in the spliceosome as the active complex formed. 
A yeast strain conditionally producing PRP8 protein was generated, and 
several temperature-sensitive pip8 mutations were outcrossed from mutagenised 
backgrounds and the mutations mapped within the gene. Extracts in which PRP8 
protein was either depleted or heat-inactivated were made from these strains and 
shown to be inactive for splicing. Splicing reactions carried out with these extracts 
accumulated a pre-spliceosome complex similar to that seen when PRP8 function was 
blocked by antibodies. 
Depletion and heat-inactivation of PRP8 protein were shown to result in loss 
of U4/U6.U5 tri-snRNPs, consistent with a requirement for PRP8 activity for the 
stable formation of tri-snRNPs, without which spliceosomes fail to form. As a 
consequence of PRP8 depletion the levels of U4, U5 and U6 snRNAs declined 
dramatically. From this result, and known genetic interactions between PRP8 and 
several putative RNA helicase genes, it was proposed that without PRP8 activity 
aberrant tn-snRNPs form, on or in which helicase activities act to unwind RNA 
structures, thereby exposing the snRNAs to the action of nucleases. 
In vivo depletion of U5 snRNA was found to have little effect on either PRP8 
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protein or the U4 and U6 snRNAs; in fact, the levels of U4 and U6 snRNAs rose as 
U5 became depleted. This indicated that the loss of U4 and U6 snRNAs seen on 
depletion of PRP8 protein was not a consequence of loss of U5 snRNAs and favoured 
the model proposed in (iii). 
These results together with previously published data suggest that PRP8 
protein activity is required for: 1) the formation of complete and functional U5 
snRNPs; 2) the formation of stable tri-snRNPs; 3) interaction of tri-snRNPs with the 
pre-spliceosome; 4) the regulation of helicase activities associated with the tri-snRNP 
and the spliceosome. 
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1.1 RNA Splicing. 
From the first reports that eukaryotic genes were not contiguous in their 
coding regions, suggestions were made as to how the non-coding, intervening 
sequences (introns) were removed (eg. Berget et al., 1977; Jeffreys and Flavell, 
1977; Kiessig, 1977). Among the proposed mechanisms, the suggestion that introns 
were deleted from, or spliced out of, the primary transcript has proven to be correct. 
Only in a few cases are DNA sequences rearranged to produce functional genes, eg. 
immunoglobulin and T-cell receptor genes, this type of rearrangement occurring along 
terminal differential pathways. Splicing is a general phenomenon, introns being found 
in the genes of a wide range of organisms, eukaryotes, archaebacteria and a 
eubacterial phage. 
Four classes of intron have been defined through sequence comparisons and 
analysis of trans-acting factors involved in their splicing: 
tRNA introns. These are spliced by protein-mediated cleavage and ligation, 
a different mechanism to other classes of intron (Knapp et al., 1979; Peebles et al., 
1979). The process is best understood in yeast (Saccharomyces cerevisiae) and is 
reviewed in Culbertson and Winey (1989). See also Zillman et al. (1991) for recent 
information and references. 
Group I introns. The first characterised of these is in the ribosomal RNA 
of Tetrahymena. They have since been found in fungal mitochondria, plant 
chloroplasts and a bacteriophage, T4. The splicing of these introns is RNA catalysed 
and in some cases is autocatalytic (reviewed in Cech, 1990). 
Group II introns. As with group I introns these have been found mainly in 
organellar genomes. Group II intron splicing is, as with group I, autocatalytic in some 
cases, but these introns differ from group I introns on the basis of sequence and 
secondary structure (Michel and Dujon, 1983). 
Introns in nuclear genes (other than tRNA genes). Although the mechanism 
of splicing of nuclear and group II introns is superficially the same (see section 1.2), 
the splicing of nuclear introns is not autocatalytic and is by far more complex 
involving numerous trans-acting factors. This complexity gives exciting possibilities 
for splicing as a method of regulating gene expression at a post-transcriptional level 
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through the use of alternative splicing factors. 
Nuclear pre-mRNA splicing has been most extensively studied in yeast and 
mammals and so results obtained from these systems will be the focus of this review. 
Studies in Xenopus, Drosophila, Schizosaccharomycespombe and both dicotyledonous 
and monocotyledonous plants have supplemented and generalised these findings. The 
development of in vitro systems (Hernandez and Keller, 1983; Kramer et al., 1984; 
Lin et al., 1985) which faithfully process exogenously supplied pre-mRNA substrates 
has allowed rapid progress in understanding nuclear splicing. 
1.2 Mechanism of Splicing and the Evolution of Introns. 
Wallace and Edmonds (1983) found branched molecules in nuclear (but not 
cytoplasmic) poly-adenylated RNA. These branches contain a 2'-5' phosphate linkage 
as well as the 3'-5' phosphate linkage normally found in polynucleotides (figure 
1. 1A). Subsequently, such branched species were found to result from pre-mRNA 
splicing and to be part of both an intermediate and a product of the reaction in vitro 
(Padgett et al., 1984; Ruskin et al., 1984; Lin et al., 1985) and in vivo (Domdey et 
al., 1984; Zeitlin and Efstradiatis, 1985). The kinetics of the reaction, as deduced 
from in vitro systems (Kramer et al., 1984), showed that cleavage at the 5' end of 
the intron (the 5' splice site) preceded that at the 3' end (the 3' splice site) and the 
reaction was established as a two step process. 
Two sequential transesterification reactions are presumed to constitute the 
splicing reaction (figure 1. 1B). In the first, the 2'-hydroxyl group of an adenosine 
residue internal to the intron attacks the 5' intron-exon bond creating the branched 
structure, a lariat, and liberating the exon. In the second, the exon 3' hydroxyl group 
attacks the 3' intron-exon bond, joining the two exons and releasing the intron. 
The pathway of splicing of group II introns is the same as that of nuclear 
introns and thus mechanistic and evolutionary relatedness was suggested (Cech and 
Bass, 1986). Certain group II introns, under appropriate conditions, self-splice in 
vitro without a requirement for an external energy source (Peebles et al., 1986; van 
der Veen et al., 1986) and thus the reaction is RNA catalysed. A major inference 
from the evolutionarily relation of group II and nuclear intron splicing is that nuclear 
splicing will also be (at least in part) RNA catalysed. 
Nuclear pre-mRNA splicing is an energy requiring process. That it takes place 
in a large, multicomponent complex dubbed the spliceosome (Brody and Abelson, 
1985; Grabowski et al., 1985; Frendeway and Keller, 1985), does not refute the 
possibility of energy-independent transesterification reactions and RNA catalysis. The 
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FIGURE 1.1 
The RNA Branch Structure. 
Structure of the 3'-5', 2'-5' branch structure produced during pre-mRNA splicing. 
The bases typically found in the branch are indicated and circled: A, branch-point 
adenosine residue; G, guanosine residue originally the first base of the intron; C, 
cytosine. 
The Mechanism of Pre-inRNA Splicing. 
The splicing reaction consists of two consecutive transesterification reactions, step 1 
and step 2. Reactive phosphate (p) and hydroxyl (OH) groups are shown, dotted 
arrows indicate nucleophilic attack. The conserved yeast intron sequences at the 5' 
and 3' splice sites and branch point are shown. El and E2 represent the 5' and 3' 
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spliceosome contains both protein and RNA trans-acting factors, the major 
components of the spliceosome being snRNPs (small nuclear ribonucleoprotein 
particles) which contain both RNA and protein. The RNA components of snRNPs, 
snRNAs (small nuclear RNAs), have been shown to be major determinants of intron 
recognition (see section 1.4), and it has been proposed that these RNA molecules are 
derived from fragments of group II introns (Cech, 1986). The energy requirement of 
nuclear splicing could thus be solely in the assembly and disassembly of the 
spliceosome: correct positioning of the cis- and trans-acting RNA components to 
assemble the catalyst, and disassembly of post-splicing complexes. 
What is the origin of introns? One hypothesis is that genes have always 
contained introns, having evolved as discontinuous structures (Darnell and Doolittle, 
1986; Gilbert et al., 1986). An intellectually compelling alternative is that they have 
arisen by the insertion of transposable elements into pre-existing genes (Cavalier-
Smith, 1985). Group II introns (or their ancestors) are perfect candidates for such 
transposable elements, particularly since, as mentioned earlier, some of them are 
capable of self-splicing in vitro. The most attractive feature of group II introns 
though, in relation to this model, is that, at least in some cases, they have the 
capacity to reverse splice into other RNA molecules. One particular intron (yeast 
mitochondrial intron bI 1, the first intron of the COB gene) has been shown to reverse 
splice into either an RNA composed of the ligated exons from which it was excised 
(Augustin a al., 1990; Morl and Schmelzer, 1990) or a foreign RNA species that 
contains a short sequence that constitutes a target for the intron (Morl and Schmelzer, 
1990). This ability, in combination with reverse transcription - some group II introns 
have potential open reading frames which could encode reverse transcriptases 
(Augustin et al., 1990) - would give them the capacity to spread and insert into novel 
sites by gene conversion into the genome. That certain introns are conserved across 
evolutionarily divergent organisms in their position in genes whereas others are not 
could be a reflection of the continuous insertion and removal of introns into coding 
sequences during evolution. 
The loss of autonomy in splicing has great advantages for higher organisms. 
Firstly, it prevents intron mobility thereby reducing the insertional mutation rate. 
Secondly, transfer of the catalytic components to trans-acting factors allows regulation 
of the splicing process by the use of alternative splicing factors and removes 
constraints on intron sequence. 
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1.3 Splicing in Yeast and Mammals. 
Yeast and mammals have certain differences with regard to the requirements 
of both cis-acting sequences (section 1.4) and in their flexibility. Mammalian systems 
are much more flexible and in vitro splicing systems will remove introns from yeast 
and plant transcripts (Ruskin et al., 1986; Brown et al., 1986). Yeast, however, will 
not splice mammalian introns (Beggs et al., 1980; Langford et al., 1983). 
The flexibility in the mammalian system is presumed to relate, at least in part, 
to the extensive use of splicing as a means of regulating gene expression. Mammalian 
genes often have multiple introns which may be hundreds of kilobases long. Introns 
and individual splice sites may be differentially used in various cell types and at 
separate times in development. In contrast, yeast introns are in general constitutively 
removed and genes have only one intron, if any (an exception being the MATa1 gene 
which has two (Miller, 1984)). Yeast introns also tend to be less than 500 base pairs 
in length (Leer et al., 1984). No examples of alternative splice site use have been 
found in yeast to date. 
Most yeast introns are close to the 5' end of genes, and this, together with the 
high level of reverse transcriptase activity in yeast, suggests that many introns have 
been removed by homologous recombination with cDNA copies of mature transcripts 
(Fink, 1987). The unicellular nature of yeast, with pressure for a short cell cycle, 
would select for loss of introns by this process unless they had an important role in 
regulating gene expression. 
1.4 Cis-acting Elements. 
As mentioned in section 1. 1, group I and II introns were classed according to 
sequence and structural features. Nuclear introns lack conserved structural 
characteristics but must retain minimal sequences for their definition and accurate 
removal. Such sequence elements were identified by comparisons of known introns, 
and mutagenesis and testing of mutant constructs in vivo and in vitro has confirmed 
their importance. 
Three sequence elements have been recognised which define the intron: 5' and 
3' splice sites and a branch point sequence (BPS) within which the 2'-5' link of the 
lariat is formed. Breathnach et al. (1978) noted the invariance of the dinucleotides 
GU and AG at the 5' and 3' ends of introns respectively, Mount (1982) extended 
these sequences. Yeast intron definition sequences are slightly different (Leer et al., 
1984; Teem et al., 1984) and are more highly conserved. 
1.4.1 The 5' Splice Site. 
By extensive comparison of higher eukaryotic and viral genes Mount (1982) 
defined the 5' splice site as (CA)AG/GURAGU (I denotes the cleavage site). Study 
of the effects of mutations in the 5' splice site sequence in a 0-globin intron in vitro 
and in vivo (Aebi et al., 1986, 1987; Eperon et al., 1986) showed that deviation from 
the consensus results, in general, in less use of that sequence as a splice site. Several 
mutations in the GU dinucleotide resulted in use of the site in the first step of the 
reaction but blocked the second step (Aebi et al., 1986; 1987). In many cases 
however, mutation of natural 5' splice sites results in the activation of "cryptic" or 
alternative splice sites (Green, 1986). 
Mutation of the yeast 5' splice site (G/GUAUGU), which is much more highly 
conserved, generally results in a complete inhibition of splicing, although in some 
cases aberrant non-productive cleavages are seen. This is particularly the case with 
mutations in the first two positions of the intron which, as in mammals, can lead to 
the accumulation of lariat intermediates (Newman et al., 1985; Fouser and Friesen, 
1986; Jacquier and Rosbash, 1986; Vijayraghavan et al., 1986), and mutations at 
position 5 which lead to cleavage upstream of the normal site (Parker and Guthrie, 
1985; Fouser and Friesen, 1986). This latter phenotype may reflect the importance 
of the G at position 5 being in definition of the cleavage site rather than 5' splice site 
recognition per Se. 
1.4.2 Branch Point and 3'ss. 
The yeast BPS (UACUAAC) was the first intron sequence shown by 
mutagenesis to be important (Langford and Gallwitz, 1983; Pikielny et al., 1983). 
The sequence is rigidly conserved, and most mutations in it abolish splicing. 
Mutations at the last A residue, which forms the branch point, often result in 
accumulation of lariats (Fouser and Friesen, 1986; Jacquier and Rosbash, 1986; 
Vijayraghavan et al., 1986). Some reports did not find this to be the case (Langford 
et al., 1984; Newman et al., 1985), and differences may be to do with varying 
sequence context between introns, but may also be due to the sensitivity of assays 
used - eg Vijayraghavan et al. (1986) used long incubations in vitro to observe lariat 
formation after seeing a very low level of complete splicing in vivo. This report 
indicates that the aberrant lariats can be spliced to produce mature message in vivo. 
After discovery of the yeast BPS, searches of mammalian intron sequences 
defined an equivalent, loosely conserved sequence YNYURAY as the mammalian 
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BPS (Keller and Noon, 1984; Reed and Maniatis, 1985). However, deletion of the 
authentic branch point in a -globin intron gave rise to the use of alternative sites 
with little constraint on sequence except that 1) an A was used as the branch residue 
and 2) all the sites used were within 22-37 nucleotides of the 3' splice site (Ruskin 
et al., 1985). A more thorough study by Reed and Maniatis (1988) utilised an intron 
with all possible cryptic BPS removed and two BPS-3' splice site combinations 
introduced in cis-competition. Apart from noting that the outer BPS-3' splice site was 
never used in vitro, indicating a loss of flexibility over the in vivo situation, this study 
showed that bases of the BPS were important for the efficiency of splicing in vitro 
and could alter 3' splice site selection in vivo. A more recent compilation of BPSs 
(Nelson and Green, 1989) defined the conserved sequence stringently as UNCURAC, 
very similar to that found in yeast, and it has been found that in both yeast and 
mammals the BPS base pairs with a complementary sequence in the trans-acting RNA 
species, U2 (see section 1.5). As with yeast, nucleotides other than A can act as 
acceptors at the branch site (Hornig et al., 1986). G and U work less well than A and 
C, and only A and C allow the second step to proceed efficiently. Thus the sequence 
context of the branch point in both yeast and mammals plays a major role in the first 
step in splicing, although the branch point residue is also important. 
The yeast 3' splice site is defined by the AG dinucleotide at the last two 
positions of the intron. In mammals the 3' splice site was originally defined as a run 
of pyrimidine residues (the pyrimidine tract) followed by NYAG (Mount, 1982). In 
both yeast and mammals the distance from the branch point to 3' splice site AG is 
typically 20-40 nucleotides (Green, 1986; Padgett et al., 1986) and if the 3' splice 
site dinucleotide is mutated then the next downstream AG is used (Langford and 
Gallwitz, 1983; Reed and Maniatis, 1985; Aebi et al., 1986; Reed, 1989). There are 
length constraints on this however, at least in yeast, as increasing distance yields less 
efficient completion of splicing (Cellini et al., 1986). The first step in the splicing 
reaction is not prevented by removal of the 3' splice site AG - either by truncation 
downstream of the branch point (Ruskin and Green, 1985a; Rymond and Rosbash, 
1985; Cellini et al., 1986) or by mutation (Reed and Maniatis, 1985; Aebi et al., 
1986; Cellini et al., 1986; Vijayraghavan et al., 1986; Fouser and Friesen, 1987). 
These results, together with those discussed above show that the 5' and 3' splice site 
dinucleotides and the branch point residue are more important for the second step of 
the splicing reaction than for the first. This separation of the sequence requirements 
of the two transesterification reactions suggests that there may also be a difference in 
the trans-acting factor requirements. 
Mutation of the mammalian pyrimidine tract often has a phenotype more akin 
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to it having a role as a branch point determining sequence rather than it being a 3' 
splice site sequence. Progressive decrease in size of pyrimidine tract results in a 
decrease in splicing efficiency (Weiringa et al., 1984) and mutation gives a drastic 
reduction in the first step in splicing (Frendeway and Keller, 1985; Ruskin and 
Green, 1985a). Reed (1989) found that maximal efficiency of lariat formation 
occurred when a pyrimidine tract was located just downstream of the BPS and that 
a branch point was selected on the basis of the strength (length and purity) of the 
pyrimidine tract downstream of it. 
When the yeast RP5 1 intron is spliced in mammalian nuclear extracts the 
branch point used is different to that used in yeast (Ruskin et al., 1986). The yeast 
consensus site is followed by purine rich sequences, whereas the site utilised by 
mammalian extracts is in a pyrimidine rich context. This is consistent with the 
pyrimidine tract having a greater role in specifying branch point than the BPS itself. 
A recent study on the roles of the BPS and pyrimidine tract in determining the 
splicing pattern of a transcript also suggests that this may be the case (Mullen et al., 
1991). This work used a four exon system (from the rat cr-tropomyosin gene) in 
which inclusion of the second and third exons in the spliced product is mutually 
exclusive (Smith and Nadal-Ginard, 1989). The relative contributions of strong and 
weak BPS and pyrimidine tracts in determining splicing pattern were tested in cis-
competition assays by placing them in various combinations in introns one and two. 
The results showed that the pyrimidine tract played a greater role in determining the 
branch point used - and hence the splicing pattern - than the BPS. 
However, this is only part of the story. To observe efficient exon ligation in 
constructs with short pyrimidine tracts the 3' splice site AG needs to be adjacent to 
it, whereas with a long pyrimidine tract the AG can be distant from it (Reed, 1989; 
Smith et al., 1989a). A number of mammalian splicing factors bind pyrimidine tracts, 
some of these also requiring an adjacent 3' splice site to bind efficiently (see section 
1.5). In most introns the pyrimidine tract is close to the 3' splice site and hence the 
branch point, pyrimidine tract and 3' splice site are functionally linked. A long 
pyrimidine tract may strengthen the interaction of factors that would not otherwise 
bind in the absence of an adjacent 3' splice site, thereby allowing spliceosome 
assembly. The variability of intron definition sequences in higher eukaryotes and in 
the affinity of factors for different sites provides a means to regulate splicing by 
alterations in the concentrations of both constitutive and alternative splicing factors. 
A recent in vivo study in yeast (Patterson and Guthrie, 1991) showed that a 
U-rich tract could increase usage of a distal 3' splice site, thus suggesting a role for 
pyrimidine rich regions in yeast splice site selection. Yeast may therefore have factors 
analogous to the mammalian pyrimidine tract binding factors. 
1.4.3 Non-conserved Sequences and Intron Size. 
Intron and exon sequences other than those discussed above can, either directly 
or indirectly, influence the efficiency of splice site and intron usage. Smith et al. 
(1989a) found that introducing a strong secondary structure downstream of the branch 
point in a-tropomyosin intron 2 resulted in a block in the second step in splicing. 
This was attributed to a block in 5' to 3' scanning from the branch point to "find" the 
3' splice site. This intron may be atypical as the BPS and 3' splice site are separated 
by an unusually large distance. Solnick (1985a) produced adenovirus pre-mRNAs with 
stable hairpin structures and found that when an exon was sequestered in a hairpin 
loop it was omitted from most of the processed transcripts both in vivo and in vitro. 
These studies showed that in principal secondary structure can have a profound effect 
on splicing. Natural examples are known where intron and exon secondary structure 
plays a physiological role in regulating splicing. One such is in the transcript of the 
yeast RPL32 gene. The 5' splice site can be part of a secondary structure involving 
exon 1 sequences which may form a binding site for the gene product, the ribosomal 
protein L32 (Eng and Warner, 1991). This provides a basis for regulation of 
expression of the gene at the level of splicing, by precluding Ul snRNP and other 
factors from binding at the 5' splice site. 
Sequences that indirectly affect splicing through protein interaction are found 
in the Drosophila sex determination pathway (reviewed in Baker, 1989; Slee and 
Bownes, 1990). Protein binding can prevent the use of a site, for example the Sxl 
protein interacts to occlude a sex non-specific 3' splice site in tra pre-mRNA 
(Sosnowski et al., 1989; Inoue et al., 1990). Protein binding can also promote splice 
site usage; the tra and tra-2 proteins interact with dsx pre-mRNA to promote the use 
of a female-specific 3' splice site (Hedley and Maniatis, 1991; Hoshijumi et al., 
1991; Ryner and Baker, 1991). The in vivo action of tra and tra-2 has been 
reproduced in vitro using recombinant proteins in a heterologous HeLa nuclear extract 
system (Tian and Maniatis, 1992). A number of proteins (including tra and tra-2) 
bound to sequences in the transcript known to be required for the female-specific 
splicing pattern. Another example of protein binding affecting splicing pattern is in 
the Drosophila P transposable element transcript. The P element transcript has three 
introns which must all be removed to produce a functional transposase. The third 
intron is removed in germ line but not somatic tissues. Genetic manipulation 
identified sequences around the 5' splice site of the third exon as important in 
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determining the splicing pattern and biochemical fractionation has identified a protein 
in somatic cell extracts that binds to these sequences (Siebel and Rio, 1990). There 
are other examples, and this appears to be a major way in which alternative splicing 
is regulated (see Smith et al. (1989b) and Maniatis (1991) for reviews of alternative 
splicing and mechanisms used). 
Structural constraints due to the large size of the splicing complex must dictate 
a minimum size for introns. This has indeed been found to be the case. The two 
M4Ta1 gene introns are the smallest known in yeast at 54 and 52 nucleotides in 
length (Miller, 1984). That these introns may represent the lower limit in size for 
efficient removal was indicated by the finding that if the 5' splice site to branch point 
distance in the first intron was reduced by 6 nucleotides (from 43 to 37) then splicing 
was abolished (Kohrer and Domdey, 1988). A reduction in size of the intron to 47 
nucleotides prevented spliceosome assembly. This data agreed with earlier work on 
the actin gene intron, in which reduction in the 5' splice site to branch point distance 
in a mini-gene construct from 44 to 30 nucleotides was found to abolish splicing 
(Thomson-Jager and Domdey, 1987). A similar constraint on intron size is found in 
mammalian introns where if the 5' splice site to BPS distance is reduced to between 
45 and 60 nucleotides splicing is also inhibited (see Himmelspach et al., 1991 and 
references therein). Himmelspach et al. (1991) demonstrated the steric nature of 
inhibition of splicing with short 5' splice site to branch point distances by using a 
variety of truncated adenovirus E1A transcripts. With a 5' splice site to BPS of less 
than 50 nucleotides spliceosome assembly was blocked after the addition of U2 
snRNPs. If this distance was reduced even further, to 34 nucleotides, then U2 
snRNPs could not bind (the spliceosome assembly pathway is described in section 
1.5). Size constraints can be important in naturally occurring introns - for example 
the c-tropomyosin intron 2 studied by Mullen et al. (1991) in which the distance 
between the 5' splice site and branch point is too small to allow the two to be used 
together, explaining the mutually exclusive use of exons 2 and 3 (Smith and Nadal-
Ginard, 1989). 
1.4.4 Links to other RNA Processing Events. 
Since in vitro splicing systems from both yeast and HeLa cells will process 
uncapped, non-polyadenylated transcripts (Kramer et al., 1984; Lin et al., 1985) it 
does not appear that these processes are obligatorily linked. The finding of introns in 
U6 snRNA genes in several organisms (Tani and Ohshima, 1989, 1991) also implies 
that in vivo there is no requirement for capping or polyadenylation to allow splicing 
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to proceed since U6 transcripts do not have these features (however, see section 1.7). 
1.5 Trans-acting Factors, Assembly of the Spliceosome. 
Trans-acting factors involved in splicing of nuclear pre-mRNA introns 
(reviewed in Lührmann etal., 1990; Green, 1991; Guthrie, 1991; Ruby and Abelson, 
1991) have been identified and shown to be required for splicing by many 
approaches. These include inhibition of splicing in vivo and in vitro by antibodies, 
oligonucleotide-directed RNase H digestion of snRNAs, biochemical fractionation and 
complementation and screening yeast either for conditional-lethal mutations affecting 
splicing in vivo, or for suppressors of defects in previously identified trans-acting 
factors or cis-acting sequences. Among the various spliceosomal factors the snRNPs 
are the most studied and best understood. Historically snRNPs were the first splicing 
factors identified and they make up the bulk of the spliceosome. 
1.5.1 snRNPs and their Involvement in Splicing. 
Mammalian snRNPs are highly abundant (105106  copies per cell) and have 
been studied extensively (see LUhrmann et al., 1990 for review). Each snRNP 
contains one or two RNAs and a set of core polypeptides (designated B, B', D 1 , D2 , 
D3 , E, F, G and G') along with snRNP-specific proteins. The snRNPs are named 
after the RNA(s) they contain; hence Ui, U2, US and U4/U6 snRNPs contain the 
Ui, U2, US and U4 plus U6 snRNAs respectively. U4 and U6 RNAs are base-paired 
together in the U4/U6 snRNP. This base-pairing is phylogenetically conserved and 
can be represented as a Y-shaped structure (Brow and Guthrie, 1988; Guthrie and 
Patterson, 1988; figure 1.3A). 
Apart from U6, all the snRNAs are transcribed by RNA polymerase II, have 
a distinctive 2,2,7-trimethylguanosine (M 3G) cap and a conserved single stranded 
sequence motif RAU4 ..6GR, flanked by double stranded stems. The core snRNP 
polypeptides bind to this conserved sequence (Mattaj, 1986). The core proteins are 
major species recognised by sera from patients suffering from the autoimmune disease 
systemic lupus erythematosus, named anti-Sm sera for the prototype patient Smith, 
and hence the conserved motif in the RNA is called the "Sm site". U6 snRNA is 
transcribed by RNA polymerase III (Parry et al., 1989) has a y-monomethy1 
phosphate cap (Singh and Reddy, 1989) and no Sm site. 
Assembly of snRNPs follows a complex pathway (reviewed in Parry et al., 
1989) Following synthesis in the nucleus the RNAs (apart from U6) are exported to 
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the cytoplasm where structural polypeptides bind and the hypermethylated M 3G cap 
is formed. Some of the core snRNP proteins (at least one D protein, E, F and G) 
appear to bind to the snRNAs as a pre-assembled unit (Fisher et al., 1985) and the 
interaction with the RNA may be through the F protein since it can be covalently 
cross-linked to it in native snRNP particles using ultra-violet light (Woppmann et al., 
1988). Re-entry of the snRNA into the nucleus depends at least on core protein 
binding and has a variable requirement on the M 3G cap (Fischer et al., 1991 and 
references therein). Nuclear localisation of snRNPs appears to be through the nuclear 
pore complex since it is inhibited by wheat germ agglutinin (a general inhibitor of 
nuclear import) and an anti-nucleoporin antibody, but appears to be targeted via a 
different pathway to most other karyophilic cellular components: import into the 
nucleus is not prevented by competitive amounts of a synthetic karyophile but is 
inhibited by the dinucleotide M 3G-G which does not inhibit the import of non-M 3G-
capped snRNAs (see Michaud and Goldfarb, 1992 for discussion and further 
references). 
Yeast snRNAs are much less abundant than their mammalian homologues at 
10-500 copies per cell (Wise et al., 1983; Reidel et al., 1986). As in mammals Ui, 
U2, U4 and U5 snRNAs are polymerase II transcribed, and these snRNAs are also 
M3G capped (Wise et al., 1983). U6 is similar to that in other systems in being an 
RNA polymerase III transcript (Moenne et al., 1990). Yeast snRNPs contain proteins 
that cross-react in immunoprecipitation assays with anti-Sm sera (Siliciano et al., 
1987; Tollervey and Mattaj, 1987). This immunoprecipitation implies conservation 
of at least some of the core proteins, although these have yet to be identified. Unlike 
mammalian snRNAs which are encoded by multi-copy gene families, yeast snRNAs 
are encoded by single copy genes which has facilitated genetic studies. One such 
study by Jones and Guthrie (1990) on the Sm site of the US snRNA showed that, 
surprisingly since the motif is highly conserved, mutations in few of the conserved 
residues had any discernable effect on in vivo function. This implied that the 
interaction of the core proteins with the Sm site was somewhat flexible. 
SnRNP-specific polypeptides have been identified by purification of snRNPs 
using biochemical and immunological fractionation procedures. Ul snRNP has three 
specific proteins (A, C and 70k), U2 has two (A' and B") and the US snRNP has at 
least eight (see LUhrmann et al., 1990 for review and references). Sequencing of 
yeast chromosome IX revealed a gene, SNPJ, coding for a protein strongly 
homologous to Ui 70k protein from other species (Smith and Barrell, 1991). The 
SNP1 gene is essential, and Smith and Barrell (1991) found that a chimeric gene with 
over half of the yeast sequences replaced with the corresponding region of the human 
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U  70k gene produced a functional protein, implying that the SNP  protein probably 
was the yeast Ui 70k homologue. Other snRNP proteins have been identified in yeast 
by genetic approaches and include PRP8, a U5 snRNP component (Lossky et al., 
1987; PRP stands for precursor RNA processing), PRP3, PRP4 and PRP6, which are 
all U4/U6 associated (Banroques and Abelson, 1989; Peterson-Bjorn et al., 1989; 
Abovitch et al., 1990; Ruby and Abelson, i991), and PRP24 which associates with 
free U6 snRNPs (Shannon and Guthrie, 1991). 
The involvement of snRNPs in splicing was first postulated by Lerner et al. 
(1980) and Rogers and Wall (1980). This was based on the observation that the 5' 
terminus of Ui snRNA is complementary to the consensus sequences of the 5' and 
3' ends of introns. Evidence for the involvement in splicing of snRNPs in general and 
Ui snRNP in particular came from the finding that antibodies directed against the Ui 
snRNP, Sm epitopes and the M 3G cap inhibited splicing (Padgett et al., 1983; 
Bozzoni et al., 1984; Kramer et al., 1984). The use of oligonucleotides to target 
RNase H to cleave specific regions of snRNAs showed that Ul, U2 and U4/U6 
snRNPs were all required for the splicing reaction to take place (Kramer et al., 1984; 
Black et al. 1985; Kramer and Maniatis, 1985; Black and Steitz, 1986). 
Antibodies and nuclease digestion were also used to show that the yeast 
snRNAs were required for splicing. Anti-M 3G antibodies immunoprecipitate splicing 
intermediates and products (Cheng and Abelson, 1986) and inhibit in vitro splicing 
reactions (Chang et al., 1988). Targeted RNase H cleavage of Ui (Kretzner et al., 
1987; Ruby and Abelson, 1988) U2 (Legrain et al., 1988; Ruby and Abelson, 1988; 
McPheeters et al., 1989) or U6 snRNA (Fabrizio et at., 1989) showed that they were 
required for splicing in vitro. U5 snRNA is resistant to nucleases (Chabot et at., 
1985) and US snRNA was shown to be required for splicing by in vivo depletion by 
using a yeast strain with a US gene (snR7) under the control of a repressible promoter 
(Patterson and Guthrie, 1987; GALl-JO promoter sequences were used making 
expression of the gene carbon source regulated). 
1.5.2 Early Events in Spliceosome Assembly, 
1.5.2.1 Ui snRNP Binding. 
Interaction between partially purified Ui snRNP and the 5' splice site was 
demonstrated by Mount et al. (1983). This was shown by immunoprecipitation of 5' 
splice site sequences resistant to RNase T 1 with anti-U1 snRNP antibodies. The 
interaction took place at 0 °C in the absence of ATP. The observation that Ul snRNP 
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interacts specifically with the 5' splice site was followed by the demonstration in both 
yeast and mammals that base pairing between Ul and the 5' splice site, as proposed 
by Lerner et al. (1980) and Rogers and Wall (1980), is indeed required (see figure 
1.2A). Cotransfection of HeLa cells with adenovirus genes containing mutations in 
the alternative 12S or 13S 5' splice sites and mutant Ui genes showed that 
suppression of splice site mutations could be achieved by compensatory mutations in 
the snRNA that restored base pairing (2uang and Weiner, 1986). Similar allele-
specific effects were seen in yeast (Seraphin et al., 1988; Siliciano and Guthrie, 1988) 
although restoration of base pairing to mutations at position 5 of the 5' splice site, 
which give rise to aberrant cleavages (see section 1.4.1), did not restore splicing to 
the wild type site. Instead, increased splicing at both the wild type and aberrant sites 
was seen, implying that although Ui snRNP recognises the 5' splice site this is not 
sufficient to define the cleavage site. 
The ATP-independent binding of U 1 snRNPs to 5' splice site sequences seen 
by Mount et al. (1983) is also seen in both mammalian and yeast in vitro splicing 
systems (Black et al., 1985; Bindereif and Green, 1987; Ruby and Abelson, 1988; 
Legrain et al., 1988). However, many methods used to fractionate or isolate splicing 
complexes, such as native gel electrophoresis or affinity chromatography, fail to show 
the presence of Ul snRNA in complexes, the first splicing specific complex seen 
containing only U2 (eg Grabowski and Sharp, 1986; Konarska and Sharp, 1986, 
1987; Pikielny et al., 1986). Bindereif and Green (1987) showed that the association 
of Ui snRNP with splicing complexes was highly sensitive to salt concentration and 
to heparin, explaining the absence of Ui in many analyses. Modified gel systems such 
as that of Zillman et al. (1988) have demonstrated the presence of Ul snRNP 
epitopes in active spliceosome complexes, and these investigators also showed, by 
targeted RNase H cleavage, that spliceosome assembly was sensitive to loss of Ui 
In yeast the requirement for U1 snRNP before the other snRNPs was shown 
in vitro using extracts depleted of U2 snRNP either in vitro, by targeted RNase H 
cleavage (Ruby and Abelson, 1988; Legrain et al., 1988), or in vivo, by 
transcriptional repression (Seraphin and Rosbash, 1989). The experiments of Seraphin 
and Rosbash (1989) utilised extracts from cells depleted in vivo of either Ui or U2 
snRNA. When Ul was depleted no complexes could be detected by native gel 
electrophoresis under conditions that resolved early complexes, whereas when U2 was 
depleted 2 complexes (designated CC1 and CC2) containing Ul snRNA were 
resolved. These "commitment complexes" could be chased into spliceosomes upon 
addition of Ui depleted extract. Competition experiments in which an excess of non- 
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FIGURE 1.2 RNA-RNA Interactions. 
Ui and U2 snRNAs interact directly with substrate RNA. Base pairing interactions 
Ul:5' splice site and U2:branch point are indicated, the yeast consensus intron and 
snRNA sequences are shown. The putative U2:U6 interaction equivalent to the 
mammalian interaction shown in B is also illustrated. 
The base pairing interaction between mammalian U2 and U6 snRNAs shown to 
be important for splicing in vivo and spliceosome assembly in vitro. 
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labelled competitor RNA was added prior to the Ui depleted extract showed that 
these complexes indeed committed RNA to the splicing pathway since labelled RNA 
in them was spliced. 
Ruby and Abelson (1988) found that formation of U1-pre-mRNA complexes 
required both 5' splice site and branch point sequences. A recent study by Seraphin 
and Rosbash (1991) also showed a requirement for the branch point in commitment 
complex formation. Substrates lacking a functional BPS or truncated to within about 
20 nucleotides of a non-functional BPS formed only CC 1, whereas substrates with a 
functional BPS formed both complexes. In a direct competition assay for binding 
early factors in U2 depleted extract both BPS deleted and 5' splice site mutant 
transcripts competed poorly relative to wild type. These results together implied a 
role for the BPS in early complex formation and the simplest explanation of these 
data and those of Ruby and Abelson (1988) is for some factor other than the U2 
snRNP interacting with the branch point. It should be noted that the experiments of 
Seraphin and Rosbash (1991) do not show a progression of CC1 to CC2 (or vice-
versa) and the relationship may not be a linear one. 
A similar situation to that found in yeast is emerging in the mammalian 
system. Using gel filtration, Michaud and Reed (1991) isolated a complex "E" (Reed, 
1990) that contains stably bound Ui snRNP. This complex, which forms in the 
absence of ATP, also contains U2 snRNP but much less stably bound than in later 
complexes. Complex E was similar to the yeast U1-pre-mRNA commitment 
complexes in that it could be chased into spliceosomes on addition of nuclear extract. 
When the nuclear extract was pre-incubated with a competitor substrate to sequester 
early spliceosome assembly factors the E complex was still efficiently chased into 
- spliceosomes whereas isolated non-specific complexes were not (Michaud and Reed, 
-1991), indicating the commitment of the RNA in the E complex to the splicing 
pathway. Michaud and Reed (1991) also state that formation of the E complex could 
occur on substrates with only a 5' or a 3' splice site. This agrees with 
immunoprecipitation studies of Ziliman et al. (1987) who observed Ui snRNP 
binding to a substrate lacking a 5' splice site. Thus in both yeast and mammalian 
systems the binding of Ui snRNP appears to be an important factor in the 
commitment of an RNA to the splicing pathway and, since there appears to be Ui 
interaction at both ends of the intron, the 5' and 3' ends of the intron may be 
juxtaposed at very early stages of spliceosome assembly. 
The binding of U 1 snRNP to the 5' splice site may not take place purely 
through an RNA-RNA interaction. Heinrichs et al. (1990) used purified Ul snRNP 
and derivatives of it lacking Ui specific proteins and assayed 5' splice site binding. 
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Binding was dependent to a large extent on the C protein. Although C protein does 
not show any RNA binding activity on its own, when added to Ui snRNPs lacking 
it they regained 5' splice site binding competence. Thus U1C may bind the substrate 
RNA, or alter the Ul snRNA conformation allowing it to bind, or bind to and 
stabilise the RNA duplex formed between Ul snRNA and the substrate. 
1.5.2.2 Protein Factors. 
Several mammalian factors other than Ui snRNP have been shown to bind 
specifically to intron sequences at low temperature and/or in the absence of ATP. 
These are U2 accessory factor (U2AF; Ruskin et al., 1988), pyrimidine tract binding 
protein (PTB; Garcia-Blanco et al., 1989), intron binding protein (IBP; Gerke and 
Steitz, 1986; Tazi et al., 1986) and hnRNP proteins Al, C and D (Swanson and 
Dreyfuss, 1988). These proteins all bind specifically to pyrimidine tracts, with 
varying requirement for an associated 3' splice site. The binding takes place without 
a requirement for other spliceosomal components, pointing to interaction with introns 
early in the spliceosome assembly pathway. 
Another mammalian factor which may be required very early in spliceosome 
assembly is ASF-1 or SF2. SF2 was identified by biochemical fractionation as being 
required for the first step in splicing (Kramer and Maniatis, 1985), and it is required 
for formation of complexes containing Ul and U2 snRNPs (Kramer et al., 1990a). 
In a concentration-dependent fashion, SF2 alters usage of alternative 5' splice sites 
favouring a proximal one (Kramer et al., 1990b) which implies interaction of S172 
with factors that recognise the 5' splice site - eg Ui snRNP. Cloning of an S1 72 
cDNA revealed identity to ASF- 1, a protein which had been purified on the basis that 
it was an alternative splicing factor involved in 5' splice site choice (Ge et al., 1991; 
Kramer et al., 1991; see Lamond, 1991 for discussion). It. has recently been 
demonstrated that hnRNP Al protein has an activity antagonistic to that of SF2, at 
least in vitro (Mayeda and Kramer, 1992). Thus an excess of S1 72 over hnRNP Al 
resulted in the activation of proximal 5' splice sites, an excess of hnRNP Al over 
SF2 favoured distal 5' splice sites. These effects of hnRNP Al were only seen with 
alternative splice sites, not cryptic ones, suggesting that the concentration of essential 
splicing factors may play a general role in alternative splicing. Both SF2 and hnRNP 
Al display RNA annealing activities (Kramer et al., 1990a; Munroe and Dong, 1992) 
and it is tempting to speculate that they might promote the binding of a trans-acting 
RNA to the substrate (see Mayeda and Kramer, 1992 for more discussion). 
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1.5.3 Formation of the Pre-spliceosome. 
1.5.3.1 U2 snRNP Binding. 
As mentioned in the previous section, the first splicing specific complex 
resolved by many separation techniques contains U2 snRNP and pre-mRNA. The 
binding of the U2 snRNP is the first ATP requiring step in spliceosome assembly and 
the complex is often referred to as the pre-spliceosome. 
In yeast both the 5' splice site and Ui snRNP (as well as U2 snRNP) are 
required for pre-spliceosome formation (Ruby and Abelson, 1988; Seraphin and 
Rosbash, 1989). In mammalian systems, the formation of pre-spliceosomes does not 
require a 5' splice site (Frendeway and Keller, 1985; Konarska and Sharp, 1986; 
Bindereif and Green, 1987), but does require U  snRNP (Zillmann et al., 1988). The 
basis for this was demonstrated by Barabino et al. (1990) by comparing complexes 
formed in extracts either depleted of Ui or with the 5' terminus of Ui snRNA (and 
hence 5' splice site base pairing) blocked by a modified anti-sense 
oligoribonucleotide. In Ul depleted extracts no stable binding of snRNPs was 
detected, whereas with Ul 5' splice site blocked extracts U2 bound stably enough to 
allow it to be retained in a non-denaturing gel. Thus Ui snRNP has a role in 
promoting U2 snRNP binding independent of its ability to base pair to the 5' splice 
site. 
U2 snRNP binds to the BPS in both mammals and yeast. Initially this was 
shown in a HeLa in vitro system by RNase protection and immunoprecipitation of 
branch point fragments with anti-U2 snRNP antibodies (Black et al., 1985). Later, 
genetic experiments in both yeast and mammals showed that this interaction involved 
base pairing (Parker et al., 1987; Wu and Manley, 1989; Zhuang and Weiner, 1989; 
see figure 1.2A). The binding of U2 snRNP is prevented if the region of U2 snRNA 
that base pairs to the BPS is blocked with an antisense oligonucleotide (Lamond et 
al., 1989). The base pairing interaction between U2 and the BPS is predicted to result 
in the branch point A residue becoming bulged out of a helix in a structure 
remarkably similar to that predicted for hairpin VI of group II introns (see Jacquier 
1990 and references therein). This is the residue that becomes branched in group II 
introns and this physical and structural similarity between group II intron and pre-
mRNA splicing is one of the strongest arguments in support of nuclear introns being 
derived from the same ancestors as group II introns. 
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1.5.3.2 Protein Factors. 
The interaction of U2 snRNP with the BPS requires several factors other than 
the Ui snRNP, and in the absence of U2 snRNP the branch point region still becomes 
inaccessible to directed RNase H cleavage (Barabino et al., 1990) indicating that at 
least some of these factors may bind before the U2 snRNP. U2AF was identified by 
biochemical fractionation of HeLa splicing extract as a factor required for binding of 
partially purified U2 snRNP to substrates lacking a 5' splice site, and competition 
assays showed that U2AF binds prior to U2 snRNP (Ruskin et al., 1988). Purification 
and cloning of U2AF has revealed a 65kDa protein which binds stably to the 
pyrimidine tract/3' splice site with no requirement for ATP (Zamore et al., 1992 and 
references within). Binding of U2AF to pyrimidine tracts increases as the length and 
pyrimidine content increase (Zamore et al., 1992) and is impeded if the AG is 
removed (Ruskin et al., 1988). SC-35 is a protein originally identified through its 
recognition by a monoclonal antibody raised against partially purified spliceosomes 
(Fu and Maniatis, 1990). Immunodepletion of SC-35 inhibits splicing (Fu and 
Maniatis, 1990) and in depleted extracts complexes similar to the E complex 
(Michaud and Reed, 1991) form, but pre-spliceosomes do not (Fu and Maniatis, 
1992) implying a role for SC-35 in stabilising U2 binding. Other mammalian factors 
required for U2 binding are SF1 and SF3 (Kramer et al., 1987; Kramer, 1988; 
Kramer and Utans, 1991). 
In yeast, two genetically identified factors, PRP5 and PRP9, are required for 
U2 snRNP binding (Abovitch et al., 1990; Ruby and Abelson, 1991). Abovitch et al. 
(1990) showed that yeast extracts from a strain carrying a temperature-sensitive allele 
of the pip9 gene heat treated prior to extract preparation accumulated U 1 -pre-mRNA 
commitment complexes. In addition, epitope-tagging of PRP9 allowed 
immunoprecipitation, by antibodies against the epitope, of some U2 snRNA implying 
that PRP9 protein may be associated with U2 snRNPs or with a sub-population of 
them (Abovitch et al., 1990). Sequencing of the PRP5 gene revealed homology to a 
family of ATP-dependent RNA helicases (Dalbadie-McFarland and Abelson, 1990). 
This is only one of several putative helicases associated with splicing in yeast (for 
review see Wassarmann and Steitz, 1991; Schmid and Linder, 1992) and its role 
could be ensuring that U2 snRNA and/or the pre-mRNA are in a conformation 
compatible with their base pairing interaction. ATP hydrolysis by helicases could 
account for much of the ATP requirement of nuclear pre-mRNA splicing. 
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1.5.4 U4/U6 and U5 snRNP Addition. 
The transition from pre-spliceosome to later complexes involves the binding 
of the U4/U6 and U5 snRNPs and presumably other factors. By native gel 
electrophoresis and affinity chromatography these snRNPs appear to associate 
simultaneously (Pikielny et al., 1986; Bindereif and Green, 1987; Cheng and 
Abelson, 1987; Konarska and Sharp, 1987) and in both yeast and mammals they are 
found associated in a single U4/U6.U5 tri-snRNP (Cheng and Abelson, 1987; Lossky 
et al., 1987; Konarska and Sharp, 1987; Black and Pinto, 1989). 
Initial interaction of the U4/U6 and US snRNPs with the spliceosome appears 
to be primarily through previously bound factors as there is little change in the RNase 
protection pattern of the substrate on their binding (Bindereif and Green, 1987). A 
number of interactions have been identified that may be involved in this step. The 
first is an interaction between the U2 and U6 snRNAs. Lamond et al. (1989) found 
that blocking the 5' end of U2 snRNA with a modified antisense oligoribonucleotide 
did not impair binding of the U2 snRNP to the pre-mRNA, but that the binding of 
U4/U6 and U5 was prevented. The 5' end of U2 snRNA has since been shown to 
base pair to U6 snRNA using psoralen cross-linking, which is specific for base paired 
nucleic acids (Hausner et al., 1990; see figure 1.2). Since complementarity between 
these regions of U2 and U6 is phylogenetically conserved, it was proposed that this 
constituted an important interaction at some step in splicing (Hausner et al., 1990). 
Using co-transformation of substrate and snRNA genes into mammalian cells both 
Datta and Weiner (1991) and Wu and Manley (1991) showed that this base pairing 
was required for splicing in vivo. Mutations in U2 that reduced the complementarity 
to U6 decreased splicing of reporter constructs; this could be alleviated in an allele-
specific fashion by U6 snRNA mutations that restored complementarity. These 
experiments were elegantly designed taking advantage of the previously determined 
requirement of U2:BPS base pairing (Wu and Manley, 1989;1'..uang and Weiner, 
1989) to avoid interference in the assays by the wild type U2 snRNA. Recent in vitro 
work by Wolff and Bindereif (1992), using a system in which endogenous U6 snRNA 
was degraded and replaced by exogenously supplied U6, showed that mutations in the 
region of U6 that base pairs with U2 did not prevent U6 assembly into snRNP 
complexes but did prevent spliceosome formation. Thus the U2:U6 base pairing 
interaction is important for spliceosome assembly. 
The highly conserved complementarity of U2 and U6 implies that it is 
important. Mutational analyses of yeast U2 (Shuster and Guthrie, 1990) and U6 
snRNAs (Fabrizio et al., 1989; Madhani, et al., 1990) showed that growth or in vitro 
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splicing was impaired by decreased complementarity. These observations suggest that 
the interaction is important for spliceosome assembly and overall splicing rate in 
yeast, but that the U2:U6 base pairing may not be essential. 
Studies by Chabot es al. (1985) suggested an ATP-independent interaction of 
US snRNP with the 3' splice site. A potential interaction site for US snRNP is the 
protein factor IBP. As mentioned in section 1.5.2.2 this factor binds specifically to 
pyrimidine tract-3' splice site sequences. Under certain conditions IBP co-fractionates 
with US snRNP (Gerke and Steitz, 1986; Tazi et al., 1986), and thus the interaction 
observed by Chabot es al. (1985) was probably through IBP. 
An intriguing observation was made recently by Vankan et al. (1992) using 
a Xenopus oocyte system. When U6 snRNA was destroyed by targeted RNase H 
digestion, or when certain U4 or U6 snRNA mutants that could not assemble into 
U4/U6 particles were used to replace the endogenous snRNAs, a pre-mRNA-U1-U2-
U4 complex was detected. It is not possible to rule out the existence of a U6 fragment 
remaining after RNase H digestion that assembled into the complex along with U4, 
but the results with mutant snRNAs (particularly those with mutant U4) where U4/U6 
snRNPs did not assemble, argue for this interaction of U4 with the pre-spliceosome 
being specific. The method of selection of spliceosomes used in this work (injecting 
biotinylated pre-mRNA substrate into oocytes and affinity selecting from cell lysates 
with streptavidin coated beads) is very different from - and possibly less stringent 
than - the native gel analysis used in studies of yeast and mammalian systems in vitro 
where no U4 binding has been observed when U6 is destroyed (eg Fabrizio and 
Abelson, 1990; Wolff and Bindereif, 1992). Therefore, although free U4 snRNPs are 
not normally seen, the U4-pre-spliceosome interaction observed by Vankan et al. 
(1992) may be relevant. 
U4/U6 and U5 snRNPs are generally considered to associate with the pre-
spliceosome as a single entity. Several considerations indicate this: 1) They associate 
at the same time so far as can be determined from systems that resolve splicing 
complexes; 2) U4/U6.U5 tri-snRNPs complexes have been identified in both 
mammalian and yeast splicing extracts (but they have not been observed in Xenopus - 
see Vankan et al., 1992); 3) U4/U6 and U5 snRNPs can not assemble independently 
into forming spliceosomes when one or the other is depleted from HeLa splicing 
extracts (Barabino et al., 1990; Lamm et al., 1991) and when splicing extract is 
prepared from yeast cells depleted in vivo of U5 snRNA, U4/U6 snRNPs fail to 
assemble into splicing complexes (Seraphin es al., 1991). 
U4/U6.U5 tri-snRNP complexes have recently been purified from HeLa cell 
nuclear extract and shown to contain at least 5 proteins not seen in isolated U4/U6 
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and U5 snRNPs (Behrens and Lührmann, 1991). Proteins in a micrococcal nuclease 
digest of tri-snRNPs were sufficient for isolated U5 and U4/U6 snRNPs (which can 
not associate on their own) to assemble into tri-snRNPs, indicating a role for the tn-
snRNP specific proteins in formation or stability of the particle (Behrens and 
Lührmann, 1991). 
The most direct evidence for U4/U6.U5 tri-snRNPs being a functional unit in 
spliceosome assembly has come from the study of the effects of heat shock on 
splicing in HeLa cells. Depending on the severity of the heat treatment several stages 
of spliceosome assembly are affected in vitro (Bond, 1988; Shulka et al., 1990). 
U4/U6.U5 tri-snRNPs are deficient in extracts from heat shocked cells, and pre-
spliceosomes accumulate in splicing reactions carried out with these extracts. 
Recently, Utans et al. (1992) showed that the micrococcal nuclease fraction of tn-
snRNPs (Behrens and Lührmann, 1991) could restore tri-snRNPs and splicing in heat 
shock extracts. Purified tri-snRNPs also restored splicing competence, but isolated U5 
plus U4/U6 snRNPs could not. Since intact U5 and U4/U6 snRNPs are present in 
heat shock extract (as assessed by gradient sedimentation) the heat labile factor was 
deduced to be one or more of the U4/U6.U5 tri-snRNP specific polypeptides. 
Several protein factors have been found in yeast that affect the formation of 
complexes containing U4/U6 and US snRNPs. The U5 snRNP protein PRP8 is a 
component of tri-snRNPs (Lossky et al., 1987) and heat-inactivated extracts from a 
prp8 strain fail to form sliceosomes (Lustig et al., 1986). Heat-inactivated extracts 
from pip3, pip4 and pip6 strains fall to form complete spliceosomes (Abovitch et al., 
1990; Ruby and Abelson, 1991). In addition, antibodies against PRP4 protein inhibit 
splicing in vitro (Banroques and Abelson, 1989; Peterson-Bjorn et al., 1989) and 
result in the accumulation of complexes migrating as pre-spliceosomes in native gels 
(Banroques and Abelson, 1989). 
RNA sequences that have been shown to be required for tri-snRNP formation 
are the 5' end of yeast U4 snRNA (Bordonne et al., 1990), which is the binding site 
of PRP4 protein (Xu et al., 1990) and a conserved triplet in U6 at the end of the U4-
U6 interaction domain (see figure 1.3A). Wolff and Binderief (1992) found that 
deletion of these three bases from HeLa U6 snRNA gave a greater than 90% 
reduction in the formation of tri-snRNP. Fabnizio et al. (1989) showed that a yeast 
U6 snRNA carrying the mutation UGA to UCA could form U4/U6 snRNPs in vitro 
but was not active in splicing. Madhani et al. (1990) found that the mutation UGA 
to GGA in yeast U6 had a lethal phenotype in vivo and resulted in formation of very 
little U4/U6 or U4/U6.U5. Taken together these results imply a role for this part of 
U6 in snRNP complex formation. Wolff and Bindereif (1992) also found that bases 
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23-33 of U6 snRNA were important for U4/U6.U5 function; deletion of residues 1-23 
had no effect, whereas deletion of residues 1-33 resulted in formation of an aberrant 
tri-snRNP. This particle did not enter spliceosomes, and had increased mobility in a 
non-denaturing gel, implying loss of (a) protein component(s). This region of U6 
snRNA may therefore represent the binding site for a protein important in the entry 
of the tri-snRNP into spliceosomes. 
1.5.5 Destabilisation of U6 from U4. 
By various native gel systems a complex lacking U4 snRNA is resolved after 
one containing U2, U4, U5 and U6 (Pikielny et al., 1986; Cheng and Abelson, 1987; 
Lamond et al., 1988). The simplest interpretation of this is that U4 is lost from the 
spliceosome after the U4:U6 base pairing is destabilised. The recent demonstration 
by Yean and Lin (1991) that stalled yeast spliceosomes lacking U4 snRNA can be 
chased through the splicing reaction by the addition of protein factors shows that U4 
is not essential during the biochemical reaction of splicing. However, analysis of 
purified spliceosomes (Reed et al., 1988; Ruby and Abelson, 1988; Whittaker et al., 
1990) suggests that U4 may be in active complexes, and post-splicing complexes can 
be affinity selected with modified antisense oligoribonucleotides specific to U4 
snRNA (Blencowe et al., 1989) indicating that U4 snRNA is present in the post-
splicing complex. These results imply that U4 is associated with spliceosomes 
throughout the reaction, but is lost (like Ui 5nRNA) under certain fractionation 
conditions. 
The destabilisation of U4 from U6 has been proposed to result in the exposure 
of residues of U6 which are important - possibly catalytic - in the splicing reaction 
(Brow and Guthrie, 1989; Guthrie, 1989). This is supported by the extreme 
conservation of the primary sequence of U6 genes between many organisms (Brow 
and Guthrie, 1988; Guthrie and Patterson, 1988). Recently U6 snRNA has been 
cross-linked by UV light (which demands direct contact) to regions of the intron 
around the 5' splice site in pre-mRNA and to the branch point in the excised intron 
(Sawa and Shimura, 1992) providing the first direct evidence for U6 being close to 
the site of the splicing reaction. 
The yeast U4:U6 interaction is stable to approximately 53 °C (Brow and 
Guthrie, 1988) and thus the destabilisation in the spliceosome is presumed to be an 
active process. This constitutes another point in the splicing pathway at which ATP 
and a helicase function might be required. Genetic studies in yeast have identified 
several candidate factors including a putative helicase, PRP28 (Strauss and Guthrie, 
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1991) and a protein, designated PRP24, which is associated with free U6 snRNP 
(Shannon and Guthrie, 1991). 
PRP2 protein is a yeast factor that acts after the destabilisation of U6 and U4, 
but before or at the first step in the splicing reaction. Since PRP2 has motifs 
characteristic of an ATPase/helicase (Chen and Lin, 1990) it could participate in the 
final rearrangements of RNA sequences prior to the splicing reaction, and its 
association with the spliceosome prior to and during step one is consistent with this 
(King and Beggs, 1990). PRP2 protein has recently been shown to have RNA-
dependent ATPase activity, again consistent with this proposal, but no helicase 
activity was found with the substrates tested (Kim et al., 1992). SF4 is a potential 
mammalian homologue of PRP2 (Kramer et al., 1987; Utans and Kramer, 1990) as 
it also acts after the formation of spliceosomes but prior to the first step in splicing. 
PRP2 and SF4 have several other features in common; they are approximately the 
same size (100 and 1 lOkDa) and both factors can associate with pre-formed 
spliceosomes. No ATPase activity was reported by Utans and Kramer (1990) for S1 74 
fractions, but this is not surprising as such activity might only be revealed in 
spliceosomes. 
Complementation studies have shown that, in addition to PRP2, a heat 
resistant factor b is required to allow the splicing reaction to proceed in spliceosomes 
formed in heat-inactivated extracts from prp2 strains (Lin et al., 1987). The function 
of this factor is unknown. 
1.6 The Splicing Reaction and Spliceosome Dissociation. 
Amongst the many interactions involved in the assembly of the spliceosome 
are those that form the active site or modify it. Some of these are becoming apparent, 
mainly through the use of genetic approaches in yeast (see below). It could be 
imagined that once the spliceosome were assembled, with all the components 
correctly aligned, then the splicing reaction would rapidly proceed through the two 
transesterifications without any further requirement for other factors. However, this 
is not the case. After completion of step 1, ATP hydrolysis is required to allow the 
reaction to proceed to step 2 (Sawa et al., 1988; Vijayraghavan and Abelson, 1990). 
Since there are differences in the requirement for cis-acting sequence elements 
between steps 1 and 2 (section 1.4) there may be a conformational change or shift in 
the spliceosome. This may involve remodelling of RNA-RNA, RNA-protein and 
protein-protein interactions. In keeping with this, factors have been identified that are 
required for step 2, but not step 1. 
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Factors required for step 2 are the products of the yeast PRP16, PRP1 7, 
PRP18 and PRP29 genes (Schwer and Guthrie, 1991; Vijayraghavan et al., 1989; 
Ruby and Abelson, 1991) and the mammalian SF3 and SF4a activities defined 
biochemically by Kramer and Maniatis (1985). Of these PRP16 has been cloned and 
is a putative helicase (Burgess et al., 1990 and see below, section 1.6.1). The in vivo 
defect of temperature-sensitive ppi8 strains has been reproduced in vitro 
(Vijayraghavan and Abelson, 1990) and this, together with manipulation of the cloned 
gene should allow further biochemical characterisation of this second step factor. 
1.6.1 PRP16 and other ATPases/Helicases. 
PRP16 was initially defined by a dominant suppressor mutation, p,p16-1, that 
overcame the defect conferred by a mutation of the branch point A to C (Couto et al., 
1987) in a pre-mRNA that undergoes the first step of the splicing reaction 
inefficiently (Vijayraghavan et al., 1986; section 1.4.2). Thus the mutant was 
proposed to affect the fidelity of branch point formation and to act before step 1 
(Couto et al., 1987). However, following immunodepletion or heat-inactivation of a 
temperature-sensitive mutant extract the splicing reaction is blocked after step 1 
(Schwer and Guthrie, 1991) and PRP16 activity is not required for step 1 but is for 
step 2. Thus the prpl6-1 mutation confers an extra property on the PRP16 protein. 
Sequencing showed that the prpl6-1 mutation mapped within the ATP binding domain 
conserved in ATP-dependent helicases (Burgess et al., 1990). From this Burgess et 
al. (1990) proposed a model in which the abnormal function of the prpl6-1 protein 
was due to relaxation in fidelity of target recognition caused by a change in the rate 
of ATP binding or hydrolysis. This model is supported by the demonstration that 
purified PRP16 protein displays RNA-dependent ATPase activity (Schwer and 
Guthrie, 1991) - although it remains to be seen what activity the mutant protein has. 
Schwer and Guthrie (1991) demonstrated binding of PRP16 to spliceosomes in the 
absence of ATP, and only on addition of ATP did the reaction proceed. PRP16 may 
therefore only bind or hydrolyse ATP when the spliceosome has a particular structure 
or has reached a certain point in the reaction. This could produce a change in local 
conformation or unwinding of RNA allowing the second step to proceed. Thus PRP16 
may indeed be an ATP-driven switch as suggested by Burgess et al. (1990). 
PRP16 is highly homologous to PRP2 and to PRP22 (a factor required for 
message release; see section 1.6.5) which, with a few others (but not PRP5 or 
PRP28) form a subclass of the DEAD-box proteins (the DEAH-box family). The 
requirement for PRP2 protein just prior to step 1, PRP16 protein between steps 1 and 
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2 and PRP22 protein prior to message release raises the possibility that the three 
proteins have similar functions at different points in the splicing reaction. The action 
of these proteins, when the spliceosome is in the correct conformation for the reaction 
to proceed beyond certain points could ensure both fidelity and uni-directionality. The 
prpi6-1 protein may take over the normal function of PRP2, at least in the mutant 
branch point substrate, as it seems to act when PRP2 normally does. This would 
imply that PRP2 and PRP16 have very similar targets, for instance a different 
conformation of the same spliceosomal components at the active site. The mutant 
prpl6-1 protein might have lost some of its normal activity; while haploid strains 
carrying the pip16-1 allele are viable, they accumulate intron-exon 2 lariats of wild 
type messages (Couto et al., 1987). 
1.6.2 The US snRNA. 
A similar approach to that used by Couto et al. (1987) was adopted by 
Newman and Norman (1991) to identify factors involved in 5' splice site recognition. 
They isolated suppressors of a 5' splice site mutation in which the invariant G residue 
at position 1 was substituted by an A. This inhibits step 2 of splicing and the products 
of step 1 accumulate. A dominant trans-acting suppressor mutant was isolated that 
activated a cryptic splice site 12 nucleotides upstream of the authentic 5' splice site. 
This resulted in the production of an in-frame mRNA with a short deletion. Cloning 
and sequencing identified the suppressor as a mutant form of US snRNA with a single 
base change in a phylogenetically conserved loop (loop 1 U6 to C6; figure 1.3B). 
Further work (Newman and Norman, 1991, 1992) has shown that mutations in this 
loop of U5 can: 1) activate several cryptic 5' splice sites around the Gi to A mutant 
site; 2) allow step 2 to proceed from the A-A branch produced in step 1 from G 1 to 
A mutant substrate; 3) allow step 2 to occur when the 3' splice site is mutated from 
AG to AA, which normally blocks the second step. Taken together these observations 
suggest interactions of U5 snRNA at both the 5' and 3' ends of the intron. Through 
examining mutations that gave rise to particular events Newman and Norman (1992) 
proposed that base pairing to sequences upstream of the 5' cleavage site or 
immediately downstream of the 3' splice site was responsible for the phenotypes of 
the mutants. They were even able to predict correctly the effects of certain US 
mutations and which US loop sequences would be selected from random sequence 
pools when screening for particular events. 
The base pairing observed was redolent of that seen in group II splicing 
between the D3 loop of the intron and exon sequences adjacent to the splice sites 
FIGURE 1.3 
The U4:U6 Complex. 
The U4 and U6 snRNAs are shown base-paired together at stem I and stem II as in 
the U4/U6 particle. For simplicity only certain bases (mentioned in the text) are 
shown. Sequences and numberings are according to the yeast snRNAs. Suppression 
of the cold-sensitive U4 G14 to C mutation by mutations in prp24 is indicated by a 
dotted arrow. The dotted line shows the approximate region of HeLa U6 snRNA 
which can be cross-linked to substrate and substrate derived molecules. 
Structure of US snRNA. 
Bases of loop 1 that are conserved between yeast and man are shown. Those bases 
underlined are available for chemical modification in U5 snRNPs and U4/U6.U5 tn-
snRNPs. Interactions with exon sequences are indicated by dotted lines. The loop 1 
mutation U6 to A was isolated by Newman and Norman (1991) as a suppressor of the 
intron mutation Gi to A and causes aberrant cleavages in vivo. El and E2 represent 
the 5' and 3' exons, IVS the intron. This, and A are not to scale. 
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known to be important for splicing (see Newman and Norman, 1992 for references 
and a fuller discussion). Newman and Norman (1992) proposed that, since U residues 
can base pair to any other of A, G or C within helices (Holbrook et al., 1991), the 
U-rich nature of the U5 loop could enable it to base pair with many different exon 
sequences (see figure 1.3B). This is a much less stringent situation than that found 
in group II introns and thus perhaps an interaction of U5 with exon sequences has 
been maintained in nuclear splicing even though other factors normally specify the 
cleavage site. In evolutionary terms the addition of U5 snRNA to Ui and U2 as a 
potential "escaped domain" of an ancestral group II intron adds weight to the origin 
of nuclear intron splicing from group II splicing (see Jacquier, 1990 for discussion 
of Ui and U2). Whatever the origin of the interaction U5 is one of the factors close 
to the site of the splicing reaction and may be one that holds the free exon 1 in place 
after step 1 of the splicing reaction. 
As well as being an evolutionarily conserved part of U5 snRNA, loop 1 is 
freely accessible to chemical modification in both US snRNPs and U4/U6.U5 tn-
snRNPs, and is the only part of US snRNA that has been successfully cleaved in 
targeted RNase H experiments (Black and Pinto, 1989; figure 1.3B). Also, modified 
antisense oligonucleotides to loop 1 allowed specific depletion of the U5 snRNA from 
HeLa splicing extracts (Lamm et al., 1991). Thus the conserved loop of US is 
available to interact with other RNA sequences or proteins in the spliceosome. 
1.6.3 The U6 snRNA. 
As mentioned in section 1.5.5 U6 snRNA has been proposed to be an 
important factor in the splicing reaction. Extensive mutagenesis has been carried out 
on yeast U6 snRNA to identify important bases. Mutant U6 genes were constructed 
by doped synthesis or site directed mutagenesis and this was followed by screening 
for mutations that affected function either in vivo (Madhani et al., 1990) or by 
reconstitution of mutant U6 snRNAs into snRNPs in vitro (Fabrizio and Abelson, 
1990). Two regions of U6 (bases 47-52 and 58-61; figure 1.3A) were defined in 
which mutation or deletion had a large effect on splicing - either a lethal or 
conditional lethal effect in vivo or a block of the first or second step of splicing in 
vitro. These results support the proposition by Brow and Guthrie (1988) that U6 
comes into very close proximity with the intron. The U6 genes of 
Schizosaccharomyces pombe and Rhodotorula dacroydum contain introns within the 
first and second of these regions respectively, and there are several introns within the 
conserved region of U6 in Rhodosporidium hasagawae (Tani and Ohshima, 1989, 
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1991). Brow and Guthrie (1989) suggested that the introns could have been inserted 
into the U6 snRNA by a reverse splicing event, the sequence being transferred to the 
genome by reverse transcription and gene conversion. If U6 is catalytically active, U4 
may act as an anti-sense regulator, sequestering the active residues in U6 snRNA until 
the appropriate point in splicing has been reached, consistent with the observed 
destabilisation of the U4:U6 interaction in the spliceosome. In the absence of U4, U6 
has been predicted to form a structure almost identical to one formed by the catalytic 
domain of the negative strand of tobacco ring spot virus ((-)sTRSV; see Tani and 
Ohshima, 1991). The (-)sTRSV undergoes self-catalysed cleavage during replication, 
and Tani and Ohshima (1991) proposed that U6 might have a similar mechanism of 
action, being catalytic in the splicing reaction. 
In the (-)sTRSV model the highly conserved region of U6 snRNA around and 
including residues• 47-52 would be very close to the substrate. As mentioned in 
section 1.5.5, Sawa and Shimura (1992) showed, using UV cross-linking, interactions 
between HeLa U6 and the 5' splice site in pre-mRNA and the branch point in excised 
intron. Mapping the cross-links within U6 by targeted RNase H digestion of U6 
showed that the interactions were with sequences in this same conserved part of the 
RNA. 
Mutagenesis of U6 in both HeLa and Xenopus systems (Bindereif et al., 1990; 
Vankan etal., 1990, 1992; Wolff and Bindereif, 1992) has not contradicted the above 
results and speculations on the role of the conserved region around residues 47-52 
(yeast numbering). However, recent work has shown that residues analogous to those 
in region 58-6 1 of yeast U6 do not appear to have equivalent importance in Xenopus 
(Vankan et al., 1992). Mutations at 2 positions which in yeast gave rise to 
accumulation of intermediates had no effect. In addition, mutation at a position in 
stem 1 that when mutated in yeast had little or no effect, gave a complete block in 
splicing in Xenopus. More data is required to give a detailed picture of similarities 
and differences between systems and to define the exact role of individual residues 
of U6. 
1.6.4 PRP8. 
From the discussion in sections 1. 6.2 and 1.6.3, US and U6 snRNAs probably 
form part of the active site of the spliceosome. These snRNAs also join the 
spliceosome at the same time as part of the U4/U6.U5 tri-snRNP (section 1.5.4). 
Another component of this particle also contacts the substrate during the splicing 
reaction and is the only protein component of the spliceosome which has been shown 
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to do so. This is PRP8. 
PRP8 (originally RNA8) is one of the complementation groups defined by 
Hartwell (1967) and the activity of the gene product was shown by Lustig et al. 
(1986) to be required for splicing. Cloning and sequencing of PRP8 showed it to be 
a 280kDa protein (Jackson, 1987). Using antibodies raised to 0-galactosidase-PRP8 
fusion proteins, Lossky et al. (1987) were able to show that PRP8 is a component of 
the U5 snRNP and of the U4/U6.U5 tri-5nRNP. Whittaker et al. (1990) showed by 
immunoprecipitation of intermediates of the splicing reaction and of lariat intron 
product, that PRP8 protein was associated with splicing complexes and with a post-
splicing intron containing complex. Affinity purification of spliceosomes confirmed 
that PRP8 protein was a stable component of the spliceosome. Most relevant to this 
discussion is that using UV cross-linking Whittaker and Beggs (1991) were able to 
show a direct interaction between PRP8 and the substrate of the reaction. The 
interaction only took place on substrates that could be assembled into spliceosomes, 
and using 3' deletion derivatives of in vitro splicing substrates it was shown that the 
first step of the reaction was sufficient to allow cross-linking. 
PRP8 protein is one of the few spliceosomal components (other than the 
snRNAs) that have been shown to be evolutionarily conserved. Antibodies raised 
against several non-overlapping regions of PRP8 protein react with a protein in HeLa 
nuclear extract associated with the U5 snRNP (Anderson et al., 1989) and this protein 
has also been shown to be a component of the human U4/U6.U5 tri-snRNPs and 
affinity purified spliceosomes (Pinto and Steitz, 1989). A Drosophila melanogaster 
U5 snRNP protein also cross reacts with several of these antibodies (Paterson et al., 
1991) as do tobacco, pea (H.Kulesza, G.Simpson, J.W.S.Brown and J.D.Beggs, 
personal communication) and mouse (P.Hodges, personal communication) nuclear 
proteins. The proteins recognised by the anti-PRP8 antibodies are all larger than 
200kDa and the putative HeLa homologue has also been reported to cross-link to pre-
mRNA in the spliceosome (Garcia-Blanco et al., 1990). 
Genetic studies have indicated that PRP8 protein may act in conjunction with 
the U5 conserved loop implicated in exon binding by Newman and Norman (1992). 
Guthrie and Patterson (1988) reported that growth impeding mutations in the 
conserved loop of U5 snRNA were lethal in combination with a temperature-sensitive 
pip8 allele (but not with several temperature-sensitive alleles in other splicing factors) 
i.e. they were synergistic lethal. The individual defects in PRP8 and U5 may be due 
to weakened interactions with the substrate and/or other factors and when combined 
the effect could be that the US snRNP no longer binds tightly enough to its target to 
allow the splicing reaction to proceed. 
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In addition to its associations with U5 5nRNA and substrate, PRP8 has been 
implicated in the stability of the U4/U6 interaction in tri-snRNPs and spliceosome 
complexes. This is based on genetic interactions found by Guthrie and colleagues 
between the putative RNA helicase protein PRP28 and both PRP8 and PRP24. PRP28 
was isolated as a cold-sensitive mutant deficient in the first step in splicing (Strauss 
and Guthrie, 1991). Mutations in PRP24 were isolated by Shannon and Guthrie 
(1991) as suppressors of a U4 snRNA mutation (figure 1.3A), and 
immunoprecipitation studies showed that PRP24 was a U6 binding protein and that 
the U4 mutation caused the U4 5nRNA to become co-precipitated by anti-PRP24 
antibodies. The mutation in U4 that the PRP24 mutations suppress destabilises the 
U4:U6 base pairing and Shannon and Guthrie (1991) postulated that the U4-PRP24-
U6 complex wasintermediate in the cycle of U4/U6 association and dissociation in 
which the RNAs are not base paired that was hyperstabilised in the U4 mutant strain. 
The genetic interaction between PRP24 and PRP28 found by Strauss and 
Guthrie (1991) was that mutations in them were synergistic lethal. Thus PRP24 and 
PRP28 proteins were postulated to act in a concerted fashion to unwind the U4/U6 
interaction in the spliceosome with PRP28 as the helicase, PRP24 binding to U6 in 
the unwound form. In a screen for suppressors of the cold-sensitive prp28 allele, a 
temperature-sensitive allele of pip8 was isolated (Strauss and Guthrie, 1991). 
Assuming that the mutations were loss of function, Strauss and Guthrie (1991) 
suggested that PRP8 protein acts in opposition to PRP28 plus PRP24 in the context 
of the U4/U6.U5 tri-snRNP: PRP8 favouring the base paired form of U4/U6, PRP28 
acting to unwind them. 
The above data supports a model, as proposed by Whittaker et al. (1990), in 
which PRP8 is a scaffold in the spliceosome. The conservation of size together with 
the conservation of widely spaced epitopes is significant in that PRP8 may have a 
number of highly important interactions with other factors and/or several functions 
critical for the splicing reaction. 
1.6.5 Disassembly of the spliceosome. 
The disassembly of the post-splicing complex requires ATP (Sawa and 
Shimura, 1991). An important aspect of this process is that the spliced mRNA is 
released from the spliceosome whereas the lariat intron is retained in a post-splicing 
complex: gel electrophoresis (Konarska and Sharp, 1987; Lamond et al., 1987), and 
affinity selection procedures (Blencowe et al., 1989; Whittaker et al., 1990) recover 
post-splicing complexes containing substantially more intron lariat than mRNA. This 
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is biologically important as swift release of the message expedites its transport from 
the nucleus, while retention of the intron allows recycling of its nucleotides within the 
nucleus. Yet again, a putative helicase protein, PRP22, has been identified in yeast 
that acts at this point, being required for release of spliced message from the 
spliceosome (Company et al., 1991). PRP22 protein may disrupt the interactions of 
U5 with exon 1 and exon 2 or possibly intron:snRNA or snRNA:snRNA interactions. 
Sawa and Shimura (1991) identified an activity (designated SRF for splicing product 
release factor) in mammalian cells which was required for disassembly of 
spliceosomes. This was assessed by release of lariat intron from a solid support to 
which the pre-mRNA had been attached via a biotinylated DNA tail and streptavidin. 
SRF and PRP22 may be homologous. 
In addition to PRP22, two other yeast splicing factors, PRP26 and PRP27, 
have been identified that are involved in disassembly of the post-splicing complex and 
intron degradation. The function of PRP27 protein is not known, but the PRP26 gene 
has been cloned and shown to encode the yeast 2'-5' phosphodiesterase or 
"debranching" enzyme (Chapman and Boeke, 1991). Yeast strains lacking PRP26 
protein accumulate excised introns in lariat form, and these are linearised efficiently 
by extracts from either yeast or bacteria over-expressing the protein from the cloned 
gene. A similar 2'-5' phosphodiesterase activity has been found in HeLa cell extracts 
(Ruskin and Green, 1985b). 
1.7 Models. 
From the data discussed in sections 1.5 and 1.6, a model of spliceosome 
assembly can be proposed. Interactions among various factors and the points of action 
of others during spliceosome assembly, the splicing reaction and spliceosome 
disassembly can also be integrated into this model which is depicted in figure 1.4. 
The model incorporates factors identified in either mammals or yeast and it is 
assumed that most, if not all, of these will have homologues or analogues in the 
other. 
Ui snRNP, U2AF and other factors including hnRNP proteins, PTB and IBP 
are the first to bind the pre-mRNA. The interaction of Ul snRNP observed at both 
ends of the intron imply that the 5' and 3' splice sites may be brought close together 
at this early step in spliceosome formation. The next snRNP to bind is U2, dependent 
upon U  snRNP, U2AF and other factors. The binding of U  and U2 snRNPs defines 
the intron and the U4/U6 and US snRNPs then associate with the pre-spliceosome as 
a pre-assembled tri-snRNP. 
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FIGURE 1.4 Model of Spliceosome Assembly and Splicing. 
The stepwise interaction of snRNPs and the proposed action points of many yeast and 
mammalian factors are shown (listed on the right hand side). The factors listed beside 
the Ui snRNP probably bind to the substrate at or around the same time as Ui. SF3 
and SF3' are two different activities defined biochemically by Kramer et al. (1987) 
and Kramer and Maniatis (1985) respectively. Points at which ATP is known to be 
required are indicated. 
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Following the binding of snRNPs and other factors, destabilisation of the U4 
and U6 snRNAs then takes place through helicase action. This and other 
rearrangements lead to the formation of the active site in which the two step splicing 
reaction takes place. Following the reaction, spliced mRNA is released and the intron 
lariat-snRNP post-splicing complex is dismantled providing free snRNPs and other 
factors to participate in another round of splicing. 
The model in figure 1.4 is based to a large extent on in vitro data. However, 
there is no reason to suppose that the in vivo situation is much different. Legrain and 
Rosbash (1989) studied the effects of mutations in intron sequences and in several 
trans-acting factors on RNA retention in the nucleus in yeast. Intron mutations at the 
5' splice site and BPS resulted in RNA export to the cytoplasm, implying that 
interaction of trans-acting factors with the intron is sufficient to prevent pre-mRNA 
exiting the nucleus. Incubation of strains carrying temperature-sensitive prp6 and pip9 
mutations at the non-permissive temperature led to increased levels of cytoplasmic 
pre-mRNA. In addition, a strain expressing a Ui snRNA with decreased 5' splice site 
base pairing potential also showed a higher level of cytoplasmic pre-mRNA than a 
wild type strain. The conclusion drawn from these data was that PRP6 and PRP9 
proteins along with U 1 snRNP were involved in recognition of intron containing 
transcripts before they were irreversibly committed to splicing. In vitro data on PRP9 
protein and Ui snRNP implicate them in early stages of spliceosome assembly 
agreeing with this interpretation. PRP6 protein is a U4/U6 snRNP component 
(Abovitch et al., 1990) and the reason for the increased RNA export in the 
temperature sensitive pip6 strain is unclear particularly as a temperature-sensitive 
prp8 mutant tested in the same way did not show export of unspliced pre-mRNA. 
One way in which the model in figure 1.4 may differ from the real", in vivo 
situation is in the way in which splice sites and introns are defined. Most work, both 
in vivo and in vitro has been on single intron constructs, the accepted view being that 
the intron is the unit being defined. Models of intron recognition have been proposed 
based around the recognition of a splice site followed by scanning downstream or 
upstream within the intron to find the other splice site. These fail on several counts. 
Firstly, in vitro it has been shown that two RNAs joined by base pairing can be 
spliced together (Konarska et al., 1985; Solnick, 1985b), this can not occur if linear 
scanning is used to define the important intron sequences. Secondly, aberrantly 
spliced transcripts have been found in vivo that have a jumbled exon order (Nigro et 
al., 1991; Cocquerelle et al., 1992) - again impossible if an intron scanning 
mechanism is working. Thirdly, the naturally occurring phenomenon of trans-splicing 
takes place through the joining of exons initially on separate pieces of RNA. Trans- 
splicing proceeds via the same reaction mechanism as cis-splicing, involves mostly 
similar or identical trans-acting factors and both cis- and trans-splicing can take place 
on the same transcript (Sharp, 1987; Agabian, 1990; Tschudi and Ullu, 1990). 
In higher eukaryotes there are usually many, sometimes extremely large, 
introns per transcript which must be correctly removed to leave the exons in the 
spliced product. Exons are often a very small proportion of the primary transcript, 
and those internal to a transcript appear to be limited in size to about 300 nucleotides 
suggesting that there might be some functional constraint on their length (Hawkins, 
1988). An alternative to intron based mechanisms, exon definition, has been proposed 
as a way of determining splice sites and the sequences to be retained in the mature 
transcript (Robberson et al., 1990). The exon definition model proposes that 
spliceosomal components assemble initially at the 3' end of an intron. This is 
followed by scanning/searching for a 5' splice site within a short distance (up to about 
300 bases) downstream. If no 5' splice site is found within this distance stable 
spliceosome assembly does not occur, if one is found then the complex is stabilised 
and the exon defined by it. Robberson et al. (1990) found that in vitro spliceosome 
assembly and splicing on a two exon construct was inefficient on substrates with a 
long second exon. Similar substrates with a 5' splice site at the 3' end of exon 2 
showed increased complex assembly and enhanced splicing unless the 5' splice site 
were greater than 300 bases from the 3' splice site of the intron, in which case 
splicing efficiency dropped. An in vivo test of exon definition was performed by 
Talenco and Berget (1990) using three exon constructs with identical intron and exon 
sequences. If the 5' splice site of the second intron was mutated then, instead of 
splicing of intron 2 being inhibited, an: exon 1 to exon 3 splice was seen, i.e. 
skipping of exon 2. Thus absence of a functional 5' splice site interfered with 
upstream 3' splice site recognition. Talerico and Berget (1990) examined known 
mutations in the 5' splice sites of internal exons and found that the most commonly 
reported phenotype was skipping of the upstream exon, lending support to what they 
had found with their experimental construct. 
The exon definition model allows for all the points mentioned above which 
argue against intron scanning. There are problems however, such as how are incorrect 
patterns of splicing suppressed to a low level? and how do the exon definition 
complexes rearrange to form spliceosomes across introns? In addition one has to 
propose different mechanisms for the definition of the first and last exons in the gene 
since they lack a 3' and 5' splice site respectively. 
It has been proposed that introns are spliced - or at least defined - during 
transcription (Aebi et al., 1986). This would at least partly explain fidelity in the 
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order of splicing of exons from transcripts containing many introns. Evidence in 
favour of this model are the electron microscopic data of Beyer and Ohsheim (1988), 
which showed probable stable snRNP assembly onto and splicing of transcripts during 
transcription. Stable snRNP assembly was more dependent upon transcription of the 
3' splice site than the 5' splice site. Recent in vitro results using substrates with more 
than one intron suggest that signals at both the 5' and 3' ends of transcripts - the cap 
structure and polyadenylation signal - affect splicing. Ohno et al. (1987) found that 
the presence of a cap structure led to preferential excision of the first intron before 
the second, and that without a cap splicing of the first intron was severely impaired. 
Niwa and Berget (1991) showed that in the absence of a functional polyadenylation 
site splicing of the ultimate intron was impaired. These points are consistent with the 
exon definition model with sequential recognition of splice sites during transcription 
and communication between factors interacting with splice sites of the first and last 
exon and the cap and polyadenylation site of the transcript respectively. 
In the context of the model shown in figure 1.4 exon definition requires a 
difference in the initial steps in the recognition of splice sites, but would not perturb 
late steps in spliceosome assembly or the splicing reaction itself. 
1.8 Summary. 
U!, U2, U5 and U6 snRNAs have a direct role in either defining the intron 
or forming the active site of the spliceosome. U4 snRNP and several protein factors 
control or monitor the progress of spliceosome assembly and its correct conformation 
through the splicing reaction. Several factors interact with the 5' splice site. The 
relatively loose binding of U 1 snRNP in assembled spliceosomes can be seen in its 
sensitivity to salt and heparin (Bindereif and Green, 1987) and may be due to it being 
displaced from the base pairing interactions that initially defined the 5' splice site. 
Other factors (eg U5, U6, PRP8) define the cleavage site. The fidelity of the splicing 
reaction may be maintained by the sequential recognition of intron sequences by 
several factors, the monitoring of particular structures or interactions during the 
reaction and directional change in spliceosome structure by irreversible ATP-driven 
conformational changes by the PRP2, PRP16 and PRP22 proteins. 
The discussion of the interactions in the spliceosome (section 1.6) is of 
necessity somewhat speculative as there is a paucity of physical data required to prove 
propositions from genetic data. Genetic interactions may be long range or indirect 
effects rather than intimate ones. However, genetic approaches are adding vastly to 
our understanding of the splicing process and give targets to aim at in physical studies 
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(as well as vice versa). What is most pleasing perhaps is that, where available, data 
from the different systems studied are generally consistent in details of the 
spliceosome assembly pathway and the reaction, showing the extreme conservation 
of the pre-mRNA splicing process. 
1.9 This Thesis. 
The aim of this thesis was to analyse the role of PRP8 protein in nuclear pre-
mRNA splicing. This was undertaken using three different approaches: inhibition of 
PRP8 function with antibodies in vitro; heat-inactivation of temperature-sensitive prp8 
protein in protoplasts; genetic depletion in vivo. The results of these investigations 
and their implications in understanding PRP8 protein function are discussed in the 
context of published data. I present: 
inhibition of splicing by antibodies against PRP8 protein and the accumulation 
of a pre-splicing complex in inhibited reactions. Detection of a change in the 
interactions of PRP8 protein in the spliceosome. 
outcrossing and mapping of temperature-sensitive prp8 mutations, and the 
development of a yeast strain in which production of PRP8 protein was dependent 
upon carbon source. 
the development of a protoplast heat-inactivation procedure, the demonstration 
that inactive extracts produced using this and genetic depletion in vivo were specific 
for PRP8 protein, and that in splicing reactions assembled with these extracts a pre-
splicing complex accumulated. 
a requirement for PRP8 function in the assembly of stable U4/U6.U5 tn- 
snRNPs and the stability of the U4, U5 and U6 snRNAs. 
the finding that in vivo depletion of U5 snRNA did not substantially affect the 
stability of PRP8 protein or other snRNAs. 
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CHAPTER 2. 
MATERIALS AND METHODS. 
2.1 MATERIALS. 
2.1.1 Suppliers of Laboratory Reagents. 
Standard laboratory reagents: Sigma, Fisons, BDH, Bio-Rad, Serva. 
Restriction endonucleases and other DNA modifying enzymes: Boehringer Mannheim, 
New England Biolabs, Pharmacia, Bethesda Research Laboratories. 
Radiochemicals: Amersham International. 
Deoxyribonucleotides and ribonucleotides: Pharmacia and Sigma. 
Acrylamide and NN'-methylene bisacrylamide: BDH Chemicals, "Electran" grade. 
Agarose: Bethesda Research Laboratories ultra-pure electrophoresis grade. 
Media reagents: Difco Labs, and Sigma. 
2.1.2 Growth Media. 
Unless otherwise stated quantities are for 1 litre volume. Solutions were 
autoclaved (section 2.2.2) and stored at room temperature. Antibiotics and amino 
acids were added to media immediately prior to use, being stored as filter sterilised, 
concentrated stocks. To make plates bacto-agar was added to 2% (w/v) prior to 
autoclaving. 
2.1.2.1 E.coli Media. 
Luria-Bertani medium (LB): lOg bacto-tryptone, 5g bacto-yeast extract, lOg NaCl, 
adjusted to pH7.2 with NaOH. 
LB-amp: LB containing 0. lg/l ampicillin. 
M9 medium: 6g Na2HPO4 , 3g KH2PO4, 0.5g NaCl, ig NIH4C1, 0.25g MgSO4 .7H20, 
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2g glucose, amino acids and/or other requirements to 20mg/i. 
2X YT: lOg bacto-peptone, lOg bacto-yeast extract, 5g NaCl. 
2.1.2.2 Yeast Media. 
YPDA: lOg bacto-yeast extract, lOg bacto-peptone, 20g glucose, 20mg adenine 
sulphate. 
YPGRA: YPDA with 20g each raffinose and galactose instead of glucose. 
YMM: 6.7g yeast nitrogen base without amino acids, 20g glucose, supplemented with 
amino acids etc. as required to 20mg/i. 
YMGR: YMM with 20g each raffinose and galactose instead of glucose. 
YMMCas/YMGRCas: YMM or YMGR plus lOg vitamin free casamino acids and 
20mg tryptophan (which is not supplied by the casamino acids). 
Pre-sporulation: 8g bacto-yeast extract, 3g bacto-tryptone, lOOg glucose. 
Sporulation: lOg potassium acetate, ig bacto-yeast extract, 0.5g glucose, 2mg each 
relevant amino acid etc.. 
2.1.3 Bacterial Strains. 
Strain NM522 (z(lac, pro), hsdz..5, supE, thi, F (lacJ,  lacZLiM15, pro); Messing 
et al., 1977) was used throughout. 
2.1.4 Yeast Strains. 
Table 2.1 Yeast Strains. 
Strain Genotype Reference/Origin 
BJ2412 a/a, ura3-52, leu2, trpl, gal2, E.Jones 
prbl-1 122, perl -407, pep4-3. Pittsburg. 
DBY745 a, adel -1 00, ura3-52, leu2. Legrain and 
Rosbash (1989). 
DBY746 a, ura3-52, leu2-3,-112, trpl-289, D.Botstein 
his3-Al. (M.I.T.). 
DBY747 a, otherwise as DBY746. Ditto. 
S150-2B a, ura3-52, leu2-3,-112 trpl-289, Wellcome. 
his3-L1. 
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Strain Genotype Reference/Origin 
JBY27 a, pip2-1, ade2, ura3, leu2-3,-112, trpl, J.Beggs (this 
his3-200, lys2-801, GAL. lab.). 
RY26 a, prp2-1, adel, ade2, ura3-1,-2, his7, R.Last (M.I.T.). 
tyrl, canR, GAL. 
DJY85 a/a, prp2-1, ura3, adel/ADE1, ade2, D.Jamieson 
trpl/TRP1, his3/HJS3, tyr11TYR1, (this lab.). 
lys2-801/LYS2, canh/CAN1. 
SPJ8.31 a, prp8-1, ura3-52, leu2, his3, GAL. S.Jackson 
(this lab.). 
RS219-4-2 a, prp8-1, ade, ural, leu2, lys2. L.Hartwell 
ts173 a, prp8-2, ade,l, ade2, ural, his 7, lyrl, Hartwell et al. 
lys2, gall. (1970). 
ts245 prp8-3, otherwise as ts173 Ditto. 
ts283 prp8-4, otherwise as ts173 Ditto. 
ts295 prp8-5, otherwise as ts173 Ditto. 
DJY75 a, prp8-7, ura, leu2-3,112, his. D.Jamieson 
(this lab.). 
DJY76 a, prp8-7, ura3-52, leu2-3,-112, his, lyrl. D.Jamieson 
(this lab.). 
JMY196a a, prp8-8, ura3-52, leu2-3,-112, trpl-289, J.Morran 
his3-Al, GAL. (this lab.). 
J17 a, prp9-1, adel, ade2, ural, his7, tyrl, J.Warner 
lys2, gall. (New York). 
J93 a, prp9-1, ade, ura, leu, tip, arg. Ditto. 
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Strain Genotype Reference/Origin 
BSY1 19 a, ade2, ura3-52, 162-3,412, trpl -289 B. Seraphin 
arg4, snR7::LEU2, pBS202. (Heidelberg; 
Seraphin et al., 
1991) 
2.1.5 Plasmid Vectors and Constructs. 
Table 2.2 Plasmid vectors and constructs. 
Plasmid Description Reference/Origin 
pBR322 General purpose E. coil cloning vector; amp', tel'. Bolivar et al. 
(1977). 
pAT153 Derivative of pBR322 lacking a 622bp HaeII Twigg and 
fragment encompassing the MOB and BOM sites; Sherratt (1980). 
amp', tel'. 
pUC 19 General purpose E. coil cloning vector with Norrander et al. 
multiple cloning site in LacZ a-peptide fragment; (1983). 
amp'. 
pTZ18R Phagemid vectors with multiple coding sites in Pharmacia. 
pTZ19R lacZ c-peptide fragment. F1 origin allows 
synthesis of single-stranded DNA; amp'. 
pFL38 Yeast plasmid based on pUC19, low copy Bonneaud et al. 
number; ARS, CEN, UR..43. (1991). 
pFL44S Yeast plasmid based on pUC19, high copy Ditto. 
number; 2j, URA3. 
YEP13 Yeast plasmid, high copy number; LEU2, ARS. Broach et al. 
(1979). 
pRS313 Yeast plasmid based on pBluescript, low copy Sikorski and 
number; ARS, CEN, HIS3. Hieter (1989). 
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Plas mid Description Reference/Origin 
pRS3 15 Yeast plasmid based on pBluescript, low copy Ditto. 
number; ARS, CEN, LEU. 
pRS3 16 Yeast plasmid based on pBluescript, low copy Ditto. 
number; ARS, CEN, URe43. 
pBM125 Yeast plasmid, low copy number containing a Johnson and 
0.81kb EcoRI-BamHl fragment containing the Davis (1984). 
GAL1-10 promoter region. The BamHI site is 
downstream of the GALl transcription start but 
before the GALl ATG; ARS, CEN, URA3. 
pRY21 pBR322 containing a 365bp DdeI-Sau3AI R.Yocum. 
fragment of GALl-JO promoter containing the 
UAS. 
pY8000 YEp24 containing the entire PRP8 gene on a Jackson et al. 
9.0kb insert. (1988). 
pY8500 YCp5O containing the entire PRP8 gene on a Jackson et al. 
12kb insert. (1988). 
pYA301 pBR322 containing the yeast actin gene. a 103 8bp Gallwitz and 
BamHI-BglII fragment containing El, IVS-1 and Sures (1980). 
part of E2 was used as a probe in Northern blots. 
pT7rp28s pSPT19 containing most of the yeast RP28 gene. M.Lossky (this 
Used to make in vitro transcripts of most of El, lab.). 
IVS-1 and E2 after linearisation with EcoRI. 
pSPrp51A SP6 transcription vector containing part of the Pikielny and 
yeast RP51 gene (including IVS1) and a poly-A Rosbash (1986). 
tail at the 3' end. Used to make in vitro 
transcripts after linearisation with BamHI. 
pFN-1 Yeast snR7 gene with a phage T7 gene 10 G. Anderson (this 
promoter at the 5' end cloned into pEMBL8(+). lab.). 
pTaq6 pUC1 18 containing a 242bp fragment of the yeast D.Brow. 
snR6 gene and it's promoter. 
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Plasmid Description Reference/Origin 
pTZ18U4G pTZ18R containing the yeast snR14 gene. M.Dalrymple 
(this lab.). 
"Ui pBluescriptKS 	containing the yeast snR19 gene A.Newman 
clone" on a 1.3kb KpnI-HindIII fragment. (Cambridge). 
pJK2 pBR322 with the unique Hindlil site deleted J.Keddy (this 
containing the N-terminal Sall fragment of PRP8 lab.). 
with an MzeI site introduced at the 5' end (see 
figure 3.1). 
pJK3 pJK2 with a 228 base pair in frame deletion from J.Keddy (this 
NheI to XbaI at the 5' end of the PRP8 coding lab.). 
sequence. 
2.1.6 Synthetic Oligodeoxynucleotides. 
All oligonucleotides were synthesised at the OSWEL DNA service, Edinburgh. 
Table 2.3 Oligodeoxynucleotides. 
Name Sequence (5' -3') 	—T—Information 
486A CrF AAG GTA AGT AT Complementary to 5' end of yeast U! snRNA. 
626C CTA CAC TTG ATC TAA Complementary to an internal region of yeast 
0CC AAA AGG C U2 snRNA. 
483A CCG TOC ATA AGO AT Complementary to the 5' end of yeast U4 
snRNA. 
485A AAT ATG GGC AAG Complementary to an internal region of yeast 
CCC U5 snRNA. 
6A TCA TCT CTG TAT TG Complementary to an internal region of yeast 
U6 snRNA. 
O1OA GTG ACC ATG GCA Sense strand - 100 bases upstream of the PRP8 
GAA OGA TO gene ATG. 
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Name Sequence (5'-3') Information 
013A AGG TAG CAA CTA Antisense strand - 100 bases downstream of the  
CGA CGG GC PRP8 gene stop codon. 
089E TAT GCC AGA TCT Partially complementary oligonucleotides to 
GCA place a BglII site between the Hindlil and NdeI 
sites in the PRP8 promoter to allow cloning of 
090E AGC TTG CAG ATC the GALJ-10 UAS as a HindIII-BglII fragment 
TCG CA from pRY21. 
228G TAG CTA GCC CAC Used to PCR the GALl-JO promoter region 
TCA TCT TGA CGT TAA from pBM 125 with an XhoI site at the GAL1O 
AGT ATA GAG end and a sequence linking the promoter to the 
start of the PRP8 gene at the other. 
229G CAC TCG AGC TGA 
GCT GTC ATF TAT ATF 
G 
060L CGA OGA TCC CAT Used to PCR the yeast snR20 gene from 
AlT TGG TTG CGT GGT genomic DNA with EcoRI and BamHI sites at 
A the 5' and 3' ends respectively. The gene is 
amplified with the EcoRI site immediately 
061L AGG GAA TFC ACG upstream of the 5' end and the BamHI site —90 
AAT CTC TV!' GCC TTT bases downstream of the end of the gene. 
TG 
MV 
2.1.7 Antisera and Antibodies. 
Antibodies used are listed in table 2.4. Figure 3.1 shows a map of the PRP8 
gene, the regions used to make fusion proteins and the sequence of the peptide used 
in generating anti-8.6 antibodies. 
Table 2.4 Antisera and Antibodies. 
Antiserum or 
Antibody 
Antigen Raised Against Origin 
anti-8. 1 PRP8 fusion protein 8.1 This lab., Jackson et al. (1988). 
anti-8.2 PRP8 fusion protein 8.2 This lab., Jackson et al. (1988). 
anti-8.3 PRP8 fusion protein 8.3 This lab., Lossky et al. (1987). 
anti-8.4 PRP8 fusion protein 8.4 This lab., Lossky et al. (1987). 
anti-8.6 PRP8 amino-terminal peptide 
(35 amino acids) 
This lab., G.Anderson. 
anti-M3G 2,2, 7-trimethylguanosine R. Lührmann (Marburg) 
Lührmann et at. (1982). 
anti-PAB poly(A)-binding protein This lab., Whittaker et al. (1990). 
2.1.8 Markers. 
Size markers for nucleic acid and protein electrophoresis were as follows: 1kb 
ladder markers (BRL; catalogue number 56155A) were used for agarose gel 
electrophoresis of DNA and RNA; Sigma pre-stained protein markers (catalogue 
number SDS-7B) or high molecular weight markers (SDS-6H) were used for SDS-
PAGE electrophoresis of proteins. 
2.1.9 Buffers. 
1OXTAE: 	0.4M Tris-acetate pH7.5, 20mM EDTA. 
1OXTBE: 0.9M Tris-borate pH8.3 20mM EDTA. 
1OXTB: 	0.9M Tris-borate pH8.3. 
10XPBS: 15mM K}{2PO4 , 80mM K2HPO4, 1.5M NaCl pH7.2. 
1OXTBS: 	0.5M Tris-HC1, 1.5M NaCl pH7.5 
20XSSC: 3M NaCl, 0.3M tn-sodium citrate pH7.0. 
2.2 GENERAL METHODS. 
2.2.1 General Guidelines. 
I have listed many methods here as step-by-step protocols with comments and 
notes where applicable. This, I hope will make them easy to follow - and hence easily 
reproducible - should anyone wish to refer to my thesis for methods, and also 
provides me with an easy to follow protocol manual for my own use. Where methods 
have followed a published protocol exactly or a manufacturer's recommended protocol 
I have cited it rather than writing the method out in detail. 
Unless otherwise stated: All procedures were carried out at room temperature. 
All small-scale procedures were performed in sterile 1 .5m1 polypropylene microfuge 
tubes (Treff), larger scale procedures were carried out in 15ml or 30ml sterile Corex 
tubes or lOmi Sterilin tubes or 50m1 Falcon tubes (Sterilin and Falcon tubes were 
sterile when purchased). 
Centrifugation of small volumes (1.5m1 or less) was carried out in an 
Eppendorf benchtop microcentrifuge at 14000 rpm, and volumes up to 50m1 were 
centrifuged in an IEC CENTRA-4X bench-top centrifuge at 4500 rpm in a 215A 
swing-out rotor. High speed centrifugation of volumes greater than 1 .5m1 was 
performed in a Sorvall RC-5B Superspeed centrifuge (GS-A, GS-3, SS34 or HB-4 
rotor) or Sorvall OTD50, 55 or 65B ultracentrifuge (Du Pont) with the appropriate 
Sorvall rotor and speed as indicated. 
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2.2.2 Sterilization Procedures. 
When necessary plastics (such as microfuge tubes) and solutions were 
sterilized by autoclaving for 20mins. at 120 °C and 15 pounds/inch 2 . Certain solutions 
which could not be sterilized in this manner, such as DTT, tryptophan, and antibiotics 
etc. and solutions made in small volumes, were sterilized by filtration through a 
disposable Acrodisc filter unit (0.45 micron size; Gelman Sciences). 
Corex tubes, glass pipettes and other glassware were dry-sterilised by baking 
at 2500C for 16hrs, a procedure which inactivates ribonucleases. 
2.2.3 Deionisation of Solutions. 
Solutions of formamide, acrylamide and glyoxal were deionised by mixing 
with 0.1-0.2 volumes of analytical grade mixed-bed resin (20-50 mesh; Bio-Rad 
Laboratories) for 30mins. The resin was removed by filtration through Whatman 
No.1 filter paper. Glyoxal was stored in microfuge tubes at -70 °C in lOOjtl aliquots, 
acrylamide and formamide were stored at 4 °C. 
2.2.4 Autoradiography. 
[32P]-labelled nucleic acids were detected by exposing X-ray film (Du Pont 
Cronex or Amersham Hyperfilm-MP) to gels and filters in light-proof, lead-shielded 
cassettes by one of the following methods, depending on the amount of radioactivity 
present: (in order of increasing sensitivity) (i) at -70 °C; (ii) at -70 °C with a calcium-
tungstate intensifying screen; (iii) with pre-flashed film at -70 °C with an intensifying 
screen. 
[35S]-labelled DNA and protein was detected by exposure of X-ray film (Du 
Pont Cronex) to gels at room temperatures without an intensifying screen. 
2.2.5 Photography. 
Photography of agarose gels containing nucleic acids stained with ethidium 
bromide was carried out by exposing Polariod 667 professional film to the gel with 
the nucleic acid visualised by short-wave length ultraviolet light (254) from a 
transilluminator (UV Products). 
2.2.6 Densitometry. 
Quantitative comparisons of radiolabelled nucleic acids were performed by 
densitometric scanning of autoradiographs with a Shimadzu Dual-Wavelength 
Chromato Scanner, model CS-930 (Howe, London), according to the manufacturer's 
operating instructions. 
2.3 MICROBIOLOGICAL METHODS. 
2.3.1 Propagation and Storage of Bacteria. 
Growth and storage of E. coil were carried out as in Maniatis et al. (1982). 
2.3.2 Preparation of Competent E.coli, and Transformation. 
Based on the method of Hanahan (1983). 
Inoculate 500mls of LB with 1 ml of a stationary phase culture of NM522. 
Grow to OD6w 0.3-0.4. 
Chill culture by placing on ice for 15-30mins. Harvest cells at 4 °C and 
resuspend in lOOmis ice cold 75mM CaCl2-  Incubate on ice for 30mins. 
Spin cells down again at 4 °C and resuspend in 20mls (4% original volume) 
TFBII. Incubate on ice for 30mins. 
Cells are now competent for DNA uptake and can be used immediately or 
rapidly frozen in liquid nitrogen and stored at -70 °C. 
Aliquot cells into 200l volumes, add DNA (about 50- lOOng plasmid, or 
a portion of a ligation mixture) and incubate on ice for 20mins. 
Incubate at 42 °C for 2-3 mins, place on ice for Smins. 
Add lml LB and incubate at 37 0C for lhr to allow expression of the 
antibiotic resistance gene. 
Plate aliquots onto LB-amp plates. If necessary IPTG and X-Gal are 
included in the plates (50 and 60j4g per 10cm plate respectively) to allow 
identification of 0-galactosidase minus (recombinant plasmid containing) colonies by 
their white rather than blue appearance. 
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Buffers: 
TFBII - 10mM MOPS (pH6.8, adjusted with KOH), 10mM RbCI, 75mM CaCl2 , 15% 
(v/v) glycerol. 
2.3.3 Propagation and Storage of Yeast. 
Yeast was grown and stored as described in Rose et al. (1990). Dissection of 
asci was carried out using a Singer MSM microdissector (Singer Instrument Co.) 
2.3.4 Transformation of Yeast. 
Yeast transformation was carried either by the method of Ito et al. (1983; 
below), or by electroporation using a geneZAPPER (IBI) according to the 
manufacturer's instructions. 
Grow lOOml culture in the appropriate medium to OD 6 0.4-0.6. 
Harvest cells and wash with 20m1 sterile dH 20. Re-sediment and resuspend 
in 5m1 dH20. Add 208pi 2.5M lithium acetate and incubate with gentle mixing at 
room temperature for Mr. 
Aliquot into 200l volumes and add l-lO/Lg DNA in a volume of 1001d 
sterile dH20. Incubate at room temperature for 30mins. 
Add 0.7m1 freshly prepared sterile 50% (w/v) PEG-4000. Mix, leave for 
lhr at room temperature. 
Incubate at 42°C for Smins, wash cells in 1 ml sterile dH 20 and plate onto 
medium selecting for cells that contain the plasmid. 
2.4 NUCLEIC ACID METHODS. 
2.4.1 General. 
Many standard DNA and RNA manipulations were carried out either 
according to Maniatis et al. (1982) or according to enzyme and equipment 
manufacturers' instructions. These included: quantitation of nucleic acids by 
spectrophotometric or ethidium bromide fluorescence; deproteinisation of nucleic acid 
solutions with phenol/chloroform (phenol was glass distilled grade, water-saturated; 
Rathbum Chemicals); precipitation of nucleic acids with ethanol; restriction 
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endonuclease digestion of DNA; agarose gel electrophoresis of DNA; isolation of 
DNA fragments from agarose gels (using the Geneclean kit; Bio 101); filling in 
recessed 3' ends of DNA; dephosphorylation of DNA; ligation of DNA fragments. 
All DNA and RNA solutions were stored in sterile distilled water (dH 20) unless 
otherwise stated (DNA at 4 °C, RNA at 1-200C). 
2.4.2 Plasniid DNA Preparations. 
2.4.2.1 Small Scale. 
Based on the method of Birnboim and Doly (1979). 
Inoculate 5mls LB-amp with a single bacterial colony and incubate at 37 °C 
with shaking overnight or for 8hrs during the day. 
Harvest 1 .5mls of the culture in an eppendorf tube in a benchtop microfuge 
for 1mm. 
Discard the LB-amp, resuspend in 100d solution A and incubate at room 
temperature 3-5 mins. 
Add 20041 solution B, mix gently by inversion and incubate on ice 3-5mins. 
Add 150d solution C, mix by vortexing briefly and incubate on ice 3-
5mins. 
Spin out the cell debris, Smins in a benchtop microfuge and transfer the 
supernate to a fresh tube. 
Extract once with phenol/chloroform, add lml absolute ethanol at 4 °C, mix 
by inversion and spin at 4 °C in a benchtop microfuge for 15mins. 
Wash the pellet once with 70% (v/v) ethanol, dry (in a vaccum desicator) 
and dissolve in 301d sterile dH 20. 
Buffers: 
50mM glucose, 25mM Tris-HC1 (pH8.0), 10mM EDTA, 1mg/mi lysozyme 
(Sigma) added just before use. 
0.2M NaOH, 1% (w/v) SDS (made up fresh). 
3M sodium acetate pH5.3. 
54 
2.4.2.2 Medium Scale. 
This is essentially a scaled-up version of the small scale plasmid preparation 
above. However, as this was used as the standard plasmid DNA preparation method, 
the DNA being stored at 4 °C for long periods of time, care was taken to extract as 
much protein as possible to remove DNases, and an RNase A step is included to 
remove RNA from the preparation. 
Steps 1) - 8) as small scale preparation except: 
Inoculate 50mls LB-amp and harvest all in a 50m1 Falcon tube after 
growing to stationary phase. 
Volumes of solutions: A - 2mls; B - 4mls; C - 3mls; 100% ethanol - l8mls. 
Replace the single phenol/chloroform extraction with 1X phenol and 2X 
phenol/chloroform extractions. 
All sedimentations are carried out in an IEC CENTRA-4X benchtop 
centrifuge except the final DNA sedimentation which is in an HB-4 rotor at 12krpm 
in 30m1 corex tubes. 
Dissolve the DNA pellet in 0.5m1 dH20. 
Add RNaseA to 0.2jg/jz1 and incubate at 37 °C for lhr. 
Extract once with phenol and then with phenol/chloroform until the 
interface is clear. Extract once with chloroform and then precipitate with ethanol. 
Wash pellet with 70% (v/v) ethanol, dry (vacuum desiccator) and dissolve 
in 2501d sterile dH20. 
This method routinely yielded 100-200jg of plasmid DNA. 
2.4.2.3 Large Scale. 
The large scale preparation of plasmids purified by centrifugation to 
equilibrium in caesium chloride-ethidium bromide gradients was only used for 
plasmids to be used for in vitro transcription reactions where the purity of the DNA 
was important to ensure that there was no contaminating RNase. The alkali lysis 
method in Maniatis et al. (1982) was used. 
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2.4.3 Yeast Genomic DNA Preparation. 
This method gave DNA that was sufficiently clean and intact for PCR 
reactions, restriction digestion and Southern blotting. All manipulations of DNA 
solutions were carried out using Gilson tips with the end cut off to give a wider 
aperture and hence decrease shearing forces during pipetting. 
Grow 200mls cells in the appropriate medium to OD 6 0.5-0.7. 
Harvest cells, wash once in 50mM EDTA and harvest again. 
Resuspend in 5mls buffer f.-S, incubate at room temperature for 1 .5hrs with 
shaking. 
Harvest cells and resuspend in lyticase buffer. Add 0.2mls lyticase at 
2500U/ml. Incubate 30mins-lhr at 30 °C with gentle shaking. Check sphaeroplast 
formation. 
Wash cells 3 times in 1.2M sorbitol and to last wash add 40mM EDTA 
(final concentration). Spin cells down slowly (2-3krpm) each time and resuspend 
gently. 
Resuspend cells in 2mls lysis buffer. Add 10Og proteinase K and SO/Li 
20% (w/v) SDS. Incubate at 37°C with gentle shaking for lhr then incubate at 65 °C 
for 30mins without shaking. Cool to room temperature. 
Extract with phenol and back extract the phenol phase with 1 ml dH 20. Pool 
the aqueous phases and extract with phenol/chloroform until the interface is clear. 
Add 1/10th volume 3M sodium acetate (jH5.3) and 2.5 volumes of cold 
ethanol mix gently by inversion. Spin lOkrpm 15mins. 
Wash the pellet once with 70% (v/v) ethanol, air dry and resuspend in 
0.5m1 0. 1X SSC, leaving to dissolve at 4 °C. 
Add RNase A to 50/hg/ml, incubate at 37°C for lhr then extract once with 
phenol/chloroform. 
Repeat step 8) but harvest the DNA by spooling on a Gilson tip (200/Al 
size) melted at the end to form a blob. 
Redissolve DNA at 4 °C in 200.d 0. 1X SSC. When DNA has dissolved 
make up to 1X SSC. 
Buffers: 
13-S: 1.2M sorbitol, 25mM EDTA (pH8.0), plus 0.225ml 0-mercaptoethanol to 5mls 
added immediately before use. 
Lyticase buffer: 1.2M sorbitol, 50mM KPO 4 (pH7.5), 30mM DIT added just prior 
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to use. 
Lysis buffer: 0. 15M NaCl, 0. 1M EDTA (pH8.0). 
2.4.4 Extraction of RNA from Yeast. 
Grow 200m1 culture in the appropriate medium to OD 6 0.4-0.7. 
Swirl culture in 250m1 Sorvall pots in ice-water bath to chill, harvest at 
5krpm 5mins in GS-A rotor at 40C. 
Wash cell pellet in lOmi TNE (cold), transfer to 15m1 corex tube and spin 
down. 
Resuspend in lml TNE, add approximately 0.3m1 glass beads and vortex 
vigorously for 1mm. 
Add 3m1 TNE, 0.2m1 20% (w/v) SDS, 4m1 phenol and vortex again for 
1mm. 
Transfer aqueous phase to a fresh tube and re-extract with 4m1 
phenol/chloroform. Repeat, transfering the aqueous phase to a fresh tube each time 
until the interface is clear (2 or 3 extractions are usually sufficient). 
Extract once with chloroform and precipitate with ethanol. 
Spin at 12krpm in an HB-4 rotor at 4 °C for 15mins, wash pellets with 70% 
(v/v) ethanol, air dry and dissolve in 150jzl sterile dH 20. Store at -20°C. 
Buffers etc.: 
TNE: 50mM Tris-HC1 (pH7.5), 5mM EDTA, 100mM NaCl. 
Glass beads (100 mesh; BDH) should be boiled for 20mins in 1M HCl, 
allowed to cool, washed extensively in dH 20 and then dried and baked at 250°C for 
l6hrs. 
Notes: 
If it is not convenient to extract RNA from cells immediately after 
harvesting they can be stored at -20 °C in ethanol and washed once TNE before 
proceeding with the extraction (at step 4). 
For smaller volumes of culture scale down the amounts of TNE etc. 
proportionately. 
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2.4.5 Labelling Restriction Fragments by Random Priming. 
Modified from Feinberg and Vogeistein (1984). 
Digest 2-1014g plasmid DNA to completion and electrophorese through an 
agarose gel to separate the fragments. 
Cut out the required restriction fragment and purify using Geneclean 
procedure. 
Run out a small amount of the fragment on an agarose gel to assess the 
concentration. 
Store the fragment at 4 °C. 
Set up oligolabelling reaction mix as follows: 50-100ng fragment made up 
to 35d with dH20 boiled 3-5mins and then cooled on ice; lOj.d OLB; 2d BSA at 
10mg/mi; 31.d [c 32P]dCTP at lOmCi/ml; 2 units DNA polymerase 1 Kienow 
fragment. 
Incubate at room temperature for 6-8hrs or overnight. 
Separate the labelled DNA from the unincorporated nucleotides by passing 
the reaction mix over a gel exclusion column (a NAP-5 column (Pharmacia) was 
used) equilibrated with 10mM sodium phosphate (pH7.0). 
Buffers: 
OLB: Make from the following: 
*Solution 0: 1.25M Tris-HCI (pH8.0),0.125M MgC1 2 . 
#Solution A: imi solution 0, 18il /3-mercaptoethanol, 5l each dATP, dTTP and 
dGTP at 0. IM. 
*Solution B: 2M Hepes (pH6.6 with 5M NaOH). 
#Solution C: Hexadeoxyribonucleotides (Pharmacia) at 90 OD units/ml in dH 20. 
Mix A:B:C in the ratio 1:2.5:1.5 to make OLB#. 
(* = store at 4°C, # = store at -20°C) 
W. 
2.4.6 5'-end Labelling of Oligodeoxynucleotides. 
Oligodeoxynucleotides to be used as probes on Northern blots were 5'-end 
labelled by addition of a radiolabelled phosphate group to the 5' hydroxyl group 
present on the molecules using T4 polynucleotide kinase and ['y 32P]ATP (3000 
Ci/mmol). 
Assemble the following reaction mix: 20pmol oligonucleotide; 3JLl 1M Tris-
HC1 (pH8.0); 1.51l 0. 1M DTT; 11 0.3M MgC12 ; 20Ci [y32P]ATP; sterile dH20 to 
30d. 
Add 5U T4 polynucleotide kinase, incubate at 37 °C for lhr. 
Separate the labelled oligonucleotide from the unincorporated label by 
passing the reaction mix over a gel exclusion column (a NAP-5 column (Pharmacia) 
was used) equilibrated with 10mM sodium phosphate (pH7.0). 
2.4.7 In vitro Transcription. 
T7 and SP6 polymerase-directed in vitro transcription reactions were 
performed essentially as described by Davanloo et al. (1984) and Melton et al. 
(1984). Plasmids from which pre-mRNA was transcribed are listed in table 2.2. 
Set up reaction mix containing : 0.2kg linearised plasmid DNA (taken 
directly from a restriction endonuclease digest) ljl lOX reaction buffer, lzl 
nucleotide mix, 10 Units RNasin (Promega), dH 20 to 9.5/Al. 
Add 0.5z1 T7 or SP6 RNA polymerase and incubate at 37 °C for 20-30mins. 
Stop reactions on ice. 
Clean the transcript: add 90d sterile dH 20, phenol/chloroform extract, back 
extract the phenol/chloroform once with 50d sterile dH 20. 
Add 20al 7.5M ammonium acetate, ll 20mg/mi E.coli tRNA, 4501d 
ethanol at 4°C. Mix and spin at 4°C for 20-30mins. 




T7 lox buffer:400mM Tris-HC1 pH8.0 SP6 lOX buffer: 400mM Tris-HC1 pH 7.5 
100mM MgC12 	 60mM MgC12 
100mM DTF 100mM DTf 
100mM NaCl 
Nucleotide mix: 5mM each ATP, GTP, CTP, UTP (Pharmacia, T7 Grade). 
Radiolabelled transcripts were made by including 3014Ci [a- 32P]UTP (800Ci/mmol) 
in the reaction and reducing the cold UTP concentration to 0.25mM in the nucleotide 
mix. 
Notes: 
For some experiments full-length transcripts were purified by running on a 6% 
(w/v) denaturing acrylamide gel, cutting out the full length transcription product 
(visualised by autoradiography) and eluting using a unidirectional electroelutor (model 
UEA; IBI) according to the manufacturer's instructions. 
2.4.8 Denaturing Polyacrylamide Gel Electrophoresis of DNA AND RNA. 
DNA and RNA were electrophoresed through denaturing acrylamide gels. 
Fragments smaller than 50 bases were electrophoresed through 10% (w/v) 
acrylamide, 8M urea gels, larger fragments through 6% (w/v) acrylamide, 8M urea 
gels. Gels for running DNA samples contained 1X TB buffer, gels for RNA 1X TBE. 
2.4.9 Denaturing Agarose Gel Electrophoresis of RNA. 
This method is a modified version of that of McMaster and Carmichael 
(1977). 
Prepare a 1.2-1.5% (w/v) agarose gel in 10mM sodium phosphate (pH7.0). 
Denature 1 volume RNA (20-50g total yeast RNA will give a good signal 
for most transcripts) for lhr with 4 volumes of glyoxal mix (treat size markers 
similarly). 
Load RNA samples into wells without covering the gel with running buffer 
and run samples in before covering the gel. 
Run at 1OV/cm mixing the buffer, occasionally. 
Buffers: 
Glyoxal mix: 100j.d glyoxal, 250d formamide, 1OJLI 0.5M sodium phosphate (pH7.0), 
40d dH20 (make up fresh before using). 
Running buffer: 10mM sodium phosphate (pH7.0). 
2.4.10 Capillary Blotting of DNA AND RNA. 
Southern and Northern blotting of agarose gels containing DNA or RNA was 
onto Hybond-N nylon membrane (Amersham) as recommended in the Amersham 
"Membrane Transfer and Detection Methods" booklet. After transfer Northern blots 
were deglyoxylated by baking at 80 °C for Mr. RNA and DNA were fixed to the 
membrane by exposure to UV light in a UV Stratalinker 1800 (Stratagene) using the 
auto-crosslink setting. 
2.4.11 Electroblotting of RNA from Polyacrylamide Gels. 
RNA electrophoresed through denaturing acrylamide gels was electroblotted 
onto Hybond-N membrane (Amersham) in a Trans-Blot Electroblotting Cell (Bio Rad) 
with plate electrodes. The acrylamide gel was lifted onto blotting paper. A sheet of 
Hybond-N membrane was placed against the gel, care being taken to avoid air 
bubbles. The gel and membrane were then assembled into a sandwich between several 
sheets of blotting paper pre-wetted with 0.5X TBE buffer and scotchbrite pads in the 
Trans-Blot gel holder. Transfer was for 30mins at 60V in 0.5X TBE buffer. RNA 
was fixed to the membrane by exposure to UV light in a UV Stratalinker 1800 
(Stratagene). 
2.4.12 Hybridisation of Southern and Northern Blots with Random Primed 
Probes. 
Northern and Southern blots were hybridised in bottles in a Hybaid 
hybridisation oven used according to the manufacturer's instructions. Pre-
hybridisation, hybridisation and washing were as below, probes were made as in 
section 2.4.5: 
Pre-hybridise at 42°C for 6-8hrs in 1X"P" Buffer, 50% (v/v) formamide, 
1M NaCl, l0g/ml denatured sonicated salmon sperm DNA (Stratagene). 
Add probe denatured by boiling for 5mins and chilled on ice. 
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Allow hybridisation to proceed overnight at 42 °C. 
Wash the membrane (still in the bottle) sequentially with 
2XlOmins. at 42 °C with lOOmis. 2X SSC. 
2X30mins. at 65 °C with lOOmis. 2X SSC + 0.5% (w/v) SDS. 
2X30mins. at room temperature with lOOmls. 0. 1X SSC. 
Blot the membrane on filter paper to remove excess liquid, cover in Saran 
Wrap and expose to X-ray film. 
Buffers: 
5X "P" Buffer: 1% BSA, 1% PVP (M.Wt. 40kDa), 1% Ficoll (M.Wt. 400kDa), 
250mM Tris-HC1 pH 7.5, 0.5% (w/v) sodium pyrophosphate, 5% (w/v) SDS. 
2.4.13 Hybridisation of Northern Blots with Oligodeoxynucleotide Probes. 
An adaption of the method of Church and Gilbert (1984) was used to probe 
Northern blots for snRNAs and for URA3 locus transcripts. As with other 
hybridisations these were carried out in bottles in a Hybaid hybridisation oven. Probes 
were labelled as in section 2.4.6. 
Pre-hybridise the membrane for 20-30mins in 7% (w/v) SDS, 0. 5M sodium 
phosphate (jH7.0), 1mM EDTA at 28 °C. 
Remove the buffer and add the probe in fresh buffer (this is necessary to 
maintain the correct concentration of SDS and sodium phosphate in the buffer). 
Hybridise overnight at 28 °C. 
Wash the membrane 3XlOmins in 5% (w/v) SDS, 0.5M sodium phosphate 
(pH7.0), 1mM EDTA. 
Blot the membranes ky  on filter paper, wrap in Saran Wrap and expose 
to X-ray film. 
Note: If the membrane is not blotted dry then the oligonucleotides will gradually 
diffuse away from the sites of hybridisation if left at room temperature. 
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2.4.14 Polymerase Chain Reaction (PCR). 
This is a general protocol used in all reactions. The usual yield was 1-2/Lg 
amplified fragment from 1-10ng plasmid or 1-2/Lg yeast genomic DNA. 
Set up reaction mix as follows: 10jd lox reaction buffer (supplied with 
enzyme); 101d 2.5mM each dNTP; 41d each oligonucleotide at 0.1 OD unit/jzl; DNA; 
dH20 to 991. 
Add enough paraffin oil to cover the surface of the mix. 
Run section 1 of the PCR programme, add i/Li Taq polymerase and run 
section 2 of the programme. 
PCR programme. 
All reactions were run on a Hybaid Thermal Reactor using the following programme: 
95°C 3mins, hold at 45°C until the polymerase is added. 
30 cycles of 92°C 1mm., 45°C 1mm., 72°C 3mins. 
(If either of the oligonucleotides used had a T. of less than 50 °C then the 45°C step 
was altered such that it was 5°C less than the T. of the oligonucleotide.) 
2.4.15 Sequencing. 
All sequencing reactions were carried out using the Sequenase version 2.0 kit 
(USB) according to the manufacturers instructions. Templates for the reactions were 
either single stranded preparations of pTZ clones (pTZ18R and pTZ19R; Pharmacia), 
PCR products or plasmids (see below for preparation of templates). Products of 
sequencing reactions were run on 6% (w/v) denaturing polyacrylamide gels in lx TB 
buffer, fixed in 10% (v/v) methanol 10% (v/v) acetic acid for 20mins at room 
temperature and dried on a vacuum gel drier (Bio-Rad). 
2.4.15. 1 Preparation of Single Stranded pTZ Templates. 
Grow N1M522 containing the recombinant pTZ clone overnight in M9 
medium plus thiamine and ampicillin. 
Inocculate l.Sml 2XYT with 301ti of the overnight and grow at 37 °C for 
lhr with vigorous shaking. 
Add 4.51i M13K07 helper phage and continue to grow at 37 0C for 6hr 
with vigorous shaking. 
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Transfer to a microfuge tube and pellet the cells. 
Transfer imi supemate to a fresh tube, add lSOpi PEG/NaC1 and incubate 
at room temperature for 20mins. 
Spin for lOmins, discard any tubes with no visible (phage) pellet. 
Remove supemate carefully making sure to remove all of it. 
Resuspend pellet in lOOjzl dH 20 and extract twice with phenol/chloroform. 
Precipitate with ethanol, wash in 70% (v/v) ethanol and dry the pellet. 
Dissolve in 251fl sterile dH20 and use 7l in annealing step of the 
Sequenase reaction. 
Buffer: PEG/NaC1: 20% (w/v) PEG 6000, 4M NaCl. 
Note: M13K07 helper phage was prepared as recommended by the supplier 
(Pharmacia). 
2.4.15.2 Preparation of Double Stranded Templates. 
PCR products and plasmids to be used directly for "double-stranded" 
sequencing were treated as below before use in the sequenase reaction. 
Clean the DNA (about lg PCR product or 2g plasmid) using the 
Geneclean kit (IBI) and resuspend in S/LI dH 20. 
Add 0.61.4l 1M NaOH and incubate at room temperature for lOmins. 
Add 0.641 1M HC1, 2/LI 5X Sequenase reaction buffer, l/Ll primer (at 
O.Spmol/jzl), 0.81d dH20 as drops on the side of the tube. 
Spin down and incubate at 37 °C for 15mins to anneal primer. 
(3o directly to Sequenase sequencing reactions. 
Buffer: Sequenase buffer (5X): 200mM Tris.HC1 pH7.5, 100mM MgCl 2 , 250mM 
NaCl. 
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2.5 PROTEIN AND IMMUNOLOGICAL METHODS. 
2.5.1 Quantitation of Proteins. 
Estimates of protein concentration were carried out using the Bradford assay 
(Bradford, 1976) with a dye concentrate purchased from Bio-Rad and used as 
recommended by them. Standard curves were generated using BSA. 
2.5.2 SDS-Polyacrylamide Gel Electrophoresis of Proteins. 
Proteins were separated by SDS -discontinuous poylacrylamide gel 
electrophoresis (SDS-PAGE) as described by Laemmli (1970). 6 or 8.5% gels were 
cast between 16xl6cm glass plates with 1.5mm spacers and 0.5cm wide wells, the 
stacking gel being at least as deep as the wells. Samples were prepared by adding an 
equal volume of 2X sample buffer (125mM tris-HC1 (pH6.8), 200mM DTT, 4% 
(w/v) SDS, 40% (v/v) glycerol, 0.02% (w/v) bromophenol blue; stored at -2C), 
heating to 100°C for 8mins and centrifuging for 3-5mins to remove any precipitated 
material. Gels were run in an ATFO electrophoresis tank at 30-150V in SDS-PAGE 
buffer (25mM Tris base, 192mM glycine, 0.1% (w/v) SDS). 
2.5.3 Coomassie Staining of Protein Gels. 
SDS-PAGE gels were stained to visualise proteins by incubating at 37 °C for 
30-60min in sufficient coomassie stainng solution (25% (v/v) propan-2-ol, 10% (v/v) 
acetic acid, 0.05% (wlv) bromophenol blue) to cover the gel. Following staining the 
gel was destaining by incubating in destaining solution (10% (v/v) methanol, 10% 
(v/v) acetic acid) at 37 °C until the background was low. For storage, gels were 
incubated in 10% (v/v) glycerol for 30min before being transferred to a sheet of 
blotting paper, covered in Saran Wrap and dried in a vacuum gel drier (Bio-Rad) at 
80°C. 
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2.5.4 Purification of Antibodies. 
2.5.4.1 Preparation of IgG Fractions. 
Antibodies were purified from crude serum under low salt conditions using the 
method of Ey et al. (1978) as described in Harlow and Lane (1988). 
2.5.4.2 Affinity Purification of Anti-8.6 Antibodies. 
Antibodies were purified by the method of Robinson et al. (1988) (below) by 
binding to the peptide against which the antibodies were raised. The peptide was 
coupled to BSA (using glutaraldehyde, described in Harlow and Lane (1988)) and the 
BSA-peptide conjugate was run on a preparative 2mm thick single-well SDS-PAGE 
gel and blotted onto nitrocellulose. The membrane was stained with Ponceau S stain 
(Sigma) to visualise the BSA-peptide band which was cut out. 
Block the nitrocellulose strip in 1% (w/v) ovalbumin, 1X TBS, 0.1 % (w/v) 
NaN3 2-4hrs at 37°C. 
Incubate overnight with lOmi 1:100 dilution of antibody in lx TBS. 
Wash at room temperature 5X10mins in lx TBS 0.1% (v/v) NP40. 
Elute the bound antibody with 2 incubations in 2m1 0. 1M glycine pH2.5, 
0.1% (w/v) ovalbumin. Smins for the first incubation, lOmins for the second. 
Neutralise the eluates immediately with 0.5m1 Tris-HC1 (pH7.5). 
Pool the eluates and dialyse overnight against 1X TBS (3 changes of 11.) 
Add NaN3 to 0.1 % (w/v) and store at 4 °C. 
2.5.5 Western Blotting. 
Following SDS-PAGE proteins were electrophoretically transfered to 
Nitrocellulose (Schleicher and Schuell) in a Trans-Blot Electroblotting Cell (Bio-Rad) 
with plate electrodes, stained with Ponceau S (Sigma) to verify transfer and probed 
for the presence of the protein of interest (PRP8) using antibodies as described below. 
Soak gel, nitrocellulose sheet, two Scotchbrite pads and 4 pieces of blotting 
paper (cut to the same size as the gel) in transfer buffer. 
Assemble the gel into a sandwich in a Trans-Blot gel holder between 1 
Scotchbnte pad and 2 pieces of blotting paper on one side and the nitrocellulose 
followed by 2 pieces of blotting paper and the second Scotchbrite pad on the other. 
Make sure to avoid air bubbles. 
Place in the Electroblotting Cell (Nitrocellulose towards the anode) with 
cooling coils, fill with transfer buffer and transfer for 3-4hr at 100V. 
After transfer allow the filter to air dry, re-wet in dH 20 and stain in 
Ponceau S for 1-2mins. Rinse with dH 20 to remove excess stain. 
Incubate in blocking solution for 1-2hr at 37 °C. 
Rinse in 1XTBS and incubate in primary antibody at the appropriate 
dilution in antibody solution overnight at 4°C or at room temperature for 1-2hr 
(approximately imi per 10cm 2 of membrane). 
Rinse twice in wash buffer and wash 3 times in 50m1 wash buffer for 15mm 
at room temperature. 
Incubate in lOmi alkaline phosphatase-conjugated goat anti-rabbit antibodies 
(Promega Biotec.) at the recommended dilution (1:7500) in antibody solution. 
As 7). 
Rinse the membrane in development solution and then incubate in 5-10mi 
development solution containing 0.33mg/mi NBT and 0. l65mg/ml BCIP (both 
Promega Biotec.) until the desired staining of bands is reached. 
Terminate the development reaction by washing the membrane in several 
changes of water. Blot the membrane dry, cover in Saran Wrap and store in the dark 
(to prevent the colour fading). 
Buffers: 
Transfer buffer: 20mM Tris base, 150mM glycine. 
Blocking solution: Either 1) 5% (w/v) BSA, lx TBS; or 2)1.5% (w/v) Marvell, lX 
TBS. 
Wash solution: 1XTBS plus either 0.1 % (v/v) NP40 or 0.05% (v/v) Tween-20. 
Antibody solution: For blocking solution 1)1% (w/v) BSA, lX TBS; for blocking 
solution 2) 1X TBS. 
Development solution: 100mM Tris-flCl (pH9.5), 100mM NaCl, 50mM MgCl 2 . 
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2.5.6 Immunoprecipitation. 
Immunoprecipitations of PRP8 protein or snRNAs from yeast splicing extract 
or mock splicing reactions (splicing reactions with no substrate RNA) were carried 
out as in Lossky et al. (1987). Antibodies were pre-bound to protein-A sepharose 
(PAS) beads. 
Swell PAS beads (Sigma) in NTN for 20mins and wash 4-5 times with imi 
NTN. Aliquot the beads into appropriate volumes (201d per reaction) and add the 
antibody (sufficient to give maximal precipitation of antigen). Incubate in 0. 1 m NTN 
with mixing for lhr, and then wash the beads 4-5 times with lml NTN. 
Dilute the extract/splicing reaction to 10mM HEPES-KOH (çiH7.5), 
150mM Na/K, 2.5mM MgC12, 0.1% (v/v) NP40 in a volume of 100-200d. Add 
to antibodies bound to PAS beads and incubate at 4 °C for 2-4hrs with mixing. 
Wash the beads 2X with imi NTN, 1X with NT removing the final (NT) 
wash carefully. 
To anaylse proteins treat for SDS-PAGE (section 2.5.2). To analyse RNA 
add 50/ti proteinase K solution and incubate at 37 °C for 30mins with mixing. 
Add 50al dH20, phenol/chloroform extract, back extract the phenol phase 
with a further 50d dH 20 and pool the aqueous phases. 
Phenol/chloroform extract twice more and precipitate with ethanol (add 1d 
E. coil tRNA at 20mg/ml to each sample as a carrier). 
Electrophorese through a 6% (w/v) denaturing polyacrylamide gel for 
Northern blot analysis (see sections 2.4.8 and 2.4.10). 
Buffers: 
NTN: 50mM Tris-Hcl (pH7.5), 150mM NaCl, 0.1% NP40. 
NT: As NTN but with no NP40. 
Proteinase K solution: 50mM Tris-HC1 (pH7.5), 300mM NaCl, 5mM EDTA, 1.5% 
(w/v) SDS, 2mg/mi proteinase K (store as -20 °C). 
Notes: Immunoprecipitations of spliceosomes were carried out as in Whittaker et al. 
(1990). The procedure was essentially as above but the immunoprecipitation 
conditions were: 300mM K, 1mM magnesium acetate, 11 m EDTA, 9mM Tns-
HC1 (pH8.0) 0.6mg/mi E.coli tRNA (as a competitor) for precipitations with anti-
PRP8 antibodies and 200mM K, 1mM magnesium acetate, 11mM EDTA, 9mM 
Tris-HC1 (pH8.0) for precipitations with anti-poly(A)-binding protein antibodies. 
2.5.7 In vitro Splicing. 
2.5.7.1 Preparation of Yeast Splicing Extracts. 
Modified from Lin et al. (1985). 
Inoculate the appropriate medium with a fresh stationary culture and grow 
overnight to OD600 0.5-0.7. (21 will give about 3-5ml extract, OD 0.55). 
Spin down at room temperature and resuspend in = SOmls 50mM potassium 
phosphate pH7.5. Spin down again and resuspend in 40mls lyticase buffer. Add 1-
1.5mls lyticase (Sigma) at 2500U/ml. Incubate 30mins-lhr 30 0C (23°C for 
temperature sensitive strains). 
Check for sphaeroplast formation. Spin down cells (slowly, 2-3krpm) wash 
cells 2X in 1.2M sorbitol resuspending gently and spinning down slowly. 
Wash out into 500m1 flask with 200mls YPDAS and allow cells to 
"recover" 1-2hrs at 23/30/36 °C. ( Use 230C for temperature sensitive strain active 
extract, 30°C for wild type and 36 °C for temperature sensitive strain inactivated 
extract, time of incubation dependent on allele being inactivated). 
Spin down cells, again slowly, and wash once with SB-3 (ice cold) and 
place cells on ice. Everything is done at 4 °C from this point on. 
Weigh cell pellet and resuspend in lml/g buffer A. Transfer to a chilled 
Dounce homogeniser and leave on ice for 5mins. 
Homogenise with 10-13 SLOW strokes, transfer to a beaker on ice with a 
magnetic bar stirring, check volume and add 1/9th  volume 2M KC1 dropwise. Leave 
30mins. 
Transfer to a cold rinsed polycarbonate SS-34 tube and spin at 17krpm for 
3Omins. 
Transfer supemate to a Ti50 polycarbonate bottle avoiding the top (lipid) 
layer as much as possible. Spin at 37krpm for lhr at 4 °C in a pre-cooled Ti50 rotor 
(Make up 31 buffer D and cool to 4 °C). 
Remove cap of tube carefully and transfer supernate to dialysis tubing, 
again avoiding the lipid layer. Dialyse for 3hrs against 11 buffer D with changes of 
buffer after each hour. 
Spin lOmins in microfuge tubes (at 4 °C) and snap freeze in aliquots. Store 
at -70°C. 
Do not thaw and refreeze more than 3 times as loss of activity occurs. 
Me 
Buffers: 
Lyticase buffer: 1.2M Sorbitol, 50mM potassium phosphate pH7.5, 30mM DTF' 
YPDAS: 1 % (w/v) Yeast Extract, 2% Peptone, 2% Glucose, .002% adenine sulphate, 
1.2M Sorbitol. 
SB-3: 50mM Tris-HC1 pH7.5, 10mM MgC12 , 1.2M Sorbitol, 3mM DTT' 
Buffer A: 10mM HEPES-KOH pH7.5, 1.5mM MgC12 , 10mM KC1, 0.5mM DTT 
Buffer D: 20mM HEPES-KOH pH7.5, 0.2mM EDTA pH8.0, 0.5mM D1T, 50mM 
KC1, 20%(vlv) Glycerol. 
sD.JJ. is added immediately prior to use. 
Notes: 
This is the standard protocol. Variations include: 
Putting the Ti-50 supernate over a NAP-10 or similar gel exclusion column 
equilibrated in buffer D instead of dialysing. This results in some dilution but 
removes ATP etc. effectively. The extract can then be reconcentrated using a 
centricon filter (Amicon). 
For making ammoniun sulphate cuts take supernate from the Ti-50 and 
transfer to a small beaker. Check volume and add required amount of ground 
(NH4)2SO4 slowly and stir for 30mins on ice. Spin at 4°C SS-34 l7krpm 20mins. 
Take up the precipitate in I/ 10' original volume buffer D and Dialyse as above (step 
10)). 
2.5.7.2 In vitro Splicing Reaction. 
Assays for the production of splicing intermediates and products were carried 
out essentially as described by Lin et al. (1985). The standard reaction was 10d 
assembled at room temperature as below, splicing extract was thawed and incubated 
3-5mins at 25°C before use. Substrates were produced by transcription in vitro 
(section 2.4.7). 
Assemble the splicing mix: 10j1 30% (w/v) PEG 8000 (Sigma), 614l 1M 
potassium phosphate (pH7.5), 1l 0.25M MgC1 2 , lzl 0.225M ATP, —0.5Ci 
substrate RNA from an in vitro transcription reaction, sterile dH 20 to 50pi. 
Aliquot the splicing mix into Spi volumes and add 51d splicing extract. 
Incubate at 25 °C for the required time (0.5-30mins). Stop on ice. 
To analyse RNA: 
Add 21d 1mg/mi proteinase K (in 50mM EDTA, 1 % (w/v) SDS) and 
incubate at 37°C for 30mins. 
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Add 100zl "splicing cocktail" buffer, extract twice with phenol/chloroform 
and precipitate with ethanol. 
Electrophorese through a 6% (w/v) denaturing acrylamide gel and detect 
by autoradiography. 
Buffers: 
"Splicing cocktail": 50mM sodium acetate pH5.3, 1mM EDTA, 0.1% (w/v) SDS, 
25g/m1 E.coli tRNA. 
2.5.8 Native Gel Electrophoresis of Splicing Complexes. 
Native gel electrophoresis was carried out according to Pikielny et al. (1986) 
except that the EDTA concentration in the gel was 10mM (the gels of Pikielny et al. 
(1986) were 1mM). This system separates three splicing complexes designated I, II, 
and III, complex II being the active spliceosome. This was verified by analysis of the 
RNA species in the three complexes (data not shown). 
l5cmXl5cmXl.5mm composite gels were made and run in an ATTO 
electrophoresis tank as follows: Dissolve 0.5g agarose in 40m1 dH 20 and cool to 
approximately 50°C. Quickly add 2.5ml 1OXTB, imi 0.5M EDTA, Sml 30% (w/v) 
acrylamide (60:1 acrylamide:bis-acrylamide) and make volume up to 50ml. Add 
0.5m1 10% APS and 501d TEMED and pour into warm plates (37 °C is fine). Insert 
comb (10 X 9mm slots is ideal). Allow the gel to set for 45mins. 
Pre-electrophorese the gel at 4 °C for lhr in 0.5X TB, 10mM EDTA at 
80V. 
Set up splicing reactions (section 2.5.7.2) and stop on ice. To 5j0 aliquots 
of the reactions add 50 ice cold Q buffer and incubate on ice for Smins. 
Add 2.5141 5X RNP load buffer, load the samples on the gel and run at 4°C 
for 8-10hrs at 80V. 
Buffers: 
Q buffer: 450mM KCL, 2.3mM Mg-Acetate, 23mM EDTA, 18mM Tris-HCL (pH 
7.5), 1.2mg/ml yeast total RNA (prepared as in section 2.4.4). 5X RNP load buffer: 
5X TB, 50mM EDTA, 50% (v/v) glycerol, 0.25% (w/v) each bromophenol blue and 
xylene cyanol FF. 
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2.5.9 Glycerol Gradient Sedimentation of snRNPs. 
Glycerol gradients were made and run essentially as described in Bordonne et 
al. (1990). Samples were prepared by incubating splicing extract at 25°C for 15mins 
under in vitro splicing conditions without transcript with or without ATP. 
Dilute sample threefold with buffer A and layer on an 11 ml  10-30% linear 
glycerol gradient in buffer A. 
Spin for 14hr at 37 krpm in a TST41.14 rotor at 4 °C. 
Collect 0.5ml fractions from the top of the gradient and store at -70 °C. 
To assess the distribution of snRNPs: extract odd numbered fractions once 
with phenol/chloroform, precipitate with ethanol and analyse by polyacrylamide gel 
electrophoresis and Northern blotting (sections 2.4.8, 2.4.10). 
Buffer: 
snRNP buffer A: 50mM Tris-HC1 pH7.5, 25mM NaCl, 5mM MgC1 2 . 
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CHAFFER 3 
INHIBITION OF SPLICING AND RECOGNITION 
OF SPLICING COMPLEXES BY ANTI-PRP8 
ANTIBODIES. 
3.1 Introduction. 
Antibodies against PRP8 have been used in a number of ways to elucidate the 
interactions of the PRP8 protein with other splicing factors. Co-immunoprecipitation 
of snRNAs with PRP8 showed that it is a component of the U5 snRNP and of 
U4/U6.U5 tri-snRNP particles (Lossky et al., 1987) and co-immunoprecipitation with 
pre-mRNA, intermediates and lariat product from in vitro splicing reactions showed 
that it was a component of spliceosomes (Whittaker et al., 1990). Jackson et al. 
(1988) showed that immunodepletion of PRP8 from splicing extracts resulted in loss 
of splicing activity demonstrating a direct requirement for PRP8 protein and/or a co-
precipitated factor for the splicing reaction to proceed. It had not, however, been 
assessed whether antibodies against PRP8 inhibited splicing directly. Since PRP8 
protein may be multi-functional (see section 1.6.4), the availability of antibodies 
against different regions of the protein raised the possibility that spliceosome assembly 
or the splicing reaction might be inhibited at different stages by the different 
antibodies. Virtually homogeneous populations of several spliceosome complexes 
containing PRP8 might thus be generated, which would be ideal substrates for cross-
linking reactions to identify contacts of PRP8 protein with pre-mRNA at that point 
in the reaction (see Whittaker and Beggs (1991) for cross-linking experiments with 
P 'J 1 re:i 
The anti-PRP8 antibodies 8.1 to 8.4 (see figure 3. 1) have been characterised 
and used extensively to probe the interactions of the PRP8 protein. When this work 
was initiated anti-8.6 antibodies, raised against a synthetic 35 amino acid peptide 
corresponding in sequence to part of the amino-terminal acidic, proline-rich region 
of PRP8 protein (G. Anderson unpublished results; see figure 3. 1) had not. Thus some 
preliminary characterisation of the anti-8.6 antibodies was carried out. This chapter 
describes this and the use of these and other anti-PRP8 antibodies in experiments to 
assess whether they inhibit splicing and, if so, at what point in spliceosome assembly 
or the splicing reaction. In addition, experiments were also carried out to assess 
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FIGURE 3.1 Anti-PRP8 Antibodies; Map of the PRP8 Gene. 
Restriction Map of the PRP8 Gene and Flanking Sequences. 
All restriction enzyme sites used for construction of 13-galactosidase-PRP8-fusion 
proteins (Lossky et al., 1987; Jackson et al., 1988) and in this thesis to construct 
plasmids are indicated. Flags mark the limits of the 12kb genomic insert in pY8500, 
the open reading frame is indicated by a thicker line, the 5' end by an arrow. 
Restriction sites: B, BgllI; C, Cal; D, NdeI; H, Hindill; L, Sail; M, BamHI; R, 
EcoRI; S, SphI; X, XbaI. N is a unique NheI site created by site directed 
mutagenesis and introduced from pJK2 (see table 2.2) into both pY8000 (to generate 
pJDY6) and pY8500 (to generate pJDY8). The mutagenesis changed the fifth amino 
acid of PRP8 protein from proline to alanine, but has no apparent effect on PRP8 
function. A plasmid, pJDY7, lacking the NheI to XbaI fragment at the 5' end of the 
gene, was constructed by substituting a Sail fragment of pJK3 (see table 2.2) into 
pY8000. This produced an in frame deletion of 228 nucleotides (76 amino acids). 
The Regions of PRP8 Protein against which Antibodies have been Raised. 
Regions of the PRP8 gene utilised for construction of 3-ga1actosidase-PRP8-fusion 
proteins 8.1 to 8.4 are indicated. Restriction site abbreviations and relative positions 
are as on the map in A. 
PRPS Peptide. 
The sequence of the amino-terminal peptide of PRP8 protein against which the anti-
8.6 antibodies were raised. The sequence (apart from the first cysteine residue) 





L S H D N*  X M R L B 	B R A C B * M M R C 	 X 	 C 1 	 1 k 
/ 8.6 	 8.3 	8.1 	8.2 	8.4 
5 amino acid Reqions against which 
peptide 	 M 	B B 	 B 	C anti bodies -have been raised 
Peptide sequence: 
CSGLPPPPPGFEEDSDLALPPPPPPPPGYEIEELD 
which splicing complexes anti-PRP8 antibodies recognised. 
3.2 Methods. 
In vitro Splicing Reactions. 
IgG wo purified from antisera as described in section 2.5.4.1. The resulting 
fractions had a protein (IgG) concentration of 2-3 mg/ml as assessed by Bradford 
assay (section 2.5.1). Varying amounts of IgG (up to lOjLg in 441 of PBS) were added 
to 51d splicing extract and incubated at 25 °C for 20-30mins, and in some experiments 
for up to lhr. It was found necessary to dilute some splicing extracts 2-fold with 
buffer D (section 2.5.7.1) to obtain full inhibition of splicing. The remaining 
components of the splicing reaction were then added giving a final volume of 
approximately 1 1l, and the reaction was incubated at 25 °C. 
The addition of 411 of PBS/IgG to 51 of splicing extract gave a K/Na 
concentration of approximately 100mM, which does not disrupt the recognition of 
PRP8 by anti-8.4 antibodies (Lossky, 1988). The final K/Na concentration in the 
splicing reaction was approximately 140mM, within the limits for efficient in vitro 
splicing as assessed by Lin et al. (1985). 
Gel Retardation Assays. 
Native gel electrophoresis was carried Out as described in section 2.5.8. For 
the experiments in section 3.6 samples were also prepared as in section 2.5.8 except 
that after incubation with Q mix, 4/Al of IgG at 4 °C, were added and a further 
incubation on ice for 20-30mins carried out prior to addition of 3.254l (1/4 volume) 
5X loading buffer and loading the samples on the gel. 4/Al of IgG represented more 
than enough for maximal immunoprecipitation of splicing complexes from this amount 
of splicing extract (Whittaker et al. ,1990; Whittaker, 1990; data not shown) and from 
the experiments in section 3.4 was at least 2-fold more than that required to 
completely inhibit splicing. 
3.3 Characterisation of Anti-8.6 Antibodies. 
Anti-8.6 antiserum and pre-immune serum recognised many proteins in yeast 
extracts. In addition to PRP8 one other prominent species of about 130kDa is detected 
on Western blots of splicing extract by the immune serum that is not detected by the 
76 
pre-immune serum (figure 3.2A compare lanes 1 and 2, position marked with an 
asterisk). Antibodies were affinity purified using the peptide against which they were 
raised (section 2.5.4.2) to assess how many proteins were recognised by those that 
were specific to the peptide. The only major species that the affinity purified 
antibodies reacted against was PRP8. The 130kDa protein specific antibodies were 
found in the fraction of the antibodies that did not bind to the peptide during affinity 
purification (figure 3.2A compare lanes 2 (immune), 3 and 4 (affinity purified) and 
5 (non-absorbed)). 
Anti-8.6 antibodies, but not pre-immune antibodies, immunoprecipitate PRP8 
efficiently from yeast splicing extracts and co-immunoprecipitate US, U4 and U6 
snRNAs. This can be prevented by pre-incubation of the antibodies with an excess 
of the peptide against which they were raised, but not by a control peptide, showing 
the specificity of the immunoprecipitation (G.Anderson, personal communication). 
Incubation with ATP had been shown to affect the precipitation of snRNPs by anti-8. 1 
and -8.4 antibodies. To establish the effects of ATP on the precipitation of snRNPs 
by anti-8.6 antibodies, splicing extract was incubated under normal splicing conditions 
minus substrate RNA with and without ATP and aliquots immunoprecipitated with 
anti-8.4 or anti-8.6 antibodies. Pre-incubation with ATP resulted in an increase in the 
precipitation of U4, U5 and U6 with anti-8.4 antibodies (figure 3.2B lanes 3 and 4), 
consistent with previous observations (Lossky et al., 1987). Anti-8.6 antibodies 
precipitated approximately the same amount of US with and without ATP, but the 
precipitation of U4 and U6 decreased when the pre-incubation was carried out with 
ATP (lanes 5 and 6). 
The precipitation of snRNAs by anti-8.6 antibodies was efficient - greater than 
50% of US and approximately 50% U4 and 25% of U6 when reactions were carried 
out without prior incubation with ATP (figure 3.2B, compare the 25% total control 
(lane 2) with the anti-8.6 immunoprecipitation (lane 5)). 
3.4 Anti-PRP8 Antibodies Inhibit Splicing In vitro. 
Experiments to assess whether antibodies against PRP8 inhibited splicing were 
first carried out using crude antisera. Antiserum was pre-incubated with splicing 
extract at 25 °C for 20mins before assembling an otherwise standard splicing reaction. 
Both pre-immune and immune sera contained a large amount of RNase activity which 
degraded the substrate RNA, even in the presence of RNase inhibitor - although to 
a lesser extent (data not shown). This was somewhat expected as serum contains high 
levels of RNases. 
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FIGURE 3.2 
Detection of PRP8 by Anti-8.6 Antibodies. 
Splicing extract (approximately 150/Ag/lane) was electrophoresed through a 8.5% 
(wlv) SDS-polyacrylamide gel and electroblotted to nitrocellulose. The blot was 
probed as follows: pre-immune serum (lane 1; PT); immune serum (lane 2; I); affinity 
purified antibodies (lanes 3 and 4; AP); non-absorbed antibodies from the affinity 
purification (lane 5; NA). The dilutions of antibody used to probe lanes 1, 2, 4 and 
5 were equivalent (1:10000) with respect to the original serum, the dilution for lane 
3 was 1:5000. All tracks were incubated in developer for the same time. Sizes of 
protein molecular weight markers (M) are indicated (kDa). * indicates a species 
detected by immune (but not pre-immune) antibodies that is not recognised by 
affinity-purified antibodies. 
Immunoprecipitation of U4, US and U6 snRNAs by Anti-8.4 and Anti-8.6 
Antibodies. 
Splicing extract (10d) was incubated under splicing conditions without substrate, with 
(lanes 4 and 6) or without (lanes 3 and 5) ATP and was subjected to 
immunoprecipitation with anti-8.4 (lanes 3 and 4) or anti-8.6 (lanes 5 and 6) 
antibodies. RNA was recovered from immune complexes, electrophoresed through 
a 6% (w/v) denaturing polyacrylamide gel, electroblotted to Hybond-N and probed 
for the presence of snRNAs with 5'-end labelled oligonucleotide probes. DNA size 
markers (lane 1; M) were end-labelled fragments of pBR322 plasmid DNA digested 
with MspI (sizes in nucleotides). 25% total (lane 2) is total RNA extracted from 2.5d 
splicing extract. The two U5 species, U5L and U5S, are both transcribed from the 
snR7 gene and differ in length at the 3' end. 
Inhibition of Splicing by Anti-8.4 Antibodies. 
Splicing reactions (1041) were assembled with radiolabelled rp28 pre-mRNA and 
splicing extract treated with the amount of anti-8.4 IgG indicated (lanes 1 to 6) or 
with PBS (-; lane 7) and incubated at 25 °C for 15mins. RNA was recovered and 
fractionated on a 6% (w/v) denaturing polyacrylamide gel. IVS-E2, lariat intron-exon 
2 intermediate species; IVS, lariat excised intron; pre-mRNA, rp28 substrate; E1-E2, 
spliced mRNA product; El, exon 1 intermediate species. 
Inhibition of Splicing by Anti-8.1 and Anti-8.6 Antibodies. 
Splicing reactions containing splicing extract treated with PBS (lanes 1 and 2), or 
anti-8.1 (lanes 3 and 4) or anti-8.6 (lanes 5 and 6) IgG, were assembled as described 
in C. 5/Al aliquots of 7 and 15min time points were analysed for RNA; 51Al aliquots 
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To eliminate nucleases IgG fractions were prepared from crude antisera and 
these fractions were tested for inhibition of splicing. Assays were carried out as 
described in section 3.2, pre-incubating IgG with splicing extract at 25°C prior to the 
addition of other components of the splicing reaction. All the antibodies which were 
known to recognise native PRP8 protein (anti-8.1, -8.4, and -8.6) inhibited in vitro 
splicing reactions. Intermediates of splicing did not accumulate in reactions inhibited 
with any of these antibodies and thus inhibition was prior to step 1. Figure 3.21) 
shows the effect of anti-8.1 (lanes 3 and 4) and anti-8.6 (lanes 5 and 6) antibodies 
compared to a buffer only control (lanes 1 and 2). The treatment of extract with 
buffer alone had little or no effect on splicing reactions when compared to non-treated 
samples (data not shown). Figure 3.2C shows a titration with anti-8.4 antibodies. 
Virtually no effect on splicing was seen with 0.2g IgG (compare lane 1 with lane 
7), whereas 4.0zg (lane 5) gave almost complete inhibition and with 8.0jg (lane 6) 
intermediates and products of the splicing reaction were not seen. It was found that 
for different splicing extracts a different amount of antibody was required to 
completely inhibit splicing (data not shown), presumably reflecting the concentration 
of splicing factors (PRP8 protein) in the extract. 
Significantly, antibodies which recognise native PRP8 protein poorly (anti-8.2 
and -8.3; Lossky et al., 1987; Jackson et al., 1988) had much less effect on splicing 
than those which do, and in some experiments had no effect at all. Figure 3.313 shows 
that whereas anti-8.1 and -8.4 antibodies inhibited splicing completely (lanes 2 and 
5), anti-8.2 and -8.3 antibodies had much less effect (lanes 3 and 4). However, anti-
8.2 and -8.3 antibodies immunoprecipitate denatured PRP8 protein efficiently and 
recognise PRP8 on Western blots (Lossky et al., 1987; Jackson et al., 1988; 
S.Teigelkamp personal communication). Thus the epitopes recognised by these 
antibodies are presumably not exposed in native protein. 
To establish that the inhibition of splicing by anti-PRP8 antibodies was specific 
and not due to cross-reaction with other proteins, control experiments were carried 
out using equivalent amounts of purified IgG from corresponding pre-immune sera. 
Figure 3.3A shows that, whereas anti-8.4 antibodies completely inhibited splicing 
(lane 2), the same amount of IgG purified from pre-immune serum had no effect. The 
same results were obtained for pre-immune IgG of rabbits used to produce anti-8.1 
and -8.6 antibodies (data not shown). 
In addition to experiments with pre-immune sera, antigen competition 
experiments were attempted using anti-8.6 antibodies and the synthetic peptide against 
which they were raised, which was free of contaminating nucleases. An amount of 
antibody known to inhibit splicing completely (8kg) was pre-incubated with various 
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FIGURE 3.3 
The Effect of Pre-Immune Antibodies on Splicing. 
Splicing reactions were assembled and analysed as in figure 3.2C. Splicing extract 
was treated with PBS (lane 1), anti-8.4 IgG (lane 2), or an equal amount of pre-
immune IgG (lane 3). 
The Effect of Anti-8.2 and -8.3 Antibodies on Splicing. 
Splicing reactions were assembled and incubated as in figure 3.2C. Splicing extract 
was treated with PBS (lane 1), or 10g of IgG from the serum indicated (lanes 2 to 
5). Half of each 10d reaction was analysed for RNA as in figure 3.2C, the other half 
was analysed for splicing complexes (see figure 3.4C). 
Antigen Competition Experiment. 
10g anti-8.6 IgG were treated with the amount of peptide (against which the 
antibodies were raised) indicated (/LgPEP; lanes 1 to 4) prior to incubation with 
splicing extract and assembling splicing reactions as described in figure 3.2C. 
Reactions assembled with extract treated with anti-8.6 antibodies alone, PBS, or 
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amounts of the peptide before adding to splicing extract. Figure 3.3C shows a 
titration of peptide up to 0.114g resulting in rescue of some splicing activity. This 
amount of peptide alone did not affect splicing (compare lanes 6 and 7). In other 
experiments, although a concentration of peptide up to lzg per reaction did not inhibit 
splicing, amounts greater than the 0. ljg shown in figure 3.3C did not result in any 
greater rescue of splicing. This may have been due to the amount of protein (IgG) 
plus peptide added inhibiting the reaction as 0.51Ag of peptide is sufficient to 
completely compete out recognition of PRP8 by 5141 antiserum (equivalent to more 
than the 814g IgG used here) as assessed by the precipitation of snRNPs (G.Anderson 
personal communication). Although no control peptide was used in these antigen 
competition experiments the rescue of splicing activity and the non-inhibition of 
splicing by the pre-immune antibodies argues for a specific effect. 
Anti-M3G antibodies which inhibit both mammalian and yeast in vitro splicing 
reactions (Kramer et al., 1984; Chang et al., 1988) were used as a positive control 
for inhibition of splicing. As expected, these antibodies inhibited splicing (not shown). 
3.5 Anti-PRP8 Antibodies Block Spliceosome Formation. 
The effect of anti-PRP8 antibodies on spliceosome assembly was examined. 
Aliquots of splicing reactions assembled from extract pre-incubated with antibodies 
or buffer were run on non-denaturing gels. The gel system used was essentially that 
of Pikielny etal. (1986), described in section 2.5.8. Inhibition of splicing by anti-8.l, 
-8.4 and -8.6 antibodies was found to result in the formation of only complex III. 
Figure 3.4A shows complexes formed in reactions inhibited by anti-8.1 and anti-8.6 
antibodies (these samples are aliquots of the same reactions (plus 2 minute time 
points) analyzed in figure 3.21)). In the experiment shown in figure 3.413, anti-8.4, 
or an equivalent amount of pre-immune antibodies, or buffer, have been pre-incubated 
with splicing extract. Complex III accumulated in the immune treated reactions over 
time (lanes 1 to 4) whereas in the samples from pre-immune treated (lanes 9 and 10) 
or mock treated (lanes 5 to 8) reactions complexes I and II were resolved showing 
formation of active spliceosomes. Consistent with the fact that they had little effect 
on splicing, anti-8.2 and -8.3 antibodies had much less (although similar) effect on 
spliceosome formation than other anti-PRP8 antibodies (figure 3.4C, compare lanes 
2 and 5 (8.1 and 8.4) with lanes 3 and 4 (8.2 and 8.3), these samples are aliquots of 
the reactions shown in figure 3.313). 
In this gel system, the accumulation of complex III is consistent with only Ul 
and U2 snRNPs interacting with the pre-mRNA substrate. Thus all the anti-PRP8 
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splicing. 
Glycerol gradient sedimentation analysis has shown a decrease in the amount 
of tri-snRNP on incubation with ATP (Bordonné et al., 1990). These experiments 
utilised different incubation conditions to those used in the experiments reported here 
and by Banroques and Abelson (1989), and the loss of tri-snRNP may have been due 
to instability of the ATP-dependent form under these conditions (see also chapter 6). 
In conjunction with the immunoprecipitation data discussed above, these results argue 
for the ATP-dependent tri-5nRNP being derived from pre-existing particles. 
U41U6.U5 tri-snRNPs are almost certainly intermediates in spliceosome 
assembly (see section 1.5.4). Assuming that this is the case then the inhibition of 
spliceosome assembly by anti-8.1 antibodies prior to U4/U6 and US snRNP binding 
is therefore explained by the fact that these antibodies disrupt tri-snRNPs: following 
immunoprecipitation from splicing extract with anti-8.1 antibodies, which precipitate 
U5 snRNPs only, no U4, U5 or U6 snRNA can be immunoprecipitated from the 
supernate by anti-8.4 antibodies (Lossky et al., 1987 and data not shown). 
Again assuming that the tri-snRNP is an obligatory intermediate in 
spliceosome assembly, the inhibition of splicing by anti-8.4 and -8.6 antibodies can 
be explained if the antibodies bind to regions of PRP8 protein important either for the 
generation of the form of tri-snRNP that enters the spliceosome or for assembly of 
the tri-snRNP into spliceosomes. Anti-8.4 antibodies were raised against a large 
fragment of the protein and hence only a subpopulation of the epitopes need to be 
exposed in complexes for effects to be observed. The binding of anti-8.4 antibodies 
to. complex II but not complex I indicates that epitopes in the 8.4 region of the protein 
are involved in interactions in spliceosomes, and detects a conformational change 
within the spliceosome revealing at least some of these epitopes as the active 
spliceosome is formed. This could be, for example, a consequence of the change in 
interaction of U4 and U6 snRNAs. An alternative would be that the antibodies 
successfully compete with a spliceosomal factor for interaction with PRP8 protein 
after the conformational change between complexes I and II and thus they displace 
it. 
Anti-8.6 antibodies bound to both of the PRP8 containing complexes that are 
resolved by native gel electrophoresis. Thus, as with anti-8.4 antibodies, they may 
displace another factor, or the N-terminus of the protein is not bound by other 
spliceosomal components or sequestered in the spliceosome. The efficiency of 
immunoprecipitation of snRNAs by anti-8.6 antibodies is consistent with nearly all 
the tri-snRNPs being precipitated (see figure 6.1 which shows the relative amounts 
of different snRNP complexes in splicing extract). Other immunoprecipitation data 
show that PRP8 and spliceosomes are both efficiently recognised by these antibodies 
(Whittaker, 1990; Whittaker and Beggs, 1991). Thus the N-terminal portion of the 
protein is probably exposed most of the time and may protrude from other domains 
of the protein on the surface of complexes. The only complex that appears not to be 
recognised by these antibodies is the ATP-dependent tri-snRNP. The acidic amino 
acid rich nature of the N-terminus of PRP8 (against a part of which anti-8.6 
antibodies were raised) is reminiscent of similar regions in transcriptional activators 
which are proposed to have dynamic protein-protein interactions (Sigler, 1988). It 
would appear that the N-terminus of PRP8 protein is similar in having a transient 
interaction with another factor or factors. Interestingly, deleting this part of the 
protein has a dominant negative effect, indicating that it is involved in a vital 
interaction possibly late in spliceosome assembly (a plasmid, pJDY7, which contains 
this deletion in the PRP8 gene (see figure 3. 1), does not complement the growth 
defect of a temperature-sensitive prp8 mutant and both the temperature-sensitive strain 
and a wild type strain transformed with pJDY7 have reduced growth rate and variable 
colony size on plating; data not shown). 
It can not be ruled out that the inhibitory effects of the anti-PRP8 antibodies 
on splicing might be caused solely by steric effects, due to the size of antibodies 
preventing nearby interactions from taking place. 
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CHAPTER 4 
STRAIN CONSTRUCTION AND 
CHARACTERISATION. 
4.1 Introduction. 
The generation and analysis of mutants is often the starting point for the 
identification of genes and the understanding of the function of their gene products. 
This approach has been very important in the study of splicing. Nine complementation 
groups (rna2-10/11, now called prp2-10111) selected from a pool of temperature-
sensitive mutants defective in macromolecular synthesis (Hartwell, 1967) were 
identified as affecting splicing by the accumulation of pre-mRNA at the non-
permissive temperature (Rosbash et al., 1981; Teem et al., 1983; Lustig et al., 
1986). The characterisation of these and other splicing factors isolated in screens 
specifically directed at identifying splicing mutants has considerably furthered our 
knowledge of the splicing process (see chapter 1 sections 5 and 6). 
At the outset of this project, the proposed method of studying the function of 
PRP8 protein was to examine the biochemical defects associated with temperature-
sensitive mutants. Seven mutant strains (containing the pip8-1 to 8-7 alleles) had been 
isolated by Hartwell and only one of these (prp8-1) had been studied. The wild type 
gene had been cloned by complementation of the growth defect of a strain carrying 
the pip8-1 allele (Jackson et al., 1987) and trans-acting suppressors of pip8-1 had 
been isolated (Jamieson et al., 1991). The prp8-7 mutation had been outcrossed into 
a non-mutagenised background and complementation analysis had shown that prp8-6 
was in fact not an allele of PRP8 (D.Jamieson, personal communication). Four of the 
mutants (prp8-2 to 8-5) were still in the original mutagenised background and it was 
necessary to outcross them. This is an important step in the characterisation of 
mutants generated by mutagenesis of cells as one can only attribute defects seen at the 
non-permissive temperature to a mutation if it is the only temperature-sensitive one 
in the strain. Therefore the remaining four Hartwell mutants and a pip8 mutant 
(prp8. 8) generated by J.Morran in a screen for new yeast splicing factors (Morran, 
1990) were outcrossed. This, and preliminary mapping of mutations is discussed in 
section 4.2. 
Complementary to work on the temperature-sensitive mutants, the study of the 
null phenotype of the PRP8 gene was considered crucial. This would give information 
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on the first step in snRNP and splicing complex assembly for which PRP8 is 
required. Since PRP8 protein may be multi-functional, study of the null phenotype 
would enable determination of whether or not the temperature-sensitive mutations 
made the protein completely defective or blocked one particular function. To study 
the null phenotype it was necessary to generate a yeast strain in which the only 
functional copy of the PRP8 gene was transcriptionally regulated such that the protein 
could be depleted in vivo. The generation of such a yeast strain is described in section 
4.3. 
4.2 Outcrossing and Characterisation of pip8 Mutants. 
4.2.1 Outcrossing. 
Mutant strains were outcrossed by sequential rounds of mating to wild type 
strains, sporulation and random spore or tetrad analysis. The wild type strains used 
were DBY745, DBY746, DBY747 and S150-2b (see table 2.1). Temperature-
sensitivity was assessed by spotting cell suspensions onto plates and incubating at 
various temperatures (23, 30, 34 and 36 °C), and strains were tested for mating type 
and the presence of the prp8 mutation by crossing to both a and a temperature-
sensitive prp2 and prp8 strains. This procedure was repeated until the pip8 mutation 
was the only temperature-sensitive mutation present as assessed by 2:2 segregation 
of temperature-sensitivity and non-temperature-sensitivity in tetrad analysis. That the 
mutation was indeed in the PRP8 gene was verified by complementation of the 
temperature-sensitive growth defect by a plasmid containing the wild type PRP8 gene. 
Apart from pip8-4 all the mutations were successfully outcrossed. Diploids 
produced between ts243 (prp8-4) and several wild type strains sporulated extremely 
poorly, and spores produced had low viability. Where possible outcrossed strains 
were selected that carried markers such as ura3 and leu2, allowing transformation 
with the available plasmid vectors carrying the URA3 and LEU2 genes. Table 4.1 
shows the strains selected from outcrossing pip8-2, prp8-3, prp8-5 and prp8-8 
mutants. 
4.2.2 Mapping Mutations. 
To map the approximate location of mutations within the PRP8 gene a series 
of four subclones of PRP8 which together spanned the entire gene was constructed 
in the multi-copy (21t-based) URA3 plasmid pFL44S (figure 4.1). Outcrossed prp8 
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Table 4.1 - Yeast Strains Generated in this Work. 
IF Strain Genotype Construction/comments. 
JDY8.22 a, pip8-2, ura3-52, leu2-3, 2X outcross of ts173 
112, lys2, his3-i1. (1XDBY746, 1XDBY747), ts 
at 34°C. 
JDY8.34 a, pip8-3, ura3-52, trpl -289. 2X outcross of ts 245 
(1XDBY745, 1XS150-2b), ts 
at 36°C. 
JDY8.35 a, pip8-3, ura3-52, ade, lys, Ditto 
his, tyr. 
JDY8.57 a, prp8-5, ura3-52, leu2-3,412, 2X outcross of ts295 into 
ade, his7, tyrl. DBY745. 
JDY8.81, all prp8-8, leu2-3,412, his3-z1, lx outcross of JMY196a into 
8.82 and trpl-289. S150-2b 
8.83. 
JDYO.2 ala ura3-52, ade2-1011+, leu-3, DBY745XDBY747. 
-112, trpl-2891+, his3-1/+. 
JDY8.01 as JDYO.2 except Transformant of JDY8.02 with 
prp8..LEU21+. LEU2 replacing one copy of 
PRP8. 
JDY8.02 a, ura3-52, ade2-101, his3-i.1, Haploid derivative of 
trpl -289, prp8::LEU2, pY8000. JDY8.01. 
JDY8.05 a, ura3-52, ade2-101, his3-z.1, JDY8.02 carrying pJDY13 
trpl -289, prp8::LEU2, pJDY13. instead of pY8000. 
JDY8.06 a, ura3-52, ade2-101, his3-i1, JDY8.02 carrying pY8500 
trpl-289, prp8::LEU2, Y8500. instead of pY8000. 
JDY9.11 a/a, prp9-1, ural/+, ade/+, J93XJ17 
trp/+, arg/+, lyr/+, gall/+. 
FIGURE 4.1 Mapping Temperature-sensitive pip8 Alleles. 
Map of the PRP8 gene as in figure 3.1. Restriction sites used in the construction 
of the mapping constructs are indicated. The regions of the PRP8 gene to which the 
prp8-1, pip8-2, prp8-5 and pip8-7 mutations were mapped are also indicated. 
Regions of the PRP8 gene cloned into the 214-based vector pFL44S to create the 
mapping plasmids pJDY1 to pJDY4. 
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strains were transformed with these plasmids. Several isolates were grown two or 
three times to stationary phase in liquid culture without uracil to select for 
maintenance of the plasmid. If the pip8 mutation was in the region of the gene 
carried by the plasmid then gene conversion would greatly increase the reversion rate 
of the mutation. Thus when aliquots of the cultures were plated at 23 °C (to assess the 
number of viable cells) and at 36°C (to select for temperature-resistant revertants) the 
mutation would be mapped by this increase in reversion frequency. 
Strains SPJ8.31 (prp8-1), JDY8.22 (prp8-2), JDY8.57 (pip8-5) and DJY76 
(jnp8) were transformed and analysed as above and in each case with one of the 
four plasmids the reversion frequency was 1X10 4-1X10 5 and with the other three it 
was less than lx iO. The prp8-1 mutation had been mapped to the 3' end of the gene 
(to the 3' side of the last Ba,nHI site, see figure 4. 1; Jackson, 1987). Since the 
plasmid that covered this region of the gene (pJDY3) gave high reversion frequency 
for strain SPJ8.31 this showed that the strategy worked. Mutations in both JDY8.22 
and JDY8.57 mapped to the region of the PRP8 gene in pJDY2, that in DJY76 to 
pJDY4. The inserts in pJDY2, pJDY3 and pJDY4 overlap (figure 4.1) and since only 
one plasmid gave the higher reversion frequency, the mutations were mapped to 
within the regions of the gene unique to that plasmid (see figure 4. 1). 
4.3 A Yeast Strain Conditionally Expressing PRP8. 
4.3. 1 Construction. 
The proposed method of constructing a strain in which transcription of the 
PRP8 gene could be repressed was, briefly, to delete one copy of the gene in a 
diploid by inserting a reporter gene in its place, to transform the diploid with a 
plasmid carrying a transcriptionally repressible PRP8 gene, sporulate and recover 
haploids carrying the reporter gene and the plasmid. 
To regulate transcription from the PRP8 gene the GALl-JO promoter was 
chosen as it is well characterised and provides tight carbon-source dependent 
regulation of expression (for review see Johnson, 1987). The upstream activator 
sequence (UAS) of the divergently transcribed GAL] and GALJO genes when placed 
upstream of heterologous promoters makes them both inducible by galactose and 
repressible by glucose (Guarente et al., 1982). 
Constructs utilising either the GALl-JO UAS alone or the whole GALl or 
GAL10 promoters have been used to repress the transcription of many genes including 
those coding for several yeast splicing-associated snRNAs: snR19 (Ul), snR20 (U2; 
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Seraphin and Rosbash, 1989) and snR7 (U5; Paterson and Guthrie, 1987; Seraphin 
et al., 1991). These GAL-snR fusions made production of the snRNAs galactose-
dependent and have allowed snRNA-depleted splicing extracts to be made and the 
effects of depletion to be studied (see section 1.5). I chose to insert the GALl-JO UAS 
into the PRP8 promoter in the hope of making the PRP8 gene similarly regulated. 
The plasmid (pJDY10) is shown in figure 4.2A. 
To generate a diploid strain with no PRP8 gene at one genomic locus the one 
step gene replacement method (Rothstein, 1983) was used. A plasmid, pJD10, was 
constructed in which the LEU2 gene is flanked by sequences from 5' and 3' to the 
PRP8 gene (and a few bases of coding sequence; figure 4.2B). Diploid strain JDYO.2 
(see table 4.1) was transformed with a PvuII fragment of plasmid pJD1O containing 
the LEU2 gene and PRP8 flanking sequences and leucine prototrophs were selected. 
These were screened for integration of the pJD 10 fragment into the PRP8 locus by 
sporulation and checking that no Leu haploids were produced (since PRP8 is an 
essential gene, spores in which the gene is disrupted or deleted will not be viable). 
Several of these isolates were then subjected to Southern blot analysis using probes 
corresponding to the 5' and 3' flanking sequences of the PRP8 gene in pJD10 to 
check for correct gene replacement. A Southern blot of one of these compared to the 
parental strain is shown in figure 4.3B. The changes in size of restriction fragments 
with all enzymes used were as expected (see figure 4.3 legend) and this strain was 
designated JDY8.01. 
Strain JDY8.01 was transformed with plasmid pJDY10 (GAL-PRP8, UR.43), 
sporulated and tetrads dissected on both YPDA and YPGRA plates. On both media 
Leu, Ura spores germinated, indicating that expression of the PRP8 gene was not 
sufficiently repressed by glucose to prevent cell growth. Thus plasmid pJDY10 was 
not useful for depleting PRP8 protein and a second URA, GAL-PRP8 plasmid, 
pJDY12, was made (figure 4.2A). In this plasmid the PRP8 gene was downstream 
of the entire GALl promoter and GALl-i 0 UAS. Sequence elements between the UAS 
and the transcription start site of the GAL] gene contribute towards glucose repression 
(see Johnson, 1987) and thus it was hoped that this would provide tighter control over 
PRP8 expression. 
Strain JDY8.01 was transformed with pJDY12 and 50 haploids from spores 
germinated on YPGRA were analysed for the presence of the LEU2 and URA3 
markers. No Leu haploids were found. It was therefore possible that this plasmid 
did not express the PRP8 gene. To assess whether or not this was the case strain 
SPJ8.31 (prp8-1) was transformed with pJDY12. pY8000 (containing the PRP8 gene 
under its own promoter), pJDY10 and pRS316 (vector only) were used as controls. 
FIGURE 3.4 Analysis of Splicing Complexes by Native Gel Electrophoresis. 
Complexes Formed in Splicing Reactions Inhibited by Anti-8.1 and -8.6 
Antibodies. 
Aliquots (5u1) of the splicing reactions shown in figure 3.213, plus 2min time points, 
were electrophoresed through a composite 0.25% (w/v) agarose, 3% (w/v) 
polyacrylamide non-denaturing gel. Complexes were designated I, II and III according 
to Pikielny et al. (1986). 
The Effect on Splicing Complex Formation of Anti-8.4 and Pre-hnmune 
Antibodies. 
Splicing reactions were assembled as described in figure 3.2C from splicing extract 
treated with IgG from anti-8.4 serum (lanes 1 to 4), or from the corresponding pre-
immune serum (lanes 5-8) or PBS (lanes 9 and 10). S/Li samples were taken at the 
times indicated and analysed as described in A. 
The Effect on Splicing Complex Formation of Anti-8.2 and -8.3 Antibodies. 
Aliquots (54ul) of the splicing reactions shown in figure 3.313 were analysed for 
splicing complexes as described in A. 
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antibodies which inhibited splicing blocked spliceosome assembly after formation of 
the pre-spliceosome but before the U4/U6 and U5 snRNPs assembled into the 
complex i.e. prior to the entry of PRP8. 
3.6 Interaction of Antibodies with Splicing Complexes. 
The experiments above demonstrate that anti-PRP8 antibodies inhibit 
spliceosome assembly prior to the formation of stable complexes containing PRP8 
protein. However, spliceosomes can be precipitated by anti-PRP8 antibodies (anti-8.4; 
Whittaker et al. (1990) and anti-8.6; Whittaker and Beggs (1991)) and therefore not 
all the epitopes recognised by these antibodies are masked. Since the U5 snRNP and 
hence PRP8 is present in several different splicing complexes (complexes I and II 
resolved in the native gel system used here) between which there may be numerous 
changes in the interactions of PRP8 it was of interest to determine exactly which 
complex(es) were recognised by the antibodies. The availability of epitopes of PRP8 
was therefore examined by adding anti-PRP8 antibodies to splicing reactions before 
loading on non-denaturing gels (see section 3.2 for details). Splicing complexes would 
be retarded in the gel if they were bound by antibodies. 
Figure 3.5 shows the result of an experiment utilising IgG from all three 
antisera which recognise native PRP8 protein and also anti-M 3G antibodies. Anti-M 3G 
antibodies (lane 3) retarded all three complexes showing that at least some of the M 3G 
caps on snRNAs were exposed. Consistent with the fact that they do not precipitate 
spliceosomes (Whittaker, 1990), addition of anti-8.1 antibodies (lane 5) did not alter 
the mobility of any complex. Anti-8.6 antibodies (lane 2) retarded complexes I and 
II showing that epitopes which these antibodies recognise are available. Anti-8.4 
antibodies (lane 6) however, only retarded the active spliceosome - complex II - 
showing a change in the interactions of PRP8 and hence visualising a difference in 
the composition or conformation of the spliceosome between complexes I and II. 
Anti-8.2 and -8.3 antibodies had no effect on the mobility of splicing complexes in 
native gels (data not shown). 
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FIGURE 3.5 Analysis of Splicing Complexes Pre-incubated with Antibodies. 
A 40d splicing reaction assembled with wild type splicing extract and rp28 pre-
mRNA was incubated at 25°C for 8mm, aliquotted into 51 volumes and incubated 
with antibodies. The samples were then analysed by non-denaturing gel 
electrophoresis as in figure 3.4A. Antibodies added to each sample are indicated; 
lanes 1, 4 and 7 (-) are samples incubated with PBS alone. 
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In this chapter the characterisation of anti-8.6 antibodies was described. The 
inhibition of splicing by these and two other antibodies, anti-8.1 and -8.4, which 
recognise the native PRP8 protein was demonstrated and was found to prevent 
assembly of U5 and U4/U6 into the spliceosome. Antibodies which recognise the 
native protein poorly had only a modest effect on splicing. The inhibition of splicing 
was shown to be specific by the use of pre-immune antibodies and antigen 
competition experiments. 
Affinity purified anti-8.6 antibodies reacted specifically with PRP8 on Western 
blots of splicing extracts (although proteins of less than about 20kDa were not probed 
with either crude serum or affinity purified antibodies). Immunoprecipitation of PRP8 
protein and snRNPs can be competed out with the peptide against which the 
antibodies were raised and pre-immune serum does not immunoprecipitate PRP8. 
Taken together, these results provide good evidence that data obtained with the 
immune serum were due to reaction with PRP8, and not through recognition of other 
proteins such as the 130kDa species seen on Western blots. 
The immunoprecipitation pattern of U4, U5 and U6 snRNAs observed with 
anti-8.6 antibodies differed to that seen with anti-8.4 antibodies. Taken alone the 
result obtained with anti-8.6, decreased precipitation of U4 and U6 snRNAs following 
incubation with ATP, would imply loss of U4/U6.U5 tri-snRNPs. However, in 
conjunction with the anti-8.4 result (increased precipitation of U4, U5 and U6), the 
simplest explanation is that the different antibodies recognise alternative forms of the 
U5 snRNP and tri-snRNP reflecting different availabilities of epitopes. This would 
be consistent with observations made by other groups. Banroques and Abelson (1989) 
reported that the immunoprecipitation of U4, US and U6 snRNAs by anti-PRP4 
antibodies (PRP4 is a U4 associated protein; Xu et al., 1990) was unaffected by ATP 
unless heparin was included in the incubation, when only U4 and U6 were 
precipitated. Thus an ATP-dependent, heparin-sensitive tri-snRNP was formed. This 
explained the apparent ATP sensitivity of the tri-snRNP in the native gel analysis of 
Cheng and Abelson (1987) in which heparin was used during sample preparation. 
Also, if the ATP-dependent form of the tri-snRNP were recognised by anti-8.4 
antibodies and not by anti-8.6 antibodies this would explain the difference in the 
immunoprecipitation pattern of the two antisera. It cannot be ascertained, however, 
whether the ATP-dependent tri-snRNPs are formed de novo from US and U4/U6 
snRNPs or are formed from pre-existing tri-snRNP particles or whether heparin 
complexes bear any resemblance to physiological snRNP complexes involved in 
FIGURE 4.2 Plasmid Construction. 
GAL-PRP8 Fusion Constructs. 
pJDY10 was constructed by cloning fragments of pRY21 (Hindill to BglII; GAL-
UAS), pJK2 (NdeI to NheI; part of the PRP8 promoter and the first 9 bases of the 
coding sequence of PRP8) and pJDY6 (NheI to NheI; the PRP8 gene minus the first 
9 bases and with all the available 3' flanking sequence) into the polylinker of pRS3 16 
(table 2.2 and figure 3.1 for description of the plasmids). A linker consisting of 
oligonucleotides 089E and 090E (table 2.3) was used during the construction to insert 
a Bglll site upstream of the PRP8 promoter fragment to allow subsequent cloning of 
the GAL-UAS. Most of the pRS316 polylinker is deleted in pJDY10, and the GAL-
PRP8 fragment is flanked by XhoI and NotI sites that are unique to the plasmid. 
Inserts in plasmids used in the construction are indicated by double lines, the part of 
the linker fragment that is retained in pJDY10 is indicated by the thick double line 
B-D. 
pJDY12 was constructed by replacing the XhoI to NheI GAL-UAS-pPRP8 portion of 
pJDY10 with a PCR fragment amplified from pBM125 (using oligonucleotides 228G 
and 229G (table 2.3)) that contained the GAL- UAS and pGALI with the first 9 bases 
of PRP8 and an NheI site at the pGALJ end and an XhoI site at the other. 
pJDY13 was constructed by transferring the XhOI to NotI GAL-PRP8 fragment from 
pJDY12 to the pRS313 polylinker. 
Restriction sites: B, BglII; C, ClaI; D, NdeI; H, HindIII; L; Sail; N, MzeI; 0, XhoI; 
S, SphI; T, NotI; X, XbaI. 
PRP8 Replacement Construct. 
pJD10 was constructed by cloning the LEU2 Bg1H fragment from YEp13, the PRP8 
promoter SphI to NheI fragment from pJK2 and the PRP8 ClaI fragment (end-filled) 
from pY8500 sequentially into the BamHI, SphI plus XbaI, and SmaI sites of the 
pUC19 polylinker. Only 9 bases of 5' and 13 bases of 3' sequence from the PRP8 
gene are included in pJD10. Both the pJK2 and pY8500 fragments contained some 
tel sequences. Restriction sites as in A plus: A, SmaI; M, BamHI; P, PvuII; R, 
EcoRI. 
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Structure of Genomic Loci in Strain JDY8.01. 
Restriction maps of the prp8::LEU2 allele (i) and the wild type PRP8 allele (ii) and 
the relationship between them. The entire PRP8 gene (thick line in ii) except 9 bases 
at the 5' end and 13 bases at the 3' end is replaced by the LEU2 fragment from 
pJD10 (figure 4.313). Restriction sites relevant to the Southern blot in B are indicated, 
as are the fragments used to make probes (NheI to Hindill fragment from pJK2, ClaI 
fragment from pY8500). Scale is indicated by the bar (1kb). Restriction sites: C, 
C1aI; H, Hindill; N, NheI; R, EcoRI; X, XbaI. 
Southern Blot. 
Genomic DNA was isolated from strains JDYO.2 (lanes 1) and a derivative of it, 
JDY8.01 (lanes 2), carrying the prp8::LEU2 allele, restriction digested with the 
restriction enzymes indicated (abbreviations as in A), electrophoresed through an 
0.8% agarose gel, blotted to Hybond-N and hybridised sequentially to 32P-labelled 
DNA fragments (indicated in A) corresponding to sequences 5' and 3' to the PRP8 
gene. Probes were made by labelling the fragments indicated in A by the random 
priming method. The location of EcoRI and ClaI sites flanking the PRP8 gene and 
the XbaI site 5' to the gene were unknown. Thus the only restriction fragment of 
known size was the 4.2kb 3' XbaI fragment. Expected changes in restriction fragment 
size calculated from the maps in A and the sizes of fragments observed (determined 











EcoRI[ +0.4 +1.0 1.9,2.2 - +0.3 6.0, 7.2 +1.2 
ClaI -4.0 +1.7 2.7',7.0 -4.3 5.8, 7.6 +1.8 
XbaI +5.8 +to site 
S'to gene 
3.1, 8.6 +5.5 (2.3), 
4.2, 8.6 
+4.4 
= restriction fragment only seen in JDY8.01. 
Sizes of restriction fragment were approximately as expected. The same novel XbaI 
fragment in JDY8.01 was seen when the blot was probed with either 5' or 3' flanking 
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Five transformants of each were tested for their ability to grow at 36 °C (the restrictive 
temperature) on glucose-containing medium (YMMCas) and galactose-containing 
medium (YMGRCas). Cells carrying pRS316 did not grow on either medium whereas 
those carrying pY8000 or pJDY1O grew on both (this again indicated that expression 
of PRP8 from pJDY10 was not repressed on glucose). However, cells carrying 
pJDY12 grew on YMGRCas but not on YMMCas indicating that the PRP8 gene was 
expressed under inducing conditions but not under repressing conditions. One possible 
reason that haploids carrying pJDY12 and the prp8::LEU2 allele had not been 
generated from JDY8.01 was that expression of PRP8 from pJDY12 was low and 
insufficient to allow successful germination of the spores. Thus pJDY13 (pRS313 
(HIS3, CEN) carrying the GAL]-PRP8 fusion from pJDY12; see figure 4.2A) was 
made and used in a plasmid shuffle experiment on galactose medium with strain 
JDY8.02 (prp8::LEU2, pY8000; table 4.1) to produce strain JDY8.05 which had lost 
pY8000 (and was thus Ura, His). Strain JDY8.05 did not grow when spotted on 
glucose plates, confirming the result obtained with pJDY12 and strain SPJ8.31 that 
transcription from the GAL]-PRP8 fusion in plasmids pJDY12 and pJDY13 was 
repressible. 
4.3.2 Characterisation. 
Strain JDY8.05 was analysed further in several ways to check that it had the 
correct phenotype and genotype: 
1) Sequencing; In order to confirm that strain JDY8.05 contained the 
prp8::LEU2 allele, genomic DNA from strain JDY8.05 was prepared and a PCR 
reaction carried out with oligonucleotides 010A and 013A (see table 2.3, and figure 
4.3A). These oligonucleotides are specific to 5' and 3' flanking sequences of the 
PRP8 gene respectively and should prime amplification of the prp8::LEU2 allele. The 
PRP8 gene on plasmid pJDY13 does not contain any 5' flanking sequences and should 
not be amplified. As expected a single PCR product was generated of about 3kb 
consistent with amplification of the prp8::LEU2 allele (see figure 4.3A for map of the 
allele). The ends of this product were sequenced (section 2.4. 15) using the same 
oligonucleotides as primers. The sequence exactly matched that expected with all 
PRP8 coding sequence except 9 bases at the 5' end and 13 bases at the 3' end of the 
gene replaced by the LEU2 containing fragment (data not shown). Thus it was 
concluded that strain JDY8.05 contained the prp8::LEU2 allele and that the gene 
replacement was exact. 
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Growth Curves; Figure 4.4 shows growth curves of strain JDY8.05 and a 
derivative of it carrying pY8500 (JDY8.06, table 4.1; pY8500 is CEN, URA3, wild 
type PRP8). Typically, cells of either strain grew in galactose-containing medium 
(YPGRA) with a doubling time of 2.5hrs. In glucose-containing medium (YPDA) 
however, the growth rate of JDY8.05 reproducibly declined after 4-5hrs and 
eventually stopped whereas JDY8.06 continued to grow. Since the cells were grown 
in complete medium (removing selection for the HIS and URA markers on the 
plasmids, selection being solely for the PRP8 gene) the only effective difference 
between the two strains was the promoter directing expression of the PRP8 gene. 
Thus the growth defect of JDY8.05 in YPDA was ascribed to depletion of PRP8 
protein. 
Northern Blot Analysis; RNA extracted from strain JDY8.05 at various 
times after switching from YPGRA to YPDA medium was analysed by Northern 
blotting to assess the effect on intron containing transcripts. Figure 4.5A shows such 
an experiment where the transcripts from the actin and RP28 genes have been 
examined. As a positive control RNA from the temperature-sensitive prp8-1 strain 
SPJ8.31 grown at 23°C and 36 °C was also examined. In SPJ8.31 grown at 36 °C most 
of the actin transcripts remained unspliced (lane 2) indicating a severe splicing defect, 
whereas, although some unspliced transcripts were seen in strain JDY8.05 after 5hrs 
in glucose (lane 4), there remained a substantial amount of spliced mRNA even after 
9hrs (lane 5) when the growth of the cells was severely impaired (figure 4.4A). Rp28 
pre-mRNA is less efficiently spliced than actin and a more severe defect was seen in 
both SPJ8.31 (lane 2) and JDY8.05 (lanes 4 and 5). However, although there was a 
sizeable decrease in the amount of spliced mRNA in strain JDY8.05 some remained 
after 9hrs, and the accumulation of pre-mRNA was not as great as in SPJ8.31. The 
difference observed between heat-treating SPJ8.3 1 and growing JDY8.05 in glucose 
was probably due to depletion of PRP8 being gradual whereas the temperature-
sensitivity of SPJ8.31 is rapidly manifested (growth almost stops after 2hrs at 36 °C; 
data not shown). Inefficiently spliced transcripts might have shown a more dramatic 
effect than either actin or rp28 pre-mRNAs which (particularly actin) are efficiently 
spliced and would compete well for limiting amounts of splicing factors, in this case 
for PRP8 protein. 
Western Blotting; The level of PRP8 protein in strain JDY8.05 was 
examined by Western blotting and probing with anti-PRP8 antibodies. PRP8 protein 
is not abundant and is difficult to detect in crude protein extracts (Jackson, 1987 and 
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FIGURE 4.4 Analysis of Strain JDY8.05 - Growth Curves. 
Mid-log cultures of strains JDY8.05 (A) and JDY8.06 (B) grown in YPGRA were 
spun down (time 0) and half the cells were shifted into YPDA medium (is), while the 
other half was returned to YPGRA medium (+). OD600  was measured at hourly 
intervals and cultures were diluted in the appropriate medium to maintain conditions 
suitable for logarithmic growth. OD is the relative optical density at 600nm (arbitrary 
units), the arrow in A indicates the time at which splicing extracts were prepared 












FIGURE 4.5 Analysis of Strain JDY8.05. 
Northern Blot. 
Total RNA was extracted from strain SPJ8.31 (prp8-1) grown at the permissive 
temperature (23 °C; lane 1) or after growth at 36 °C for 4hrs (lane 2) and from strain 
JDY8.05 grown in YPGRA (lane 3) or after growth in YPDA for 5 and 9hrs (lanes 
4 and 5). 25jzg of each RNA was denatured and electrophoresed through a 1.5% 
(w/v) agarose gel, blotted to Hybond-N and hybridised sequentially to 32P-labelled 
DNA fragments encoding actin and rp28 (from plasmids pYA301 and pT7rp28s 
respectively). Probes were made as described in figure 4.313. The positions of 
unspliced precursor (pre-mRNA) and spliced messenger RNA (mRNA) are indicated. 
Western Blot. 
Splicing extracts were electrophoresed through an SDS-8.5 % (w/v) poylacrylamide 
gel, blotted to nitrocellulose and probed with anti-8.6 antibodies. Extracts were: prp2, 
DJY85 (inactive extract made as in section 5.2); +PRP8, JDY8.05 made from cells 
grown under inducing conditions; zPRP8, JDY8.05 made from cells grown under 
repressing conditions for the number of hours indicated; wild type, BJ2412. 
Approximately 240/.Lg (protein) of extract was used in lanes 1 to 5 and 9, the dilutions 
of wild type extract in lanes 6 to 8 gave 24 (X0. 1), 48 (X0.2) and 120jg (X0.5) 
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data not shown). Thus, as it was suspected that production of PRP8 protein would be 
low in strain JDY8.05, splicing extracts were used as these contain much more PRP8 
per unit of protein and volume of sample than crude cell extracts. It was found to be 
virtually impossible to detect PRP8 in splicing extracts from strain JDY8.05 even 
when cells were grown under inducing conditions. Therefore accurate measurements 
of the level of PRP8 protein relative to the amount in wild type cells were not 
feasible. Figure 4.5B shows a blot of dilutions of a wild type extract (lanes 6 to 9; 
BJ2412, the standard wild type strain used for making splicing extracts) and extract 
from strain JDY8.05 (lanes 2 to 5). The PRP8 signal was lost when wild type extract 
was diluted 10-fold and no signal was seen in extracts from strain JDY8.05. In other 
similar experiments comparison of the level of PRP8 protein in extracts of strain 
JDY8.05 grown under inducing conditions with that in a wild type, indicated that it 
was at least 20-fold less in JDY8.05. 
4.4 Discussion. 
This chapter describes outcrossing and mapping of several prp8 temperature-
sensitive alleles and the construction of a yeast strain, JDY8.05, that is deleted for 
the genomic PRP8 sequences and carries a GAL]-PRP8 fusion plasmid which 
represses expression of the PRP8 gene during growth on glucose. These were 
preliminary steps towards analysing both the null phenotype, and the temperature-
sensitive alleles for their defects in splicing. In vivo depletion of an intrinsic snRNP 
protein has not previously been reported. 
Complementation of the temperature-sensitivity of the outcrossed strains by 
plasmids carrying the wild type PRP8 gene verified that the prp8 mutations were the 
only temperature-sensitive mutations in them. Several mutations were mapped by a 
strategy which made use of the high level of gene conversion in yeast to repair them 
with wild type PRP8 sequence from plasmids which contained fragments of the gene. 
While this mapping was relatively crude, the regions of PRP8 in plasmids pJDY1-4 
being 2kb or larger, it localised the mutations in this huge probably multi-functional 
protein. If subsequent study were to show that any of these mutations had particularly 
interesting phenotypes, this localisation would make cloning easier. This could be 
done either by PCR amplification of the region of interest from genomic DNA 
isolated from the mutants or using the gap repair technique (Orr-Weaver et al., 
1983). 
Strain JDY8.05 was shown to have a very low level of PRP8 protein under 
inducing conditions and when PRP8 expression was repressed this level presumably 
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dropped, as cell growth slowed and eventually stopped, and a splicing defect was seen 
in vivo. This is consistent with the essential role of PRP8 in splicing. 
The low level of production of PRP8 protein was consistent with the fairly 
rapid inhibition of growth seen on transfer of JDY8.05 from inducing to repressing 
medium, and with the observation that transcripts which would normally be efficiently 
spliced accumulated as unspliced pre-mRNA even in cells grown under inducing 
conditions. However, while PRP8 protein was limiting such that splicing was 
inefficient, growth may have been limited by some other factor since JDY8.05 grew 
as well as JDY8.06 in YPGRA. The low level of PRP8 protein may well have been 
fortuitous as, from this observation on growth rate it would appear that very little 
PRP8 protein is required to support cell growth (the assumption was made that 
production of PRP8 protein from pY8500 in JDY8.06 was (as it is in SPJ8.31; 
Jackson, 1987) at least as high as expression from a genomic copy of the gene, and 
that there was no splicing defect in JDY8.06). A construct from which PRP8 protein 
was produced at higher levels under inducing conditions might not have been 
sufficiently repressible to limit splicing and cell growth (this may have been the 
reason that pJDY10 was not useful). 
It is not known why PRP8 protein production from pJDY13 was so poor. 
However, possible reasons include: sub-optimal sequences for translation initiation 
(GTC AAG ATG AGT compared to the yeast consensus sequence (A/T)A(A/C) 
A(A/C)A ATG TC(T/C); Hamilton et al., 1987, ATG = initiation codon); when the 
promoter was sequenced, a single base difference, presumably caused by PCR error, 
was found between that in pJDY13 and the published GALl-JO promoter sequence 
(not shown). This nucleotide is not, however, in one of the 17 base repeats known 
to be important for induction (Johnson, 1987), but may be in the binding site for 
(an)other factor(s) which is/are important for transcription from this promoter. 
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INACTIVATION AND DEPLETION OF PRP8 
RESULTS IN A BLOCK IN SPLICING AND 
ACCUMULATION OF A PRE-SPLICING 
COMPLEX. 
5.1 Introduction. 
Extracts prepared from strains temperature-sensitive for or conditionally 
producing the PRP8 protein (described in chapter 4) provided the means to determine 
the defects caused by loss of PRP8 activity. A protocol for heat-inactivation of 
extracts from strains temperature-sensitive for splicing factors (including a prp8-1 
strain) had been published (Lustig et al., 1986). It was hoped that this method could 
be applied to extracts from strains carrying a number of different pipS mutations. 
This chapter describes attempts to heat-inactivate prp8 strain extracts in vitro 
using the method of Lustig et al. (1986), and the development of an alternative 
protoplast inactivation procedure. Inactive extracts produced using this method along 
with extracts from strain JDY8.05 were analysed for the formation of splicing 
complexes. 
5.2 Heat-Inactivated Splicing Extracts. 
5.2.1 in vitro Heat-Inactivation. 
The heat-inactivation procedure of Lustig et al. (1986) was to incubate 
splicing extracts (prepared from temperature-sensitive strains grown and 
sphaeroplasted at the permissive temperature (23 °C)) at 30-32 0C in the presence or 
absence of various components of the in vitro splicing reaction (potassium phosphate, 
polyethylene glycol, ATP etc.). Subsequently, extracts from yeast strains temperature-
sensitive for splicing factors other than those tested by Lustig et al. (1986) have been 
inactivated in vitro (eg PRP18 (Vijayraghavan and Abelson, 1990) and PRP22 
(Company et al., 1991)) and it would appear that this approach may be applicable to 
the majority of splicing factors. 
Attempts were made to heat-inactivate splicing extracts from strains SPJ8.31 
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(prp8-1), DJY76 (pip8-7) and JBY27 (prp2-1). BJ2412 and DBY746 were used as 
wild type controls (see table 2.1 for full genotypes). Extract from strain JBY27 was 
readily heat-inactivated under a variety of conditions. However, it was not found 
possible to reproducibly inactivate extracts from either prp8 strain except under 
conditions that also inactivated wild type extracts (data not shown). Incubation 
conditions that were tested include: those used by Lustig et al. (1986) and variations 
on these; in vitro splicing conditions with and without ATP; splicing extract alone 
with and without ATP (this works well without ATP for extracts from prp2-1 strains, 
M.McGarvey personal communication); temperatures up to 36 0C for one hour. 
Although these did not constitute an exhaustive search, it became clear that if many 
conditions had to be tested for each and every temperature-sensitive allele of prp8 
(and possibly for individual extracts) it would not be feasible to carry out the project. 
Alternatives approaches to in vitro heat-inactivation were therefore sought. 
5.2.2 In vivo Heat-Inactivation. 
The standard protocol for preparing splicing extract (section 2.5.7.1) has one 
point at which an elevated temperature incubation can be easily inserted, that is the 
"recovery phase" when protoplasts are incubated in osmotically stabilised medium. 
The inclusion of a recovery phase was found by Lossky (1988) to increase the activity 
of extracts, presumably by allowing protoplasts to regain metabolic function 
(Hutchinson and Hartwell, 1967). 
An alternative to protoplast heat-inactivation would be to grow cells at the 
non-permissive temperature prior to making extracts without sphaeroplasting the cells, 
by eg sonicating, or vortexing in the presence of glass beads. This approach was not 
used, as a similar method developed by Seraphin and Rosbash (1989) produced only 
dilute extracts which had low splicing activity (data not shown). Also, Abovitch et al. 
(1990) reported that with extracts prepared in this way events late in spliceosome 
assembly were not readily visualised. As PRP8 protein is a component of a snRNP 
that associates with spliceosomes late in the assembly pathway this method would not 
have been useful. 
The protoplast heat-inactivation procedure was tested with strains carrying the 
prp2-1 and prp8-1 alleles (DJY85 and SPJ8.3 1 respectively). Protoplasts were 
incubated at 36°C in pre-heated medium then chilled on ice, spun down at 4 °C and 
kept at this temperature for the remainder of the extract preparation. Extracts 
produced from both strains were inactive for splicing in vitro (eg figure 5.1 lanes 8 
and 10). The protocol was also successful with a variety of other strains including 
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FIGURE 5.1 In vitro Splicing Reactions. 
In vitro splicing reactions (101) containing radiolabelled rp28 pre-mRNA substrate 
were assembled with either 5d of a single extract or 2.5141 of two extracts to test 
complementation. RNA was recovered and fractionated on a 6% (wlv) denaturing 
polyacrylamide gel. Lane T, gel purified rp28 transcript; lane M, markers, end-
labelled fragments of pBR322 plasmid DNA digested with MspI and AvaI±NheI; 
+PRP8, extract from JDY8.05 cells grown in YPGRA; APRP8, extract from 
JDY8.05 cells grown in YPDA for 6hrs; prp2, prp8 and prp9 are inactive extracts 
prepared as in section 5.2 from strains DJY85 (prp2-1), SPJ8.31 (prp8-1) and 
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JDY9.11 (prp9-1; figure 5.1 lane 6,), JDY8.22 (prp8-2; figure 5.213 lane 5) and 
DJY76 (pip8-7; figure 5.2C lane 1). The time of incubation at the non-permissive 
temperature was found to be important and had to be optimised in several cases, eg 
strains carrying the prp2-1 allele produced inactive extracts that complemented 
extracts inactivated for other splicing factors after a 45min protoplast incubation at 
36°C, but that did not if the protoplasts were incubated at this temperature for more 
than 1.5hrs. Times of incubation at 36 °C were as follows: DJY85, 45mins; SPJ8.31, 
2.5hrs; JDY9.11, lhr; DJY76 and JDY8.22, 2hrs. Extract made from the wild type 
strain BJ2412 following incubation of protoplasts at 36 °C for 2hrs showed only slight 
loss of activity compared to one prepared in the normal manner (figure 5.2A). 
5.3 In vitro Splicing in Extracts from JDY8.05. 
In order to assess the effect of depleting PRP8 protein on splicing in vitro, 
extracts were made from strain JDY8.05 grown under GAL-PRP8 inducing or 
repressing conditions. Cultures grown for 6hrs in glucose medium were chosen for 
making splicing extracts depleted of PRP8. Growth is impeded after 6hrs (figure 
4.4A) and there is a considerable defect in pre-mRNA splicing in vivo. However, 
hopefully cells would still contain other factors required for splicing. 
Figure 5. 1 lanes 3 and 4 shows the results of in vitro splicing reactions carried 
out with extracts from strain JDY8.05. While extract made under inducing conditions 
was active (+PRP8; lane 3), extract made from cells grown under repressing 
conditions did not splice pre-mRNA (PRP8; lane 4). PRP8 protein was therefore 
depleted sufficiently in the zPRP8 extract to prevent splicing in vitro. 
5.4 Inactivation and Depletion of PRP8 is Specific. 
To show that the lack of splicing activity resulting from protoplast heat-
inactivation or in vivo depletion of PRP8 protein were specific, complementation 
experiments were undertaken. Equal amounts of inactive extracts were mixed and 
incubated together at 25 °C for approximately lOmins before addition of other 
components of the splicing reaction. Splicing activity was restored when inactive 
extracts from strains temperature-sensitive for different splicing factors were 
combined (figure 5.1 lanes 11 to 13; figure 5.213 lanes 2 and 6; figure 5.2C lanes 3 
and 4). As with prp8 extracts, APRP8 extract complemented prp2 and prp9 extract 
(figure 5. 1 lanes 5 and 7). Complementation was not seen between a prp8-1 extract 
and APRP8 extract (figure 5. 1 lane 9), or between inactive extracts from two strains 
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FIGURE 5.2 In vitro Splicing Reactions. 
Splicing reactions were assembled and analysed as in figure 5.1. 
Splicing reactions assembled with extracts prepared from wild type strain BJ2412. 
Splicing extracts were prepared from sphaeroplasts incubated at either 30 °C (lane 1) 
or 36°C (lane 2). 
Complementation assays. Inactive splicing extracts were prepared as in section 
5.2: prp8-1, SPJ8.31 (prp8-1); prp2, DJY85 (prp2-1); prp8-2, JDY8.22 (prp8-2). 
prp8-2 (23) is extract prepared from sphaeroplasts of JDY8.22 incubated at 23 °C. 
Complementation assays. Inactive splicing extracts were prepared as in section 
5.2: prp8-7, DJY76 (prp8-7); prp9, JDY9.11 (prp9-1); prp2, as B. prp8-7 (23 °C) is 
extract prepared from sphaeroplasts of DJY76 incubated at 23 °C. 
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carrying different temperature-sensitive prp8 mutations (figure 5.213 lane 7); splicing 
activity in the combined extracts was no greater than the residual activity in the 
individual extracts. Thus the inactivation and depletion procedures were specific for 
PRP8 protein and possibly for closely associated factors (eg other U5 snRNP 
components). Neither PRP2, nor PRP9 is known to have any direct association with 
PRP8. 
5.5 Inactivation and Depletion of PRP8 Leads to Accumulation of Pre-
spliceosomes Containing Ui and U2 snRNPs. 
The effects on spliceosome formation of depleting or inactivating PRP8 protein 
was investigated using native gel electrophoresis (section 2.5.8). The formation of 
splicing complexes in in vitro splicing reactions carried out with extracts from strain 
JDY8.05 is shown in figure 5.3A. +PRP8 extract showed the normal pattern and 
kinetics of complex formation (lanes 1 to 5), whereas zWRP8 extract produced only 
complex III (lanes 6 to 10) which accumulated with time and relative to +PRP8 
samples after 10 and 20mins in which most of the complex III had been processed to 
later complexes (compare lanes 4 and 5 with lanes 9 and 10). Similar results to those 
shown in figure 5.3A lanes 6 to 10 were obtained in time course experiments with 
prp8 extracts (data not shown). 
The complexes that were formed by inactive extracts from temperature-
sensitive strains, and by combinations of these and iWRP8 extract are shown in figure 
5.313. i.WRP8 and prp8-1 extracts only formed complex III (lanes 2 and 8). When 
these two extracts were used together (lane 7) complex III was again the only one 
seen. However, combinations of IPRP8 extract and either prp9 (lane 3) or prp2 
extract (lane 5) led to the formation of all three complexes consistent with the 
complementation of the splicing defects previously shown. prp9 extract formed little 
if any complexes (lane 4), consistent with PRP9 protein being required for an early 
step in spliceosome assembly (U2 snRNP binding; Abovitch et al., 1990). The small 
amount of complex III observed reflects incomplete inactivation of prp9 protein in the 
extract used in this experiment. Complexes III and I were observed with prp2 extract 
(lane 6). This is consistent with the known prp2 defect which is after formation of the 
complete spliceosome (Cheng and Abelson, 1987; Lin et al., 1987). 
The above results indicate that the effect of depleting or inactivating PRP8 
protein was the same with respect to the formation of complexes on non-denaturing 
gels - the accumulation of complex III - consistent with U1 and U2 snRNPs binding 
to the pre-mRNA, but not US or U4/6 snRNPs. Although the fractionation of splicing 
118 
FIGURE 5.3 Analysis of Splicing Complexes by Native Gel Electrophoresis. 
Time course. Splicing reactions (301d) assembled with splicing extracts (151d) 
from strain JDY8.05 (+PRP8, lanes 1 to 5; A PRP8, lanes 6 to 10) were incubated 
at 25°C and aliquots (51d) removed at the times indicated. Analysis by non-denaturing 
gel electrophoresis was as in figure 3.4A. 
Complementation assays. Complexes were analysed (as in figure 3.4A) from 5d 
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complexes by native gel electrophoresis provides an informative profile of the 
intermediates in the spliceosome assembly pathway, there are several drawbacks to 
this method. The stringent conditions employed often cause loss of UI snRNP and 
destabilised U4 snRNP (Konarska and Sharp, 1986, 1987; Pikielny et al., 1986; 
Cheng and Abelson, 1987; Lamond et al., 1988). Specific but weak interactions are 
therefore often lost during the processing of samples and/or during electrophoresis. 
In order to verify the snRNA content of the complex that accumulated in the absence 
of PRP8 function the composition of splicing-specific complexes was assessed by 
another method: indirect immunoprecipitation using antibodies against poly(A)-
binding protein. This method was developed in this laboratory by E.Whittaker and 
shown to give specific immunoprecipitation of all the splicing-associated snRNAs 
(Whittaker et al., 1990). The procedure utilises the fact that yeast whole cell extracts 
contain poly(A)-binding protein which associates with exogenously supplied 
transcripts that have a poly(A) tail making them immunoprecipitable by antibodies 
against the poly(A)-binding protein. Note that there is no distinction between different 
complexes in this selection. The snRNAs that are detected represent the pool of 
complexes formed on the poly-adenylated substrate. 
Figure 5.4 shows a Northern blot of snRNAs immunoprecipitated by 
antibodies against poly(A)-binding protein from splicing reactions assembled with 
non-radioactive rp5lA substrate (Pikielny and Rosbash, 1986; rp5lA has a poly(A) 
tail of approximately 100 nucleotides). Lane 1 shows that all the splicing-associated 
snRNAs were precipitated from a +PRP8 splicing reaction. Immunoprecipitation of 
complexes from a prp2 extract (lane 3) also showed all the splicing-associated 
snRNAs. However, precipitations from either APRP8 or prp8-1 extract (lanes 2 and 
4) showed only Ui and U2 snRNAs associated with the substrate. Examination of the 
supemates from the immunoprecipitations (lanes 5 to 8) confirmed that all the 
snRNAs were present in the extracts and had not been degraded during the 
experiment. This result is consistent with those of native gel analysis. Thus in the 
absence of PRP8 or in the presence of inactive PRP8 protein (and by inference when 
the protein is inhibited by antibodies - section 3.5) U  and U2 snRNPs but neither U5 
nor U4/U6 snRNPs associate with pre-mRNA. 
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FIGURE 5.4 Analysis of the snRNA Content of Splicing Complexes. 
Splicing reactions (SOul), containing nonradioactive rp5 1 A transcript, were incubated 
at 25°C for 8mins and the complexes formed on the RNA were affinity-selected by 
immunoprecipitation with antibodies against poly(A)-binding protein. RNA was 
recovered from the immunoprecipitates (lanes 1 to 4; a-PAB) and the supernates 
(lanes 5 to 8; 25% Supernates) and the snRNA content analysed by Northern blotting 
as in figure 3.213. The Northern blot was hybridised with uniformly labelled gel-
purified fragments of snR genes. Probes for the U!, U4, U5 and U6 snRNAs were 
from plasmids "Ui clone", pTZ18U4G, pFN-1 and pTaq6 respectively (table 2.2), 
the U2 probe was a PCR product amplified using oligonucleotides 060L and 061L 
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In this chapter the development of a protocol for reliably producing in vivo 
heat-inactivated splicing extracts from a number of different temperature-sensitive prp 
mutants was described. These extracts and extracts from strain JDY8.05 were 
analysed for the assembly of splicing complexes. 
In previous studies involving heat-inactivated prp8 strain extracts (Lin et al., 
1987; Abovitch et al., 1990) the complex that accumulated was not analysed. The 
analysis of Lin et al. (1987) was restricted by the use of glycerol gradients which 
only resolved spliceosomes and not pre-spliceosome complexes. The conclusions that 
could be drawn by Abovitch et al. (1990) were limited by the method of extract 
preparation (which produced low activity extracts in which few complexes formed). 
The results obtained here do not conflict with these reports - indeed they extend them. 
The protoplast inactivation procedure was based on a reliable method of preparing 
splicing extracts with a high concentration of splicing factors. A combination of this 
and a native gel electrophoresis technique that resolved several splicing-specific 
complexes and indirect immunoprecipitation of splicing complexes located the defect 
in the prp8 extracts. 
Extracts from JDY8.05 cells grown under inducing conditions were active for 
in vitro splicing, whereas extracts made from cells grown under repressing conditions 
for 6hrs were inactive. Thus the in vivo splicing defect in JDY8.05 was reproducible 
in vitro. Native gel electrophoresis showed that inactive (zPRP8) extracts 
accumulated complex III (pre-spliceosomes). Indirect immunoprecipitation using anti-
poly(A)-binding protein antibodies from reactions assembled with a poly-adenylated 
substrate also showed that only U  and U2 snRNPs stably associated with pre-mRNA. 
Heat-inactivated prp8-1 extract showed the same phenotype as zPRP8 extract by both 
native gel analysis and indirect immunoprecipitation, and inactive extract from strains 
carrying two other pip8 alleles also formed only complex III on native gels. Inactive 
extract from DJY85 (prp2-1) and JDY9. 11 (prp9-1) showed defects consistent with 
their known roles in spliceosome assembly. Extracts from strains temperature-
sensitive for different splicing factors complemented each other or i.WRP8 extract 
except when either two different prp8 extracts or a prp8 and zPRP8 extract were 
used. These data were consistent with both the depletion and heat-inactivation 
protocols being specific for the proteins targeted. 
The results obtained here are compatible with those obtained by antibody 
inhibition of splicing (chapter 3). Three independent methods of abrogating PRP8 
function (in vivo depletion, heat-inactivation of temperature-sensitive protein and 
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antibody inhibition) all resulted in a block in spliceosome assembly at the same point, 
i.e. after the association of Ui and U2 snRNP with the substrate RNA, and imply 
that, either directly or indirectly, PRP8 protein plays a role in promoting binding of 
U5 snRNP or the U41U6.U5 tri-5nRNP to the pre-spliceosome. The inhibition of 
splicing by anti-8.4 and -8.6 antibodies suggested that at least some of the epitopes 
that these antibodies recognised were important for spliceosome assembly, and the 
occlusion of the epitopes that anti-8.4 antibodies recognise in complex I, suggested 
that these epitopes were indeed involved in the interaction of U4/U6.U5 tri-snRNPs 
with the spliceosome. The inhibition of splicing by anti-8.1 antibodies and the 
disruption of U4/U6.U5 tri-snRNPs by them suggested a role for PRP8 protein in tn-
snRNP formation. Another possibility is that, since PRP8 protein is a component of 
the US snRNP it may be required for the integrity or stability of this particle. The 
depletion and inactivation strategies developed here allow the effect on tri-snRNPs the 
U5 snRNP and snRNAs to be examined. This is explored in the next chapter. 
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CHAPTER 6. 
THE EFFECTS ON snRNPs AND snRNAs OF 
DEPLETING AND INACTIVATING PRP8 
PROTEIN. 
6.1 Introduction. 
U5 and U4/U6 snRNPs failed to assemble into spliceosomes when PRP8 
protein was depleted or heat-inactivated (chapter 5). As discussed (section 5.6), 
possible explanations for this would be that, without PRP8 activity U5 snRNPs were 
unstable, or that U4/U6.U5 tri-snRNPs failed to form or were unstable, or that tn-
snRNPs formed but did not associate with pre-spliceosomes. If the stability of either 
US snRNPs or tri-snRNPs was affected by loss of PRP8 activity then the integrity of 
the snRNAs might also have been affected. 
To assess the effects of loss of PRP8 activity on snRNPs and snRNAs, the 
snRNPs in various splicing extracts were analysed, and the levels of snRNAs in strain 
JDY8.05 under both inducing and repressing conditions was examined. Glycerol 
gradient sedimentation was chosen as a means of analysing extracts as it gives a direct 
visualisation (by Northern blotting snRNAs from fractions) of the different snRNPs 
and snRNP complexes. This method had been used successfully to resolve yeast 
snRNP complexes (Bordonné et al., 1990; Shannon and Guthrie, 1991). Other 
methods for analysing complexes, eg affinity selection or immunoprecipitation, are 
indirect. Also, complexes might be disrupted during purification, and control over 
which complexes are purified is not always possible. 
6.2 Methods. 
Glycerol Gradient Sedimentation. 
Glycerol gradients were prepared and fractions collected as described in 
section 2.5.9. RNA was purified by extraction with phenol/chloroform and 
precipitation with ethanol, and the distribution of snRNAs assessed by preparing 
Northern blots of the RNA from odd numbered fractions and probing with kinased 
oligonucleotides complementary to U4, U5 and U6 snRNAs. Samples for gradient 
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fractionation were prepared by incubating splicing extracts under splicing conditions 
with no pre-mRNA, with or without ATP for 15mins before diluting with 3 volumes 
of gradient buffer and layering onto the gradients. These conditions, which differ 
from those used in other studies, were chosen as they were known to allow stable 
splicing complex formation and efficient splicing in vitro. Figure 6.1 shows that 
incubation with ATP had only a slight effect on the distribution of snRNPs. This 
contrasts with the dramatic loss of tri-snRNPs on incubation with ATP seen by 
Bordonné et al. (1990). Possible reasons for this are discussed below (section 6.6). 
6.3 Depletion of PRP8 Protein Results in Loss of U41U6.U5 Tri-snRNPs and a 
Change in the Sedimentation of U5 snRNPs. 
Figure 6. lB shows the distribution of snRNPs in a typical gradient of splicing 
extract from a wild type strain. Some U4, U5 and U6 snRNAs were found near the 
bottom of the gradient. This was shown by Bordonné et al. (1990), using 
immunoprecipitation with anti-PRP4 antibodies, to represent U4/U6.U5 tri-snRNP 
particles. Free U5 and U6 snRNPs, and U4/U6 snRNP were also resolved, further 
up the gradient. 
Gradients of LPRP8 extract (figure 6.2A) showed two marked differences to 
those of wild type extract. Firstly, tri-snRNP was hardly detectable. Secondly, free 
U5 snRNPs had a reduced sedimentation velocity, the majority being in approximately 
the same position as free U6 particles. U4/U6 snRNPs and free U6 behaved the same 
way as those in wild type extract (note that the experiments shown in figures 6. 1B, 
6.2 and 6.3 are not hybridised with the same probes and thus a direct comparison of 
the amount of snRNAs in the extracts can not be made). The change in sedimentation 
of U5 implies a difference in composition, in keeping with loss of PRP8 and perhaps 
other proteins from the U5 snRNP. The depletion of U4/U6.U5 particles shows that 
the incomplete U5 snRNP either fails to associate with or does not associate stably 
with U4/U6 snRNPs. 
When +PRP8 extract was analysed (figure 6.213) it was found to have a 
distribution of snRNPs intermediate between those of wild type and L1PRP8 extracts. 
A smaller proportion of the snRNAs was in the form of tri-snRNP than in wild type 
extract and most of the free U5 snRNP sedimented as in zPRP8 extract. This is 
consistent with the low level of galactose-induced expression of PRP8 (see section 
4.3.2) and also with the limiting amount of complete U5 snRNPs being preferentially 
assembled into stable tri-snRNPs. 
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FIGURE 6.1 Glycerol Gradient Sedimentation of snRNPs. 
Wild type (BJ2412) splicing extract (equivalent to 1mg protein) was incubated 
under splicing conditions without substrate and ATP for 15mins, diluted 3-fold in 
gradient buffer, and layered onto and sedimented through a 10-30% linear glycerol 
gradient. 0.5m1 fractions were collected (numbered consecutively from the top of the 
gradient). The snRNA content of alternate fractions was analysed by recovering RNA 
and Northern blotting as in figure 3.2B. Probes were 5'-end labelled oligonucleotides 
complementary to the snRNAs. Fraction numbers, snRNAs and the position of 
complexes as deduced from the distribution of snRNAs are marked. 
Wild type splicing extract was treated and analysed exactly as in A except that 
ATP was included in the incubation prior to sedimentation. M; markers as in figure 
3.2B. 
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FIGURE 6.2 Glycerol Gradient Sedimentation of snRNPs. 
Splicing extracts from strain JDY8.05 (A: APRP8, B: +PRP8) were treated and 
analysed exactly as in figure 6.1B. 
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FIGURE 6.3 Glycerol Gradient Sedimentation of snRNPs. 
Splicing extracts (A: prp8-1 (inactive SPJ8.31 (prp8-1) extract), B: prp2-1 (inactive 
DJY85 (prp2-1) extract)) were treated and analysed exactly as in figure 6. 1 B. 
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6.4 Heat-Inactivated prp8 Protein Dissociates from snRNPs. 
In order to assess the effect on snRNPs of heat-inactivating prp8 protein 
inactive SPJ8.3 1 (prp8-1) extract (prepared as in section 5.2) was sedimented through 
gradients and fractions were analysed for the distribution of snRNAs. Figure 6.3A 
shows that the sedimentation pattern of snRNPs from prp8-1 extract was very similar 
that seen with i.PRP8 extract - free US sedimenting at approximately the same rate 
as free U6 and only a small amount of tri-snRNP detected. As a control for this 
experiment inactive DT/85 (prp2-1) extract was also analysed. In this case the 
distribution of snRNPs was virtually identical to wild type extract (compare figures 
6.3B and 6.1B). Thus despite the heat-labile nature of the U4/U6.U5 tri-snRNP in 
mammalian cells (Bond, 1988; Shulke et al., 1990), the yeast tri-snRNP was not 
affected by the heat treatment used in the preparation of these extracts. The result 
with prp8-1 extract implied that at the non-permissive temperature in SPJ8.31 
protoplasts the PRP8 protein dissociated from the U5 snRNP. 
Further evidence for the possible dissociation of inactivated heat-sensitive prp8 
protein from snRNPs was provided by immunoprecipitation. Extracts were subjected 
to immunoprecipitation with anti-PRP8 antibodies and the precipitate analysed for 
snRNAs by Northern blotting. U4, U5 and U6 snRNAs were not detected in the 
precipitate from an inactive prp8-1 extract (figure 6.4A lane 3), whereas all these 
species were precipitated from a wild type extract or an inactive prp2 extract (lanes 
2 and 4). The prp8-1 extract used in this experiment was the same one as used in the 
experiment shown in figure 5.4 and thus contained all the splicing-associated 
snRNAs. Immunoprecipitation from inactive prp8-2 or prp8-7 extracts also showed 
no precipitation of U4, US or U6 snRNAs (data not shown). Thus the prp8-1 , prp8-2 
and prp8-7 mutations had the same phenotype, and depletion and inactivation of PRP8 
were functionally equivalent in terms of snRNP stability and interactions between the 
US and U4/U6 snRNPs. 
6.5 Depletion of PRP8 Protein Results in Loss of U4, U5 and U6 snRNAs. 
The effect of depletion of PRP8 protein on the levels of the splicing-associated 
snRNAs in strain JDY8.05 was examined. Figure 6.4B shows a Northern blot of 
RNA from cells grown in YPGRA and transferred to YPDA at time 0. The levels of 
U4, both U5L and U5S, and U6 snRNAs all fell rapidly with respect to a control 
non-spliced RNA (a URA3 transcript). This decrease occurred mostly in the first 4 
to 5 hours when the level of PRP8 protein was presumably also decreasing but 
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FIGURE 6.4 
The Effect of Heat-Inactivating prp8 on the Immunoprecipitation of snRNAs. 
Splicing extracts were subject to immunoprecipitation with anti-8.6 antibodies and 
analysed by Northern blotting as in figure 3.213. wt, wild type (BJ2412) extract; 8-1, 
inactive SPJ8.31 (prp8-1) extract; 2-1, inactive DJY85 (prp2-1) extract. The same 
prp8-1 extract was used in this experiment as that shown in figure 5.4. 
The Effect of Depleting PRP8 Protein on the snRNA Content of JDY8.05. 
Total RNA was extracted from JDY8.05 at one hour intervals following the switch 
from YPGRA to YPDA (carried out as in figure 4.4), and analysed for the levels of 
various transcripts by Northern blotting. The URA3 transcript is a non-spliced control. 
Probes were 5'-end labelled oligonucleotides. 
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logarithmic growth was maintained. No effect was seen on either U! or U2 snRNA, 
the levels of which remained constant with respect to the control. 
In order to quantify this effect, RNA preparations from several independent 
time course experiments were analysed for Ui, U2, U4, U5 and U6 snRNAs by 
densitometric scanning of autoradiographs (section 2.2.6; exposures which had not 
saturated the sensitivity of the film were chosen). The levels of U2, U4, U5 and U6 
were normalised against U 1 and expressed as a percentage of the starting value. The 
averaged results of two such experiments are shown in figure 6.5A and B. This 
densitometric analysis showed that, while U2 remained virtually constant, U5L fell 
by about 20-fold, U5S by approximately 10-fold, U4 by 3- to 4-fold and U6 by 7- to 
10-fold with respect to Ui. 
The change in the relative abundance of snRNAs could have been a 
consequence of changing carbon source (glucose instead of galactose plus raffinose). 
As a control for such an effect the experiment was performed with strain JDY8.06. 
Figure 6.5C shows that there was no effect on the relative levels of snRNAs in this 
strain on switching growth medium from YPGRA to YPDA. 
6.6 Discussion. 
Glycerol gradient sedimentation proved to be extremely useful for the analysis 
of snRNPs and snRNP complexes in splicing extracts. Using this technique it was 
shown that depletion and inactivation of PRP8 protein led to a loss of U4/U6.U5 tn-
snRNPs and a decrease in the sedimentation rate of the U5 snRNP. Northern blotting 
of total RNA from strain JDY8.05 showed that depletion of PRP8 protein resulted in 
loss of most of the U4, U5 and U6 snRNAs, but not of the U! or U2 snRNAs. 
The conditions for incubation of splicing extracts prior to glycerol gradient 
analysis were chosen on the basis that they were optimised for splicing in vitro. These 
were identical conditions to those used in section 3.3 and by Lossky et al. (1987) for 
pre-incubation of splicing extract prior to immunoprecipitation with anti-PRP8 
antibodies, and U41U6.U5 tri-snRNPs appeared to be relatively stable on incubation 
with ATP. These conditions differed from those used in previous analyses (Bordonné 
et al., 1990; Shannon and Guthrie, 1991). In the experiments of Bordonné et al. 
(1990) incubation of splicing extract with 2mM MgCl 2 , 0.5mM ATP and 20mM 
creatine phosphate led to a marked decrease in the amount of tri-snRNP. It may be 
that some component of the in vitro splicing reaction stabilises the "+ ATP" form of 
tri-snRNPs. This could be, for example, the volume excluder polyethylene glycol 
which is, at 2-4% (w/v), highly stimulatory to splicing (Lin et al., 1985). A direct 
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FIGURE 6.5 
A) and B) Densitometric Analysis of snRNAs. 
Levels of snRNAs in JDY8.05 were estimated by densitometric scanning of 
autoradiographs of Northern blots of two independent time courses. Values for U4, 
U5 and U6 were normalised against the level of U 1 snRNA, averaged between the 
two experiments and plotted as a percentage of the starting amount as 100%. B) U5L 
and U5S; C) U4 and U6. The 1 lhr time points were only obtained from one 
experiment. 
C) The Effect of Switching Strain JDY8.06 from YPGRA to YPDA on the Levels 
of snRNAs. 
Total RNA was extracted from JDY8.06 at 0, 2, 4, 6 and 9 hours after the switch 
from YPGRA to YPDA (carried out as in figure 4.4), and analysed as in figure 6.413 
to assess the effect on levels of snRNAs. M, markers as in figure 3.213. 
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comparison of the effects of ATP on tri-snRNPs during incubation under various 
conditions might resolve this discrepancy, but has not yet been carried out. 
Previous immunoprecipitation data (Lossky et al., 1987) could not exclude the 
possibility that PRP8 protein associates independently with U5 and U4/U6 snRNPs. 
Since the sedimentation of U5 snRNP and not U4/U6 snRNP was affected in LPRP8 
extracts it can be concluded that PRP8 protein does not associate with U4/U6 snRNP. 
The almost total lack of U4/U6.U5 tri-snRNP in LPRP8 extract and in inactive prp8-
1 extract showed that PRP8 activity is either essential for the formation of this 
particle or for its stability. 
U4, both forms of U5 and U6 snRNAs became depleted in JDY8.05 when it 
was grown under conditions that repressed PRP8 protein synthesis (preliminary 
experiments indicated that incubation of SPJ8.31 (prp8-1) at the non-permissive 
temperature had similar effects; data not presented). Loss of U5 snRNA was not 
unexpected since PRP8 protein might be required for U5 snRNP stability. However, 
loss of U4 and U6, was somewhat surprising and could be explained in several ways. 
One possibility is that transcription of the snRNAs is coordinately regulated, depletion 
of PRP8 leading to decreased transcription. This seemed unlikely as U6 is transcribed 
by a different polymerase to the other snRNAs - polymerase III rather than 
polymerase II (Moenne et al., 1990) - and U  and U2 were not affected. Even if the 
transcription of these snRNAs had ceased immediately after cells were switched to 
repressing medium the levels of the snRNAs would not have declined so rapidly due 
only to cell division. Another possibility, instability of free U4/6 snRNPs, also 
seemed unlikely since in vivo depletion of U5 snRNA had little effect on U4 and U6 
snRNAs (Seraphin et al., 1991 and see chapter 7) and the residual U4 and U6 
remaining after PRP8 depletion were predominantly in U4/U6 snRNPs (figure 6.2A). 
The most likely explanation is that U4/U6 snRNPs associated with the incomplete U5 
snRNPs to form defective, unstable tn-snRNPs which were degraded. Several 
observations make this an attractive notion. 
As discussed in the Introduction (section 1.6.4) a prp8 mutant has been 
isolated that suppresses a defect in the putative helicase PRP28 which may unwind 
U4 and U6. On the basis of this and other observations, Strauss and Guthrie (1991) 
proposed a model in which the base paired form of U4/U6 is stabilised in the tn-
snRNP by the action of PRP8 countering that of PRP28 and the U6 binding protein 
PRP24. Genetic interactions have also been found between PRP8 and another putative 
helicase - DEDI (Jamieson etal., 1991). Several independent cold-sensitive mutations 
in the DEDJ gene partially suppress the temperature-sensitive defect in a strain 
carrying the prp8-1 mutation. As the prp8-1 defect has a number of phenotypes at the 
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non-permissive temperature equivalent to PRP8 depletion, including loss of tn-
snRNPs, this implies that the modified DED1 protein stabilises the tri-snRNP at high 
temperatures. Presumably decreased helicase activity redresses the balance between 
the opposing effects of the DED 1 and PRP8 proteins. Thus there are at least two 
putative RNA helicases with which PRP8 protein might normally interact, and whose 
activity might be regulated by this interaction. In the situation where PRP8 is not 
present in U5 snRNPs or U4/U6.U5 tri-snRNPs, either through depletion or heat-
inactivation, the activity of these (and/or other) helicases might be unregulated leading 
to unwinding of normally stable RNA structures (eg the stem of the conserved U5 
loop) or base-pairings normally only unwound in the spliceosome (eg the U4:U6 
interaction). This would expose the RNAs to nuclease activities and hence lead to 
their degradation. 
U6 snRNA is in excess over U4 snRNA in yeast (Siliciano et al., 1987). The 
7- to 10-fold and 3- to 4-fold reductions in the levels of U6 and U4 snRNAs 
respectively shows that the level of U6 declines much faster than that of U4. The 
greater loss of U6 and U5 over U4 on loss of PRP8 function indicates that these two 
RNAs might be more exposed to the action of nucleases. Unlike U5 and U6 which 
are in close proximity with the substrate of the splicing reaction (Newman and 
Norman, 1991, 1992; Sawa and Shimura, 1992; see Introduction sections 1.6.2 and 
1.6.3) and may therefore be exposed in the spliceosome, U4 is probably not active 
in the reaction; indeed, it has been found that U4 is dispensable for the splicing 
reaction in vitro once it has been destabilised from U6 (Yean and Lin, 1991). In 
addition, U4 has been shown to be less susceptible than U6 to digestion by 
micrococcal nuclease (Xu et al., 1990). Insensitivity to nuclease digestion might be 
expected to prevent U4 being degraded when it is unwound from U6 and exposed in, 
or released from, the spliceosome. Thus even when U4 is unwound from U6 it may 
be stable, and the observation that U4 is lost to a lesser extent than U5 and U6 is 
consistent with this. Free U4 snRNP left after degradation of U5 and U6 snRNA 
could then associate with free U6 and U5 snRNPs to go through another cycle of non-
productive formation of PRP8-deficient tri-snRNP. 
As mentioned earlier (section 4. 1), when this project was started the analysis 
of the defects caused by existing prp8 mutations was a main aim. It was hoped that 
the phenotypes of these mutants might be different, as this would indicate distinct 
functions for PRP8 protein. The three mutations analysed all have similar if not 
identical phenotypes to PRP8 depletion, indicating a defect in the stability of the 
interaction of the mutant proteins with the U5 snRNP. In vivo PRP8 protein is a 
component of a number of splicing complexes and these defects may be manifested 
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at different points during the cycle of complex assembly and disassembly eg 
formation of U5 snRNPs, formation of tri-snRNPs and spliceosome disassembly. In 
vitro when the protein has been inactivated before the experiments are carried out 
such differences would not be seen. All the temperature-sensitive pip8 mutations 
isolated by Hartwell (1967) are recessive and thus the finding that those that have 
been analysed cause complexes to be unstable is perhaps not surprising: mutations 
causing defects in PRP8 protein that lead to accumulation of stable complexes might 
have a dominant phenotype in vivo due to sequestering factors in dead-end complexes 
(see Herskowitz, 1987 for review of dominant negative mutations and how they might 
act). To obtain information on functions of PRP8 protein in the spliceosome mutations 
of a type other than temperature-sensitive recessive would have to be isolated. 
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CHAPTER 7. 
PRP8 PROTEIN AND U4 AND U6 snRNAs ARE 
STABLE IN THE ABSENCE OF U5 snRNA. 
7.1 Introduction. 
The results presented in chapter 6 established that in vivo depletion of PRP8 
protein resulted in a decrease in the level of U5 snRNA and also the amount of U4 
and U6 snRNAs. As discussed (section 6.6), it was likely that in the absence of PRP8 
protein the snRNAs were unstable due to the formation of aberrant tri-snRNP 
particles. In this chapter experiments are described which assess the effect of 
depleting U5 snRNA (and hence the U5 snRNP) in vivo on other snRNAs and PRP8. 
These experiments allowed a distinction between the effect on U4 and U6 snRNAs 
being a direct result of depleting PRP8 protein rather than due to the consequent loss 
of U5 snRNPs. 
In order to carry out these experiments strain BS-Yl 19 was obtained from 
B.Seraphin (Heidelberg; Seraphin et al., 1991). This strain carries a chromosomal 
disruption of the snR7 locus and a copy of the snR7 gene under the control of a 
chimeric snR19-GAL promoter (Seraphin and Rosbash, 1989) on a centromeric 
plasmid. Thus, as with the PRP8 gene in strain JDY8.05, expression of snR7 is 
galactose dependent, and growth of BS-Y1 19 on glucose results in depletion of the 
U5 snRNA by transcriptional repression. Using this strain Seraphin et al. (1991) had 
shown that upon depletion of U5 snRNA, splicing was inhibited in vitro and 
spliceosome assembly was blocked, with U4/U6 snRNPs failing to associate with pre-
spliceosomes. Seraphin et al. (1991) also reported that depletion of U5 snRNA had 
little effect on other snRNAs, although no quantitative data were presented to support 
this. 
Preliminary experiments confirmed that BS-Y119 behaved as reported by 
Seraphin etal. (1991). Following the switch from expressing to repressing conditions 
(YPGRA to YPDA) growth deviated from logarithmic after approximately 10 hours 
(data not shown). Splicing extract made from BS-Y1 19 cells grown in YPDA for 
1 lhrs was inactive for splicing in vitro, and the defect could be complemented by 
prp2 extract (figure 7. 1A). 
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FIGURE 7.1 The Effects of In vivo Depletion of U5 snRNA on In vitro Splicing, 
PRP8 Protein and other snRNAs. 
Splicing Reactions. Reactions were assembled and analysed as in figure 5.1. 
Extracts: +U5, BS-Y119 cells grown in YPGRA; AU5, BS-Y119 cells grown in 
YPDA for 11 hrs;  prp2, as in figure 5.1. M, sizes of markers as in figure 5.1; T, gel-
purified rp28 transcript. 
Western Blot and Coomassie Stained Protein Gel. 
Lanes 9 and 10. Equal amounts (as assessed by Bradford assay) of +U5 (+) and 
zU5 (-) extracts prepared as in A run on a 6% (w/v) SDS-polyacrylamide gel and 
coomassie stained to visualise proteins. 
Lanes 1 to 8. Western blot of +U5 (+) and zU5 (-) extracts run on a 6% (w/v) 
SDS-polyacrylamide gel, blotted to nitrocellulose and probed with affinity-purified 
anti-8.6 antibodies. Equal amounts of the two extracts (as in lanes 9 and 10) were run 
in lanes 1 and 2. Lanes 3+4, 5+6 and 7+8 are equal volumes of serial 2-fold 
dilutions of the amount used in lanes 1 and 2. PRP8 is marked. 
Northern Blot. 
Total RNA extracted from BS-Y119 0, 5, 11 and 16hrs after switching from YPDA 
to YPGRA was analysed for snRNAs as in figure 6.4B. M, position of markers as 
in figure 3.2B. A shorter exposure of the U6 snRNA (which is over-exposed in the 
main panel) is included. 
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7.2 The Effect of Depleting US snRNA on other snRNAs. 
In order to assess the effect of U5 snRNA depletion on the levels of other 
snRNAs, total RNA extracted from strain BSY1 19 grown in YPGRA and at several 
times after transfer to YPDA was analysed by Northern blotting. A blot is shown in 
figure 7. 1C, and the data from densitometric analysis of this blot are in table 7.1. To 
control for differences in loading, absolute values were normalised against the level 
of Ui snRNA. As expected from the results of Seraphin et al. (1991) U5 snRNA had 
fallen by about 20-fold after eleven hours. Interestingly little U51, was found to be 
present in strain BS-Yl 19 even when grown under inducing conditions: no mention 
was made of this by Seraphin et al. (1991), all the Northern blots presented being of 
RNA from extracts in which the U5 snRNA was absent through depletion. 
The amount of both U4 and U6 snRNAs increased as U5 snRNA became 
depleted whereas the amount of U2 snRNA remained relatively constant (figure 7. 1C 
and see table 7. 1). Nearly 3X the initial amount of U6 and 1 .5X that of U4 were seen 
after five hours growth in glucose. As U5 became extensively depleted and cell 
growth was impaired (after eleven and sixteen hours growth in glucose), the levels 
of U4 and U6 decreased and became less than the initial amount. It should be noted 
that this experiment was only carried out once - i.e. only one set of RNA preparations 
were made - and few time points were taken, but several blots showed the same 
effects on the distribution of RNAs. 
Table 7.1 snRNA levels (relative to Ui. as a % of starting value) in BS-Yl 19 
grown in glucose. 
Time 
(hours) 
0 5 11 16 
U2 100 110 75 90 
U5 100 65 5 2 
U4 100 140 125 60 
U6 100 270 130 40 
7.3 Depletion of U5 snRNA has Little Effect on PRP8. 
To assess the effect of depleting U5 snRNA on the levels of PRP8 protein, 
Western blots of splicing extracts from strain BSY1 19 grown under inducing 
conditions (+U5) and after growth in repressing conditions for eleven hours (-U5) 
were probed for PRP8 protein. Equal amounts of +U5 and -U5 extracts were used 
(as assessed by Bradford assay and Coomassie staining of proteins fractionated by 
SDS-page). Figure 7. lB (lanes 9 and 10) shows a Coomassie stained gel of +U5 and 
-U5 extract. The equal intensity of the bands indicates that the amount of protein in 
the two lanes was approximately the same. The same relative amounts of the two 
extracts and sequential 2-fold dilutions down to 1/8th of the starting amount were 
Western blotted and probed with affinity purified anti-8.6 antibodies (figure 7. lB 
lanes 1 to 8). Although the signal for PRP8 was slightly less in the -U5 extract than 
the +U5 extract, detection of PRP8 was lost between 4- and 8-fold dilutions of each 
showing that the difference in concentration of PRP8 between the two extracts was 
probably not more than 2-fold. The conclusion drawn from this and other similar 
blots was that depletion of U5 snRNA had little or no effect on the level of PRP8 
protein. 
7.4 Discussion. 
In vivo depletion of U5 snRNA (and hence of U5 snRNPs) did not have a 
substantial effect on the level of PRP8 protein. Therefore, unlike US snRNA which 
is unstable in the absence of PRP8 protein, PRP8 protein is relatively stable in the 
absence of U5 snRNA. In confirmation of the results of Seraphin et al. (1991), 
depletion of U5 snRNA did not reveal a similar effect on the levels of 'U4 and U6 
snRNAs to that seen on depletion of PRP8 protein. U4 and U6 snRNAs were 
observed to increase in abundance (relative to U 1 snRNA) during the initial stages of 
U5 depletion and to decrease when US was extensively depleted. Thus the loss of U4 
and U6 snRNAs seen on PRP8 depletion was not an indirect effect caused by loss of 
U5 snRNAs. Also, it is clear that U4/U6 snRNPs and U6 snRNPs are not 
intrinsically unstable particles. These data favour the model proposed in chapter 6 in 
which depletion of PRP8 results in the formation of U5 snRNPs that interact with 
U4/U6 snRNPs to form defective particles in or on which unregulated helicase and 
nuclease activities act to expose and destroy the RNA components. 
PRP8 protein (and other US snRNP proteins) remaining in an RNA-free form 
upon depletion of U5 snRNA might have an affinity for U4/U6 snRNPs and bind to 
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them. Binding of PRP8 protein to U4/U6 could act to stabilise these particles in the 
absence of U5 snRNP. This possibility could be tested by immunoprecipitation from 
U5-depleted extracts with anti-PRP8 antibodies and Northern blotting for U4 and U6 
snRNAs, and also by examining the sedimentation of U4/U6 snRNPs in these extracts 
in glycerol gradients. The location of PRP8 protein (nuclear or cytoplasmic) in U5-
depleted cells was not examined. 
An explanation for the increased amount of U4 and U6 snRNAs as U5 
synthesis was repressed is that these snRNAs are more stable in the form of U6 and 
U4/U6 particles than in tri-snRNPs or during the splicing reaction. As the amount of 
free U5 snRNP decreased it would become limiting with respect to the formation of 
tri-snRNPs, and U6 and U4/U6 snRNPs would accumulate unless the level of 
transcription of the snRNAs were decreased. An alternative explanation would be that 
transcription of U4 and U6 snRNAs increased in response to the change to a more 
easily metabolised carbon source (glucose). However, if this were the case Ui and 
U2 transcription would also be expected to rise, which did not seem to be the case. 
In addition, the experiment with JDY8.06 (figure 6.5C), which contains a wild type 
snR7 gene, showed no increase in U4, U5 or U6 relative to U  and U2 when the 
carbon source was changed to glucose. The decrease in the levels of U4 and U6 seen 
as U5 became extensively depleted might have been due to transcriptional repression 
in response to their accumulation. As mentioned in section 7.3, only one set of RNA 
preparation was made from strain BS-Yi 19 and more experiments need to be carried 
out to verify the changes seen. 
The lack of U51, seen in BS-Yl 19 was somewhat puzzling as, so far as could 
be assessed from available information (Seraphin etal., 1991), the GAL-snR7plasmid 
contained the whole gene. The relationship between U5S and U51, is not understood, 
and it may be that U5S is a stable degradation product of U51, or that the two species 
are produced by differences in transcriptional termination (Patterson and Guthrie, 
1987). The snR19-GAL promoter in BS-Y1 19 might have affected the termination of 
snR7 transcripts. It has been reported that U5L is not necessary for cell viability 
(Guthrie and Patterson, 1988) and under the growth conditions used here U51, 
presumably does not carry out any essential function that U5S can not. 
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CHAFFER 8. 
FINAL DISCUSSION, SPECULATION AND 
FUTURE WORK. 
The results presented in this thesis, together with previously published work 
(Lossky et al., 1987; Jackson et al., 1988; Whittaker et al., 1990; Whittaker and 
Beggs, 199 1) can be used to suggest points where PRP8 protein is required in splicing 
complex assembly and splicing. Firstly, PRP8 is necessary for the formation of 
complete and functional U5 snRNPs (and PRP8 protein does not associate 
independently with U6 or U4/U6 snRNPs). Secondly, PRP8 activity is required for 
the formation of stable U4/U6.U5 tri-snRNPs, as evidenced by the lack of these 
particles when PRP8 protein is depleted or heat-inactivated, and by the disruption of 
them by anti-8.1 antibodies. Depletion of PRP8 protein causes the loss of U4, U5 and 
U6 snRNAs. This might be due to an association of U5 and U4/U6 snRNPs to form 
aberrant, PRP8-deficient tri-snRNPs in or on which helicase and nuclease activities 
act in an unregulated fashion to unwind and destroy the snRNAs. Thirdly, since anti-
8.4 and -8.6 antibodies block spliceosome assembly after U2 snRNP binding, PRP8 
protein is probably required for stable association of the tri-snRNP with the pre-
spliceosome complex. Fourthly, when other factors, including the substrate, are 
correctly aligned in the spliceosome, PRP8 protein regulates the activities of the 
PRP28 and PRP24 proteins in unwinding U6 from U4. At some time before or after 
the U4:U6 interaction is destabilised PRP8 comes into contact with the substrate 
RNA. Figure 8.1 illustrates the roles of PRP8 protein in complex formation, the 
effect of antibodies, and of depletion or heat-inactivation of the protein. In this model 
it is assumed that, as in mammals (Utans et al., 1992), the U4/U6.U5 tri-snRNP is 
an obligatory intermediate in spliceosome assembly. The data presented in this thesis 
and in other published work are consistent with this assumption (sec Introduction 
section 1.5.4). 
The results obtained in this work, the conservation of the very large size of 
PRP8 protein and of widely spaced epitopes (Anderson et al., 1989; Paterson, et al., 
1991), and the fact that both PRP8 and its putative mammalian homologue contact the 
substrate (Garcia-Blanco et al., 1990; Whittaker and Beggs, 1991), supports the 
notion that PRP8 might function as a scaffold in the spliceosome (Whittaker et al., 
1990), regulating or monitoring interactions between various components. An 
attractive scenario is for PRP8 protein to correctly position the U5 snRNA at the exon 
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FIGURE 8.1 PRP8 Protein in Splicing Complex Assembly. 
A model of where PRP8 protein is required in the assembly of splicing complexes, 
and the effect of depletion or heat-inactivation of the protein. Blocks in complex 
assembly caused by antibodies are indicated (crosses). "ATP" represents points at 
which ATP is or may be required. An ATP-dependent conformational shift in the 
U4/U6.U5 tri-snRNP is indicated by a change in the relative positions of PRP8 















sequences just upstream to the 5' splice site (and possibly downstream of the 3' splice 
site) to which U5 base pairs (Newman and Norman, 1992), potentiating this weak 
interaction. Preliminary mapping of PRP8-substrate interactions (Whittaker, 1990) 
suggested that one interaction was around the 5' splice site in pre-mRNA, which 
would agree with the proposal that PRP8 is involved in the U5:exon 1 interaction, as 
would the observation that a U5 loop mutation is synergistic lethal in combination 
with pip8-1 (Guthrie and Patterson, 1988). Another PRP8-substrate interaction 
tentatively mapped by Whittaker (1990) was to the branch point in substrate derived 
molecules. This pattern of 5' splice site and branch point interactions resembles the 
cross-linking of HeLa U6 snRNA to substrate within the spliceosome (Sawa and 
Shimura, 1992) and it may be speculated that PRP8 protein is one of the spliceosomal 
components that aids the correct positioning of U6 snRNA around these regions of 
the substrate. 
From the above ideas and the known genetic interactions between PRP8 and 
the putative helicase proteins PRP28 and DED1 it could be proposed that PRP8 
protein plays a role in regulating dynamic RNA-RNA interactions both in the tn-
snRNP and in the spliceosome, perhaps ensuring the correct directionality of events. 
A prediction of these speculations is that it might be possible to detect genetic and 
physical interactions between PRP8 and the US and U6 snRNAs and other 
components of the tri-snRNP. 
Physical interactions of PRP8 protein within the U5 snRNP and in the 
U4/U6.U5 tni-snRNP have not been characterised. The data obtained with anti-8.1 
antibodies suggest that at least some of the epitopes which these antibodies recognise 
are involved in tri-snRNP formation. The availability of extracts depleted of U5 
snRNA (from strain BS-Y1 19), and a published protocol for reconstituting functional 
U6 snRNPs in extracts depleted of endogenous U6 5nRNA (by targeted RNase H 
cleavage; Fabrizio et al., 1989), make it feasible to do experiments to establish 
whether or not physical contacts exist between PRP8 protein and these RNA species. 
The approach of choice would be reconstitution of snRNPs using in vitro transcribed, 
radiolabelled snRNAs, followed by UV cross-linking and analysis as carried out to 
establish the PRP8-substrate interactions (Whittaker, 1990; Whittaker and Beggs, 
1990). Proteolytic cleavage and immunoprecipitation could be used to map RNA-
binding sites on the protein. One potential RNA-binding site on PRP8 protein has 
been identified. Fusion proteins containing a very basic region of PRP8 next to the 
acidic, proline rich N-teminus bind RNA on North-Western blots (Anderson, 1989). 
Although the binding detected was non-specific with respect to RNA sequence, it may 
be specific in the context of the intact protein or US snRNP. This may be the region 
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of the protein that contacts the substrate since this interaction has not been mapped. 
The protein composition of yeast snRNPs is not known, and the identification 
of Sm-antigens and other components of the yeast U5 snRNP would give insight into 
the evolutionary conservation of proteins involved in splicing as opposed to the 
snRNAs and mechanism of the reaction (particularly since the U5 snRNP is the most 
complex splicing-associated snRNP in HeLa cells; LUhrmann et al., 1990). Large 
scale purification of U5 snRNPs and tri-snRNPs would provide material for 
identifying interactions in, and components of these particles. Appropriate methods 
for this purification include: affinity selection with modified antisense 
oligoribonucleotides (as used successfully to deplete U5 snRNP from HeLa nuclear 
extracts; Lamm et al., 1991); large scale glycerol gradient sedimentation; 
immunoaffinity purification (anti-8.6 antibodies would be particularly useful for this 
since bound material could be eluted in an intact form using the synthetic peptide 
against which these antibodies were raised). 
The study of purified yeast U5 snRNPs and tri-snRNPs (and U4/U6 snRNPs) 
and comparison with the equivalent mammalian particles might, at least partly, 
explain apparent discrepancies between the mammalian and yeast systems with regard 
to the effects of ATP on this particle. As discussed in chapters 3 and 6, ATP affects 
either the formation or the conformation of yeast tri-snRNPs, the ATP-dependent 
species being precipitable by anti-8.4 antibodies and unstable under certain conditions. 
In HeLa cell nuclear extracts the formation of the tri-snRNP appears to be ATP -
dependent (Konarska and Sharp, 1987; Black and Pinto, 1989) - but this is not the 
case when isolated components are used (Behrens and Lührmann, 1991). Incubation 
of purified HeLa tri-snRNPs (but not U5 and U4/U6 snRNPs) with ATP leads to the 
phosphorylation of a U5-specific polypeptide (Behrens and Lührmann, 1991). This 
shows a direct effect of ATP on the tri-snRNP and that this particle contains a kinase 
activity. Thus ATP has effects on both yeast and mammalian tri-snRNPs. 
Experiments with purified yeast snRNPs and tri-snRNPs would establish whether 
there are yeast tri-snRNP specific polypeptides as found in HeLa (Behrens and 
Lührmann, 199 1) and whether a kinase activity is associated with the yeast tri-snRNP. 
Differences between yeast and mammals and discrepancies between reports may be 
due to assay conditions, to slight differences in the affinity of U4/U6 and U5 snRNPs 
for each other and in the stability of the tri-snRNP in yeast and mammals. Intuitively 
this seems more likely than any substantial difference in the properties of this particle 
as the splicing machinery and spliceosome assembly appear to be very similar in 
mammals and yeast. 
The studies using antibodies, temperature-sensitive mutants and depletion of 
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PRP8 protein all gave information on events early in the assembly of splicing 
complexes. The results suggest regions of the protein that might be important for 
particular interactions and possible functions for the PRP8 protein. In order to gain 
information on the role(s) of the protein in the splicing reaction further dissection of 
both the protein and of its interactions are required. 
A biochemical approach being attempted is cross-linking PRP8 protein to 
substrate RNA in reactions that are blocked at different stages by using temperature-
sensitive mutations in factors that act after PRP8 protein has entered the spliceosome 
(PRP2, PRP16, and PRP22 proteins; S.Teigelkamp personal communication). It is 
hoped that this will provide information on how the interactions of PRP8 protein with 
the substrate change during splicing. An alternative, and potentially more informative 
approach, since it would give information on PRP8-dependent steps, is to isolate 
mutations in PRP8 that block the splicing reaction at a later stage than existing 
mutations eg after spliceosome formation. As mentioned in chapter 6, such mutations 
would be expected to have at least partially dominant phenotypes by titrating out 
limiting splicing factors (the N-terminal deletion of PRP8 may be such a mutant since 
it has a partially dominant phenotype; see section 3.7). Dominant negative PRP8 
mutations could be produced by random mutagenesis in vitro in a transcriptionally 
regulated construct and identified by screening for those that, when expressed, inhibit 
cell growth in a wild type background. This approach has been used successfully with 
the PRP2 gene (M.Plumpton, personal communication): a mutant has been isolated 
which appears to form an irreversible interaction with the spliceosome (PRP2 protein 
normally has a transient interaction with the spliceosome; King and Beggs, 1991). 
The construct used in the work presented in this thesis (pJDY 13) would probably not 
be useful for the isolation of dominant mutations since it is expressed at a level much 
lower than the wild type PRP8 gene. Thus, even if a mutant protein produced at this 
low level competed well for interactions with other splicing factors to produce dead-
end complexes, it would probably not titrate out these factors. A GAL-PRP8 construct 
has recently been made that appears to produce more PRP8 protein upon induction 
than does pJDY13 and yet is repressible to a level that does not support cell growth 
on glucose (A.Brown, personal communication). Hopefully, mutagenesis of this 
plasmid followed by in vivo screening will allow the isolation of dominant negative 
mutations in PRP8 and facilitate the investigation of other functions of PRP8 protein 
in the spliceosome. 
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